# 已获批准的寡核苷酸疗法的化学、结构和功能

[toc]
## Abstract 摘要

Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice-switching oligonucleotides (SSOs), RNA interference (RNAi) and an RNA aptamer against a protein. Among the diseases targeted by this new class of drugs are homozygous familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscular dystrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome, acute hepatic porphyria, and primary hyperoxaluria. Chemical modification of DNA and RNA was central to making drugs out of oligonucleotides. Oligonucleotide therapeutics brought to market thus far contain just a handful of first- and second-generation modifications, among them 2′-fluoro-RNA, 2′-*O*-methyl RNA and the phosphorothioates that were introduced over 50 years ago. Two other privileged chemistries are 2′-*O*-(2-methoxyethyl)-RNA (MOE) and the phosphorodiamidate morpholinos (PMO). Given their importance in imparting oligonucleotides with high target affinity, metabolic stability and favorable pharmacokinetic and -dynamic properties, this article provides a review of these chemistries and their use in nucleic acid therapeutics. Breakthroughs in lipid formulation and GalNAc conjugation of modified oligonucleotides have paved the way to efficient delivery and robust, long-lasting silencing of genes. This review provides an account of the state-of-the-art of targeted oligo delivery to hepatocytes.

<span style=color:blue>过去25年中，已经批准了18种核酸治疗剂来治疗各种疾病。它们的作用方式包括反义寡核苷酸（ASOs）、剪接调节寡核苷酸（SSOs）、RNA干扰（RNAi）和针对蛋白质的RNA适配体。这种新型药物治疗的疾病包括同型家族高胆固醇血症、脊髓肌萎缩症、杜氏肌营养不良症、遗传性转甲状腺素介导的淀粉样变性、家族型脂肪乳症、急性肝性神经病和原发性肾小管中毒。化学修饰DNA和RNA是将寡核苷酸转化为药物的关键。到目前为止，已上市的寡核苷酸治疗药物中只包含了少数几种第一代和第二代修饰，其中2'-氟内酰胺RNA、2'-O-甲基RNA和50多年前引入的磷酸硫酸盐等化学修饰成为了中心。另外两种有优先选择的化学体系是2'-O-(2-甲氧基乙基)-RNA（MOE）和以磷酸二酰胺为基础的形态恩酰基吗啡核酸（PMO）。鉴于它们在赋予寡核苷酸高靶向亲和力、代谢稳定性和有利的药物代动力学和动力学特性方面的重要性，本文综述了这些化学体系及其在核酸治疗药物中的应用。脂质配方和修饰寡核苷酸的甘氨酰胺酰联已为有效传递和稳健持久的基因沉默打开了道路。本文对靶向寡核苷酸输送到肝细胞的现代技术进行了介绍。</span>

## INTRODUCTION 简介

Half a century may seem like an eternity but occasionally it feels like the years just flew by. Consider what has been achieved in roughly that time frame as we went from: the Wright brothers’ first flight (1903) to manned space flight (Gagarin/Sheppard, 1961), Turing's paper on computable numbers and the decision problem (Turing machine, 1936) to the release of the Cray-2 supercomputer (1985), and Sanger's sequencing of bovine insulin (1953)  to the completion of the human genome project (2003). These amazing feats have in common that they happened within some short 50 years! Viewed from such a perspective, chemically modified oligonucleotide drugs getting US FDA approval, VITRAVENE® (fomivirsen)—1998, MACUGEN® (pegaptanib sodium)—2004, and KYNAMRO® (mipomersen)—2013, just half a century after the publication of the structure of DNA (1953), is no small achievement.

<span style=color:blue>半个世纪可能看起来像是永远，但偶尔也会感觉年岁飞逝。考虑到在大约这个时间范围内所取得的成就：我们从莱特兄弟的第一次飞行（1903）到有人驾驶的太空飞行（加加林/谢伯德，1961），图灵论文中的可计算数字和决策问题（图灵机，1936）到Cray-2超级计算机的发布（1985）（5），以及桑格测序牛胰岛素（1953）到完成人类基因组计划（2003）。这些惊人的成就有一个共同点，就是在短短的50年内就完成了！从这样的角度来看，化学修饰寡核苷酸药物获得美国FDA批准，VITRAVENE®（fomivirsen）-1998，MACUGEN®（pegaptanib sodium）-2004和KYNAMRO®（mipomersen）-2013，仅仅在发现DNA结构（1953）后的半个世纪，这是一项不小的成就。</span>

A look back at the beginnings of molecular biology makes clear how little was known about concepts we now take for granted, concepts that foreshadowed a watershed of techniques and discoveries that can be traced back to early insights. The model of the DNA double helix sparked intense interest in the structural properties of RNA. It was unclear at the time how the ribose 2′-hydroxyl group would affect the conformation of RNA and whether RNA could form a duplex at all. In a landmark publication in 1956, Rich and Davies demonstrated the existence of an RNA duplex by mixing poly-A and poly-U. Remarkably, the same paper also put forth the concept of nucleic acid hybridization, i.e. the spontaneous pairing using specific interactions between two long nucleic acid strands. In 1960, Rich presented evidence that DNA and RNA can hybridize such that the resulting duplex is held together by hydrogen bonds (H-bonds) between purine and pyrimidine residues. This finding provided a mechanism for information transfer between DNA and RNA.

<span style=color:blue>回顾分子生物学的起步，可以清楚地看到我们现在视为理所当然的概念所知甚少，这些概念预示着一系列技术和发现的分界点，可以追溯到早期的洞察力。DNA双螺旋模型激起了人们对RNA结构性质的浓厚兴趣。当时还不清楚核糖2'-羟基基团将如何影响RNA的构象，以及RNA是否能够形成双链。Rich和Davies在1956年的一篇具有里程碑意义的文章中通过混合Poly-A和Poly-U证明了RNA双链的存在。值得注意的是，同一篇文章还提出了核酸杂交的概念，即利用两条长的核酸链之间的特定相互作用自发配对。1960年，Rich提出了DNA和RNA可以杂交的证据，从而使产生的双链被嘌呤和嘧啶残基之间的氢键（H-键）所支撑。这一发现提供了在DNA和RNA之间进行信息传递的机制。</span>

Hybridization reactions are the  backbone of modern molecular biology; approaches from the Southern blot to microarrays and the polymerase chain reaction (PCR), as well as genome sequencing and the forensic sciences, all depend at their core on nucleic acid hybridization. The same applies to the inhibition of biological information transfer, first successfully demonstrated by Zamecnik and Stephenson using the antisense and antigene approaches . In just a few years in the late 1950s and early 1960s, discoveries were made that laid the foundation for therapeutic intervention targeting RNA (e.g. hybridization via antisense, alternative splicing or RNA interference) and identified the RNA duplex as a key component of RNA structure (and, we now know, as an important actor in therapeutic intervention in the form of siRNA duplexes). Indeed, the earliest suggestion that RNA might have both a phenotype and a genotype, hinting at the existence of an RNA world, also dates back to the early 1960s.

<span style=color:blue>杂交反应是现代分子生物学的支柱；从Southern blot、微阵列和聚合酶链反应（PCR）的方法，到基因组测序和法医科学，所有这些方法的核心都依赖于核酸杂交。同样适用于抑制生物信息传递，这是由Zamecnik和Stephenson通过反义和抗基因方法首次成功实现的。在20世纪50年代末和60年代初的短短几年内的发现为干预RNA（如通过反义、选择性剪接或RNA干扰进行杂交）铺平了基础，并确定了RNA双链作为RNA结构的关键组成部分（而我们现在知道，它还是siRNA双链治疗干预的重要因素）。实际上，最早提出RNA可能具有表型和基因型（暗示着RNA世界的存在）的建议也可以追溯到20世纪60年代初。</span>

Beginning in 1955, nucleotide and oligonucleotide syntheses started in the laboratories of Todd, Khorana, Letsinger and Eckstein . Following these initial discoveries, DNA and RNA oligonucleotide syntheses and methods for the same were developed in the laboratories of Caruthers and Ogilvie, respectively. Phosphorothioate oligonucleotide synthesis was developed by Stec. These synthetic revolutions led to the discovery of the genetic code, and paved the way to molecular biology, chemical biology, and nucleic acid-based medicine (see also https://www.trilinkbiotech.com/a-short-history-of-oligonucleotide-synthesis).

<span style=color:blue>从1955年开始，核苷酸和寡核苷酸合成在Todd、Khorana、Letsinger和Eckstein的实验室中开始。在这些最初的发现之后，Caruthers和Ogilvie的实验室分别开发了DNA和RNA寡核苷酸合成和相应的合成方法。磷酸硫代酯寡核苷酸合成是由Stec开发的。这些合成革命导致了遗传密码的发现，并铺平了分子生物学、化学生物学和基于核酸的医学的道路（也可参见https://www.trilinkbiotech.com/a-short-history-of-oligonucleotide-synthesis）。</span>

Figure  1 depicts a brief history of key discoveries, nucleic acid structure analysis, and breakthroughs in DNA and RNA synthesis as well as modification strategies on the way to FDA-approved oligonucleotide therapeutics. Chemical modification efforts at the levels of nucleosides and nucleotides got underway >50 years ago and the syntheses of 2′-fluorothymidine, 2′-fluoro-2′-deoxyuridine (2′-F-U), nucleoside phosphorothioates (PSOs) , and 2′-*O*-methylated (2′-*O*-Me) polyadenylic acidwere all reported in the 1960s (Figure 2A).

<span style=color:blue>图1描述了关键发现、核酸结构分析以及在制备FDA批准的寡核苷酸治疗药物上进行DNA和RNA合成和修饰策略的突破性历程。五十多年前，核苷和核苷酸水平的化学修饰工作已开始，2'-氟胸腺嘧啶、2'-氟-2'-脱氧尿嘧啶（2'-FU）（46）、核苷酸磷硫酸酯（PSOs）（33）和2'-O-甲基聚腺苷酸（2'-O-Me）在1960年代均已报道（图2A）。</span>

图 1.

![Timeline of the development of chemical modifications (magenta), oligonucleotide synthetic approaches (black), interference in biological information transfer (green), structures of DNA and RNA (blue), and FDA-approved oligo therapeutics (orange).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig1.jpeg)

<span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>化学修饰（洋红色）、寡核苷酸合成方法（黑色）、生物信息传递干扰（绿色）、DNA 和 RNA 结构（蓝色）以及 FDA 批准的寡核苷酸疗法（橙色）的发展时间表。</span>


图 2.

![(A) Native DNA, RNA and chemical modifications that are approved in therapeutics so far. (B) Different delivery systems; LNP = lipid nanoparticle.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig2.jpeg)

<span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>(<span style="font-weight:bold">A</span>) 迄今为止在治疗学中获得批准的天然 DNA、RNA 和化学修饰。 (<span style="font-weight:bold">B</span>) 不同的传递系统； LNP = 脂质纳米颗粒。</span>

The 2′-F and 2′-*O*-Me modifications figure prominently in MACUGEN, an anti-VEGF aptamer for the treatment of wet age-related macular degeneration, and GIVLAARI® (givosiran), an siRNA for the treatment of acute hepatic porphyria (Figure 3). The 2′-*O*-Me modification is also present in ONPATTRO® (patisiran), the first FDA-approved RNAi therapeutic (2018), indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) . The delivery system for ONPATTRO is a lipid nanoparticle (LNP, Figure 2B). VITRAVENE, an antisense drug indicated for cytomegalovirus retinitis and the very first oligonucleotide therapeutic to receive clinical approval was a fully PS-modified 21mer oligo-2′-deoxynucleotide. These first-generation chemistries are still commonly encountered in the backbones of oligonucleotide therapeutic candidates that are currently in phase I to III clinical trials in the US. This is especially true for the phosphorothioates (PS-DNA/-RNA) but 2′-*O*-Me/2′-F modified oligonucleotides are also represented and include LEQVIO® (inclisiran, Figure 3 Table 1), an siRNA against hypercholesterolemia that was approved by regulators in the European Union in 2021 and the US FDA in 2022.

<span style=color:blue>2'-F和2'-O-Me修饰在马库根（MACUGEN）和GIVLAARI®（givosiran）等寡核苷酸治疗药物中具有重要作用，用于治疗湿性年龄相关性黄斑变性和急性肝性卟啉症的siRNA（图3）。2'-O-Me修饰物还存在于ONPATTRO®（patisiran）中，这是首个FDA批准的RNAi治疗药物（2018年），用于治疗遗传性转甲状腺素介导的淀粉样变性（hATTR）的多神经病。ONPATTRO的传递系统是脂质纳米粒（LNP，图2B）。反义药物VITRAVENE用于巨细胞病毒性视网膜炎，是第一个获得临床批准的全思环磷酸酯修饰的21肽联脲基-2'-脱氧核糖核酸寡核苷酸，这些第一代化学物质仍然普遍存在于当前在美国I至III期临床试验中的寡核苷酸治疗候选药物骨干中，尤其是磷酸硫酸酯（PS-DNA/-RNA），但2'-O-Me/2'-F修饰的寡核苷酸也有代表，并包括LEQVIO®（inclisiran）（图3，表1），这是一种用于治疗高胆固醇血症的siRNA，已被欧洲联盟监管机构于2021年批准，并于2022年获得美国FDA批准。</span>

图 3.

![Currently approved oligonucleotide drugs and mRNA vaccines, year of approval (between 1998 and 2022), and indication. From top left to bottom right: VITRAVENE®, MACUGEN®, KYNAMRO®, EXONDYS 51®, VYONDYS 53®, SPINRAZA®, HEPLISAV-B®, ONPATTRO®, TEGSEDI®, WAYLIVRA®, GIVLAARI®, OXLUMO®, VILTEPSO®, AMONDYS 45®, LEQVIO®, AMVUTTRA®, COMIRNATY® and SPIKEVAX®. The mechanisms of action are: antisense oligonucleotide (ASO), aptamer, splice-switching oligonucleotide (SSO), small interfering RNA (siRNA) and mRNA (vaccine).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig3.jpeg)

<span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>目前批准的寡核苷酸药物和 mRNA 疫苗、批准年份（1998 年至 2022 年）和适应症。 从左上到右下：VITRAVENE®、MACUGEN®、KYNAMRO®、EXONDYS 51®、VYONDYS 53®、SPINRAZA®、HEPLISAV-B®、ONPATTRO®、TEGSEDI®、WAYLIVRA®、GIVLAARI®、OXLUMO®、VILTEPSO®、 AMONDYS 45®、LEQVIO®、AMVUTTRA®、COMIRNATY® 和 SPIKEVAX®。 作用机制是：反义寡核苷酸（ASO）、适体、剪接转换寡核苷酸（SSO）、小干扰RNA（siRNA）和mRNA（疫苗）。</span>

**表 1.**

批准的基于寡核苷酸的疗法的总结

| ![graphic](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067figu18.jpeg) |
| ------------------------------------------------------------ |
| ![graphic](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067figu19.jpeg) |

Among second-generation antisense modifications, 2′-*O*-(2-methoxyethyl)-RNA (MOE-RNA) has emerged as the most successful chemistry (Figure 2A). The synthesis of MOE-modified building blocks and oligonucleotides was first reported in 1995 and MOE chemistry subsequently moved from bench to bedside within about 20 years (图1). The first of three MOE-based therapeutics approved by the FDA was KYNAMRO for the treatment of homozygous familial hypercholesterolemia (图3, 表1). The 20mer antisense oligonucleotide is an all-PS modified gapmer with a central DNA decamer gap and pentameric MOE flanks. The gapmer approach is needed to elicit RNase H, the endonuclease that cleaves the RNA target opposite the DNA window.

<span style=color:blue>在第二代反义修饰中，2'-O-(2-甲氧基乙基)-RNA（MOE-RNA）已成为最成功的化学修饰体系（图2A）。MOE修饰的构建块和寡核苷酸的合成于1995年首次报道，约20年后，MOE化学从实验室转移到临床（图1）。被FDA批准的三种基于MOE的治疗药物中，第一种是KYNAMRO，用于治疗家族性高胆固醇血症（图3，表1）。20mer 反义寡核苷酸是一种全 PS 修饰的Gapmer，具有中央 DNA 十聚体间隙和五聚体 MOE 侧翼。Gapmer方法需要引发RNase H，即裂解RNA靶标的内切酶，以发挥作用。</span>

SPINRAZA® (nusinersen) that was approved three years later acts via an entirely different mechanism (Figures 1and 3). The all-PS/MOE-modified RNA 18mer is used in the treatment of spinal muscular atrophy and modulates alternate splicing of the survival motor neuron 2 (*SMN2*) gene. The third therapeutic is TEGSEDI® (inotersen) that resembles KYNAMRO in that it is also a PS-modified 5-10-5 gapmer with MOE flanks and a central DNA gap. The drug was approved in 2018 for the treatment of the polyneuropathy in hereditary transthyretin-mediated amyloidosis. Lastly, another MOE based 5-10-5 gapmer, WAYLIVRA® (volanesorsen), was approved by the European Commission as an adjunct therapy to diet for treatment of a rare lipid disorder, familial chylomicronemia syndrome.

<span style=color:blue>SPINRAZA®（努西尼生）是三年后获批的一种通过完全不同机制起作用的药物（图1和3）。这种全PS/MOE修饰的RNA 18mer用于治疗脊髓性肌肉萎缩，并调节生存运动神经元2（*SMN2*）基因的可变剪接。第三种治疗药物是TEGSEDI®（依诺替生），它与KYNAMRO相似，也是一种PS修饰的5-10-5 Gapmer，在MOE侧翼和中央DNA间隙部分。该药物于2018年获批用于治疗遗传性甲状腺素介导的多神经病。最后，另一种基于MOE的5-10-5 Gapmer WAYLIVRA®（沃拉诺生）已获得欧洲委员会的批准，作为饮食辅助疗法用于治疗罕见的脂质紊乱症，家族性乳糜微粒增多症。</span>

An antisense-like approach similar to the one exemplified by SPINRAZA and using a splice-switching oligonucleotide that targets exon 51 of the dystrophin mRNA was pursued for treatment of certain forms of Duchenne muscular dystrophy (DMD). EXONDYS 51® (eteplirsen), a phosphorodiamidate morpholino (PMO)30mer with an uncharged backbone was approved in 2016 (Figures1, 2A and 3). Another PMO oligonucleotide, VYONDYS 53 (golodirsen), that targets exon 53 of the dystrophin transcript (about 8% of the DMD community) was approved by the FDA in 2019.

<span style=color:blue>对于治疗某些类型的杜氏肌营养不良症（Duchenne muscular dystrophy，DMD），采用与SPINRAZA类似的反义链方法，并使用针对dystrophin mRNA的外显子51的剪接切换寡核苷酸（splice-switching oligonucleotide）进行研究。EXONDYS 51®（埃特普利生）是一种磷酸二胺基甲酰吗啉（phosphorodiamidate morpholino，PMO）30mer，具有无电荷的骨架结构，于2016年获得批准（图1，2A和3）。另一种针对dystrophin转录本外显子53（约占DMD患者8%）的PMO寡核苷酸VYONDYS 53（戈洛地生）于2019年获得FDA批准。</span>

Over the course of the last 25 years, countless new nucleic acid modifications were introduced besides the first- and second-generation chemistries discussed above, and their activities have been evaluated at least in vitro. From the outset, it was clear that chemical modification of DNA and RNA was key to the successful therapeutic deployment of the antisense strategy, whereby increasing the binding affinity of the antisense oligonucleotide (ASO) was a particular concern. But there was an early recognition in the field that, besides affinity, multiple other hurdles needed to be overcome on the path to successful oligonucleotide drugs. These include chemical stability, resistance to degradation by a host of cellular exo- and endonucleases, i.e. metabolic stability, target site accessibility, delivery and biodistribution, i.e. binding to proteins and receptors, pharmacokinetics and pharmacodynamics as well as toxicity and complement activation.

<span style=color:blue>在过去的25年中，除了上述讨论的第一代和第二代化学修饰方法之外，还引入了无数种新的核酸修饰方法，并且它们的活性至少在体外得到了评估。从一开始就清楚，对DNA和RNA进行化学修饰对于成功应用反义链策略的治疗至关重要，其中提高反义链寡核苷酸（antisense oligonucleotide，ASO）的结合亲和力是一个特别关注的问题。但早期在这个领域就意识到，除了亲和力之外，在成功开发寡核苷酸药物的过程中还需要克服多个其他障碍。这些障碍包括化学稳定性，对多种细胞外核酸酶和内切酶的降解抵抗能力，即代谢稳定性，靶点位点的可接近性，输送和生物分布，即与蛋白质和受体的结合，药代动力学和药效学以及毒性和补体激活等。</span>

Looking back, it is quite extraordinary that the breakthroughs achieved in bringing 18 oligonucleotide (nucleic acids) drugs to market (Figure 3, Table 1) are chiefly based on just a handful of sugar and backbone modifications, namely the very early 2′-F, 2′-*O*-Me, and PS chemistries as well as the 2′-*O*-MOE RNA and neutral PMO backbone analogs (Figure 2A). We included two mRNA vaccines in Figure 3 although these are technically not oligonucleotides. However, these mRNAs also feature chemical modification (*N*-Me-pseudouridine, and 2′-*O*-Me in the cap, Figure 2A, and, like ONPATTRO, their delivery entails LNPs (Figure2B).

<span style=color:blue>回顾过去，令人难以置信的是，将18种寡核苷酸（核酸）药物推向市场的突破主要基于仅有的几种糖和骨架修饰，即早期的2'-F、2'-*O*-Me和PS化学修饰，以及2'-*O*-MOE RNA和中性PMO骨架模拟物（图2A）。尽管这两种mRNA疫苗在技术上并不是寡核苷酸，但我们在图3中包括了它们。然而，这些mRNA也具有化学修饰（*N*-Me-假尿苷和2'-*O*-Me在帽子上，图2A），并且像ONPATTRO一样，它们的传递涉及脂质纳米粒（LNPs）（图2B）。</span>

In this critical review and perspective article, we review the chemistries of FDA-approved antisense (ASO), splice-switching (SSO), small interfering RNAs (siRNAs) and aptamer oligonucleotides, and discuss properties of the 2′-F, 2′-*O*-Me, 2′-*O*-MOE, PS and PMO analogs that cemented their status as privileged modifications in oligonucleotide therapeutics. Particularly as far as the phosphorothioates are concerned, recent research has uncovered the origins of altered protein binding affinities and interaction modes as a consequence of replacing non-bridging phosphate oxygens by sulfur and cast a light on the benefits of stereopure PS modification. Another focus of this review concerns GalNAc conjugation chemistry for optimized delivery of oligonucleotides to liver (Figure 2B). GIVLAARI, LEQVIO, OXLUMO, and AMVUTTRA all employ GalNAc conjugation chemistry. For other summary articles, specifically regarding advances and challenges in the delivery of nucleic acid therapeutics, please see excellent recent reviews. Throughout this article we will refer to approved nucleic acid therapeutics with their US trade names.

<span style=color:blue>在这篇批判性评论和前瞻性文章中，我们回顾了FDA批准的反义寡核苷酸（ASO）、剪接转换寡核苷酸（SSO）、小干扰RNA（siRNA）和适配体寡核苷酸的化学特性，并讨论了2'-F、2'-*O*-Me、2'-*O*-MOE、PS和PMO模拟物的性质，这些模拟物巩固了它们作为寡核苷酸治疗中的特权修饰的地位。特别是对于磷酸硫酯化合物，最近的研究揭示了通过将非桥接磷酸氧原子替换为硫而导致的蛋白结合亲和性和相互作用模式变化的起源，并突显了立体纯的PS修饰的优点。本文的另一个重点是GalNAc连接化学在优化寡核苷酸递送到肝脏方面的应用（图2B）。GIVLAARI、LEQVIO、OXLUMO和AMVUTTRA都采用了GalNAc连接化学。关于核酸治疗递送方面的其他综述文章，请参阅出色的最新综述。在本文中，我们将使用美国的商标名称来指代已批准的核酸治疗药物。</span>

## OLIGONUCLEOTIDE THERAPEUTICS: TARGETS AND CHALLENGES 寡核苷酸治疗学：靶点与挑战

### Physicochemical properties of oligonucleotides 寡核苷酸的物理化学性质

DNA and RNA are polyanions and form duplexes that are held together by H-bonding and stacking interactions between nucleobases. Stacking is ultimately more important for pairing stability than H-bonds; the latter of course provide specificity. The core of a nucleic acid duplex is essentially hydrophobic as water molecules are squeezed out upon base pairs collapsing on each other (hydrophobic effect) . The negative charges of phosphates are dotting the outside and the grooves created by the two strands winding around each other represent regions of varying negative electrostatic potential. Metal ions such as Mg2+, Ca2+, Na+ and K+ provide neutralizing charges, whereby both a diffuse counterion atmosphere (e.g. around DNA) and specific metal ion binding sites (e.g. Mg2+ in RNA) affect folding and stability.

<span style=color:blue>DNA和RNA是聚阴离子，形成的双链由核碱基之间的氢键和堆积相互作用保持在一起。堆积相互作用对于配对稳定性比氢键更为重要，而氢键当然提供了特异性。核酸双链的核心基本上是疏水的，因为水分子在碱基对相互叠合时被挤压出去（疏水效应）。磷酸的负电荷分布在外部，两条链缠绕在一起形成的沟槽代表了具有不同负电静电势的区域。镁离子（如Mg2+）、钙离子（Ca2+）、钠离子（Na+）和钾离子（K+）提供了中和电荷，扩散的对离子环境（例如在DNA周围）和特定的金属离子结合位点（例如RNA中的Mg2+）影响折叠和稳定性。</span>

Cellular DNA is typically double-stranded and the pairing rules follow the Watson-Crick conventions, i.e. A:T and G:C. Conversely, RNA is single-stranded (tRNA, mRNA, rRNA), but folded RNAs exhibit extensive double-stranded regions. RNA duplexes are of the A-form with 11 base pairs per turn, a helical rise of <3 Å, and strongly inclined bases relative to the helical axis. RNA also displays tighter spacings between adjacent intra-strand phosphate groups compared to the physiological duplex type adopted by DNA, the so-called B-form. Base pairs in B-DNA are more or less normal to the direction of the helical axis, with an average rise of 3.4 Å and 10 base pairs per turn. DNA can also adopt the A-form and flip to left-handed Z-DNAas a result of torsional stress and dependent on sequence (CG-rich), ionic strengthand hydration level.

<span style=color:blue>细胞内的DNA通常是双链的，配对规则遵循Watson-Crick规范，即A:T和G:C。相反，RNA是单链的（tRNA，mRNA，rRNA），但折叠的RNA展示了广泛的双链区域。RNA双链属于A型结构，每个螺旋转数为11个碱基对，螺旋升高<3 Å，碱基相对于螺旋轴具有明显的倾斜角度。与DNA采用的生理双链结构（称为B型结构）相比，RNA在链内磷酸基团之间显示出更紧密的间距。B-DNA中的碱基对与螺旋轴的方向或多或少垂直，平均升高为3.4 Å，每个螺旋转数为10个碱基对。DNA也可以采用A型结构，并在扭曲应力和序列（CG富集）、离子强度和水合水平的影响下翻转为左旋Z-DNA。</span>

The most significant difference between the backbones of DNA and RNA is the presence of the 2′-hydroxyl group in the ribose sugar of the latter. The 2′-hydroxyl group prefers an axial orientation and steric and stereoelectronic effects result in the preferred C3′-*endo* sugar conformation or pucker. In contrast, 2′-deoxyriboses in B-form DNA adopt a C2′-*endo* pucke. The 2′-OH group affects not just conformation but also stability and the water structure around the duplex. RNA duplexes are more stable than DNA duplexes of the same sequence and the gain is enthalpy-driven.

<span style=color:blue>DNA和RNA骨架之间最显著的区别是后者的核糖糖基中存在2'-羟基。2'-羟基更倾向于轴向取向，并且由于空间位阻和立体电子效应，导致首选的C3'-endo糖构象或褶皱状态。相反，B型DNA中的2'-脱氧核糖糖采用C2'-endo褶皱构象。2'-羟基不仅影响构象，还影响双链周围的稳定性和水结构。相同序列的RNA双链比DNA双链更稳定，这种增益是由焓驱动的。</span>

Both DNA and RNA can also form three- and four-stranded structures (triplexes and quadruplexes, respectively). Although DNA is capable of forming complex 3D structures in principle, as exemplified by a catalytic motif and nanostructures, it is clearly outdone by RNA as far as complex folds are concerned. As with sugar conformation and thermodynamic stability, RNA’s folding repertoire is aided by a multitude of interactions that involve the 2′-hydroxyl group, e.g. ribose zippers. Moreover, RNA base pairing is more versatile than the strict pairings in DNA, and G:U, A:C and pyrimidine:pyrimidine and purine:purine pairs as well as base triples and quadruples are commonplace. The 2′-hydroxyl group also plays a key role in RNA function and phenotype; thus, is acts as the nucleophile in self-cleaving reactions.

<span style=color:blue>DNA和RNA也可以形成三股和四股结构（分别称为三股结和四股结）。虽然DNA原则上可以形成复杂的三维结构，如催化基序和纳米结构，但在复杂折叠方面明显不及RNA。与糖构象和热力学稳定性一样，RNA的折叠能力受到众多相互作用的帮助，其中包括涉及2'-羟基的核糖拉链。此外，RNA的碱基配对比DNA更加灵活，常见的有G:U、A:C以及嘧啶:嘧啶和嘌呤:嘌呤的配对，还有碱基三联体和四联体。2'-羟基在RNA的功能和表型中也起着关键作用，因此在自剪切反应中充当亲核试剂。</span>

More than 150 natural chemical modifications of RNA have been identified, among them 2′-*O*-methylation and complex decorations of nucleobases. It is now also recognized that DNA nucleobases are not limited to A, T, G and C, and that it is more appropriate to think of an expanded set of bases in the context of epigenetics. PS modifications have been established in the DNA of bacteria and archaea and they are exclusively of the *R*p configuration. However, the PS modification does not appear to exist naturally in RNA. DNA PS modification is regulated by the *Dnd* gene cluster.

<span style=color:blue>已经鉴定出150多种RNA的天然化学修饰，其中包括2'-*O*-甲基化和核碱基的复杂修饰。现在人们也认识到DNA的碱基不仅限于A、T、G和C，更适合在表观遗传学的背景下考虑扩展的碱基组。PS修饰已在细菌和古菌的DNA中得到确认，且仅为*R*p构型。然而，在RNA中并不存在自然的PS修饰。DNA的PS修饰受到*Dnd*基因簇的调控。</span>

In line with the above-described differences in structure, stability and function between DNA and RNA, the physicochemical properties of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are quite distinct (Figure 4). A single-stranded DNA ASO has a molecular weight of typically 7 kDa and a 20mer would carry 19 negative charges. The single strand has a width of ca. 1 nM and is relatively flexible with the hydrophobic faces of bases partly stacked but otherwise accessible for protein interactions. In contrast, a typical siRNA duplex has a molecular weight of ca. 13 kDa and carries 40 negative charges. The duplex is more rigid than an ASO single strand and has a diameter of ca. 2 nM, whereby bases are tucked away in the core with virtually no hydrophobic faces exposed except for the 2-residue overhangs at the 3′-ends. These different physical/chemical properties result in marked differences in pharmacokinetic profiles. They also lead to very different chemical modification strategies, although phosphorothioates and 2′-functionality are of general importance for modification.

<span style=color:blue>根据上述所描述的DNA和RNA之间的结构、稳定性和功能差异，反义寡核苷酸（ASO）和小干扰RNA（siRNA）的物理化学性质是相当不同的（图4）。单链DNA ASO的分子量通常为7 kDa，20个碱基组成的20mer带有19个负电荷。单链的宽度约为1纳米，相对灵活，碱基的疏水面部分堆叠，但也暴露于蛋白质相互作用。相比之下，典型的siRNA双链分子量约为13 kDa，带有40个负电荷。双链比ASO单链更为刚性，直径约为2纳米，碱基被紧密包裹在核心区域，除了3'端的2个残基外几乎没有暴露疏水面。这些不同的物理/化学性质导致药代动力学特性上的显著差异。它们还导致非常不同的化学修饰策略，尽管磷酸硫酯和2'-功能性修饰是普遍重要的修饰方式。</span>

**图4.**

![Structures and physicochemical properties of single-stranded DNA (top; 21mer PS-DNA based on the VITRAVENE sequence with random phosphorothioate stereochemistry) and double-stranded siRNA (bottom; 21mer based on the ONPATTRO sequence and modification chemistry). Nucleobase C, O and N atoms are highlighted in green and backbone carbon, oxygen, hydrogen, phosphorus and sulfur atoms are colored in gray, red, white, orange, and yellow, respectively. In the RNA duplex, residues of the sense strand are colored in magenta. In the antisense strand, carbon atoms of the 3′-terminal dTdT overhang and 2′-O-methyl modifications are highlighted in black and cyan, respectively. In the single stranded ASO bases are exposed. In contrast, bases are paired and buried inside the duplex in the double-stranded siRNA.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig4.jpeg)

<center><span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>单链DNA（顶部；基于VITRAVENE序列的21碱基磷酸硫酯DNA，具有随机的磷酸硫酯立体化学结构）和双链siRNA（底部；基于ONPATTRO序列和修饰化学的21碱基）的结构和物理化学性质。碱基C、O和N原子以绿色突出显示，骨架的碳、氧、氢、磷和硫原子分别以灰色、红色、白色、橙色和黄色着色。在RNA双链中，正链的残基以洋红色着色。在反义链中，3'端的dTdT外突和2'-O-甲基修饰的碳原子分别以黑色和青色突出显示。在单链ASO中，碱基是暴露的。相反，在双链siRNA中，碱基是成对的并埋藏在双链中。</span></center>

### Antisense modes of action 反义作用模式 

Rational or structure-based drug design requires knowledge of the 3D-structure of the target, typically an enzyme or a receptor. Screening of a compound library is used to identify initial leads and provides the starting point of an optimization via structure-activity relationships (SARs) that ideally results in a tightly binding candidate molecule for further *in vitro* and *in vivo* tests. But the path to a small-molecule drug is arduous, time-consuming and costly, and more often than not fails during the preclinical phase of the evaluation or later during the various phases of a clinical trial. The major attraction of the antisense strategy is that inhibition at the level of gene expression only requires knowledge of the targeted DNA or mRNA sequence. A 17mer oligonucleotide sequence is expected to occur only once in the human genome and the antisense approach therefore promises to be more efficient than the search for an enzyme inhibitor. Thus, therapeutic intervention at the nucleic acid level offers a rational path to drug discovery, whereby high specificity is afforded by Watson–Crick H-bonding interactions between ASO and target RNA.

<span style=color:blue>合理的或基于结构的药物设计需要对目标的三维结构有所了解，通常是酶或受体。通过化合物库的筛选，可以识别出最初的引物，并通过结构活性关系（SARs）进行优化，以获得更紧密结合的候选分子，以进一步进行体外和体内测试。然而，小分子药物的开发过程艰难、耗时且昂贵，往往在临床前评估阶段或临床试验的各个阶段中失败。反义策略的主要吸引力在于，在基因表达水平上的抑制仅需要对目标DNA或mRNA序列有所了解。人类基因组中预计只会出现一次的17碱基寡核苷酸序列，因此反义方法比寻找酶抑制剂更有效。因此，在核酸水平上进行治疗干预为药物发现提供了一条理性的路径，其中通过ASO和靶标RNA之间的Watson-Crick H键相互作用实现高度特异性。</span>

Although knowledge of the target sequence readily enables the design of an ASO, it is important to bear in mind that RNA molecules don’t exist as random coils. Because RNAs adopt intricate folds and are commonly decorated by proteins, many regions along the target sequence may be inaccessible to an ASO. Although efforts were made to predict sites on an RNA that allow ASO binding, an oligonucleotide screen—basically covering a large portion of the entire transcript with individual ASOs, e.g. 5′-UTR and 3′-UTR (Figure 5)—to identify the most active oligo in cell culture offers a more viable approach. In a very recent example of an oligo screen, Alnylam researchers synthesized 350 siRNAs against all available RNA genomes of SARS-CoV and SARS-CoV-2.

<span style=color:blue>尽管对目标序列的了解可便利地实现反义寡核苷酸（ASO）的设计，但需要注意的是RNA分子并不以随机卷曲形式存在。由于RNA能够形成复杂的结构并常常与蛋白质相互作用，目标序列中的许多区域可能对ASO不可及。尽管已经努力预测RNA上允许ASO结合的位点，但通过对细胞培养中的每个ASO进行全面筛选（例如涵盖整个转录本的5'-UTR和3'-UTR区域，图5），可以获得更可行的方法。在最近的一个ASO筛选示例中，Alnylam的研究人员合成了350个针对SARS-CoV和SARS-CoV-2的所有可用RNA基因的siRNA。</span>

**图 5.**

![Cartoon of combined ASO mechanisms of action vis-à-vis an mRNA target, either in the nucleus or cytoplasm of the cell: (1) Eliciting RNase H with subsequent degradation of the target, (2) translation arrest, i.e. steric blockage and (3) modulation of splicing. mRNA regions include 5′-cap and 5′-untranslated region (5′-UTR), coding region, 3′-UTR and poly-A tail.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig5.jpeg)

<center><span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>核酸药物对mRNA靶点在细胞核或细胞质中的综合作用机制的示意图：(1) 通过激活RNase H并随后降解目标物，(2) 翻译阻断，即立体阻塞，以及 (3) 调控剪接。mRNA区域包括5'-帽子和5'-非翻译区 (5'-UTR)、编码区、3'-非翻译区和多聚A尾巴。</span></center>

For the further discussion of oligonucleotide therapeutics, it is helpful to properly define an ASO. It is a single stranded oligonucleotide that pairs with a complementary region on an RNA via Watson–Crick H-bonds and then acts, for example, via a steric block, splice site shifting or RNase-H mediated RNA degradation mechanism (Figure 5). On one hand, this contrasts with the antigene approach that targets DNA and functions via triplex formation, single-stranded decoys, and aptamers directed at DNA, RNA or proteins. On the other hand, double-stranded RNA molecules (siRNAs, ribozymes, and synthetic oligo metallonucleases all function via the antisense mechanism as well, although they are not typically referred to as ASOs.

<span style=color:blue>为了进一步讨论寡核苷酸治疗药物，正确定义ASO是很有帮助的。ASO是一种单链寡核苷酸，通过Watson-Crick H键与RNA上的互补区域配对，然后通过立体阻断、剪接位点移位或RNase-H介导的RNA降解机制等方式发挥作用（图5）。一方面，这与靶向DNA并通过三链形成、单链诱饵和针对DNA、RNA或蛋白质的适配体等机制发挥作用的抗基因方法形成对比。另一方面，双链RNA分子（siRNA、核酶和合成寡核苷酸金属核酸酶）也通过反义机制发挥作用，尽管它们通常不被称为ASO。</span>

Perhaps categorizing antisense mechanisms is more useful than focusing on definitions that concern the oligonucleotides themselves. Thus, one can distinguish between mechanisms that involve binding and modulation of function without resulting in degradation of the target and others that promote cleavage of the targeted sequence. The former includes translation arrest, inhibition of translation initiation, inhibition of exon inclusion, promotion of exon inclusion, RNA antagonists (antagomirs), RNA agonists and disruption of RNA structure. Mechanisms that result in degradation of the targeted RNA can involve RNase H (elicited by an ASO), Argonaute2 (Ago2; RNAi), microRNA (miRNA; P-body and Ago proteins), U1 RNA adaptors and various catalytic motifs as well as chemically facilitated nucleases. Both RNase H and Ago2 are endogenous factors that play roles in natural pathways. A key difference between the actions of the two nucleases is that an ASO is bound to its RNA target prior to RNase H docking and cleavage. Conversely, the guide or antisense siRNA forms a complex with Ago2 before the enzyme interacts with the target.

<span style=color:blue>也许将反义机制进行分类比关注于寡核苷酸本身的定义更有用。因此，可以区分涉及结合和调控功能而不导致目标降解的机制，以及促进目标序列的切割的机制。前者包括翻译抑制、翻译起始抑制、外显子包含的抑制、外显子包含的促进、RNA拮抗物（antagomirs）、RNA激动物和RNA结构破坏。导致目标RNA降解的机制可能涉及RNase H（由ASO引发）、Argonaute2（Ago2；RNA干扰）、microRNA（miRNA；P体和Ago蛋白）以及U1 RNA适配体、各种催化基序和化学辅助核酸酶。RNase H和Ago2都是在自然途径中发挥作用的内源因子。两个核酸酶之间的关键区别在于，在RNase H结合和切割之前，ASO已经与其RNA靶点结合。相反，引导或反义siRNA在酶与靶点相互作用之前与Ago2形成复合物。</span>

In this context, it is interesting to consider the evolution of our understanding of nucleic acid hybridization. As recounted by Alexander Rich, when he and David Davies demonstrated the spontaneous formation of a duplex by poly-A and poly-U, the observation was widely greeted with skepticism as many believed that a double helix could only be ‘made’ by an enzyme. The question therefore arises whether there are cellular factors that promote the hybridization of an ASO to its target? Indeed, it was reported that RNA binding proteins such as hnRNP A1 and YB1 significantly facilitate the hybridization of an oligonucleotide to RNA.

<span style=color:blue>在这个背景下，考虑到我们对核酸杂交的理解是如何发展的是很有意思的。正如亚历山大·里奇（Alexander Rich）回忆的那样，当他和大卫·戴维斯（David Davies）展示了聚A和聚U之间自发形成双链的现象时，这一观察结果受到了广泛的怀疑，因为许多人认为双螺旋结构只能由酶“制造”。因此，问题出现了：是否存在促进ASO与其靶点杂交的细胞因子？事实上，有报道称RNA结合蛋白如hnRNP A1和YB1显著促进寡核苷酸与RNA的杂交。</span>

Finally, in terms of a classification of antisense mechanisms and ASOs, it is important to distinguish cellular localizations, i.e. nucleus vs. cytoplasm . Thus, ASOs that modulate splicing, for example, by exon inclusion (SPINRAZA) or exon skipping (EXONDYS 51) act in the nucleus, whereas ASOs eliciting RNase H can operate either in the nucleus or in the cytoplasm. Subcellular localization of an ASO can affect its potency and the particular chemical makeup of an ASO impinges on its intracellular distribution.

<span style=color:blue>最后，在对反义机制和ASO进行分类时，区分细胞定位，即细胞核与细胞质，是非常重要的。因此，调控剪接的ASO（例如SPINRAZA通过外显子包含或EXONDYS 51通过外显子跳跃）作用于细胞核，而引发RNase H的ASO可以在细胞核或细胞质中发挥作用。ASO的亚细胞定位可以影响其效力，而ASO的化学成分也会影响其细胞内分布。</span>

The last point about an ASO’s chemistry having an effect on biodistribution is really an understatement as the chemical composition of an oligo affects pairing stability, metabolic stability, protein binding and toxicities caused by binding to Toll-like receptors, altered coagulation, immune cell and/or complement activation, off-target effects, pharmacokinetics and pharmacodynamics. Native DNA and RNA oligonucleotides are degraded rapidly in cells as they are unable to dodge attack by a host of exo- and endonucleases. RNA and RNA-like analogs exhibit higher pairing stability opposite RNA targets than DNA or DNA-like analogs. However, despite RNase H binding to both DNA and RNA duplexes, neither elicits enzyme action as the endonuclease recognizes a hybrid duplex in which the RNA is in the A-form and the DNA is in a B-like conformation.

<span style=color:blue>关于ASO的化学组成对生物分布产生影响的观点确实是一种低调的陈述，因为寡核苷酸的化学组成会影响配对稳定性、代谢稳定性、蛋白结合以及与Toll样受体结合引起的毒性、凝血功能改变、免疫细胞和/或补体激活、非靶效应、药代动力学和药效动力学。原生DNA和RNA寡核苷酸在细胞内很快被外切酶和内切酶降解，无法抵御这些酶的攻击。RNA和类似RNA的模拟物与RNA靶点形成的配对稳定性较DNA或类似DNA的模拟物更高。然而，尽管RNase H能够结合DNA和RNA双链，但它们都不能引发酶的作用，因为内切酶只识别呈A形态的RNA、呈B形态的DNA杂交双链。</span>

Uniform locked nucleic acids (LNAs) exhibit very high binding affinity for both DNA and RNA , but they also produce increased liver toxicity. Perhaps unexpectedly, uncharged peptide nucleic acids (PNAs) do not easily cross cell membranes, although the solubility can be increased with amino acids carrying charges in the PNA backbone. And, unlike PS-DNAs, PNA, PMO and regular phosphodiester-backbone oligonucleotides exhibit limited binding to plasma proteins, causing them to be rapidly excreted in the urine. Interestingly, the stabilin class of scavenger receptors has been shown to bind to PS-ASOs and aid in their cellular internalization. All these tidbits aim to illustrate that making drugs out of oligonucleotides is not easy and that modification chemistry was and remains crucial for overcoming numerous challenges on the way to nucleic acid therapeutics.

<span style=color:blue>均一锁核酸（LNA）对DNA和RNA具有非常高的结合亲和力，但也会导致肝脏毒性增加。或许出人意料的是，尽管通过在PNA骨架中引入带电氨基酸可以增加其溶解性，但无电荷的肽核酸（PNA）仍不容易穿过细胞膜。与PS-DNA不同，PNA、PMO和普通磷酸二酯骨架寡核苷酸与血浆蛋白的结合有限，导致它们在尿液中迅速排出。有趣的是，已经证明清道夫受体的稳定蛋白类可以与PS-ASO结合并有助于其细胞内摄取。所有这些细节都旨在说明将寡核苷酸转化为药物并非易事，而改性化学在克服通往核酸治疗的众多挑战中至关重要。</span>

## SIMPLE BEGINNINGS: PHOSPHOROTHIOATES AND VITRAVENE 简单的起点：磷酸硫酸酯和VITRAVENE

VITRAVENE (fomivirsen) was the first antisense therapeutic approved by the FDA, and the only antiviral oligonucleotide-based drug brought to market to date. Several ongoing clinical trials in various phases are assessing the efficacy of oligonucleotides against HBV and HCV targets and there is continued interest in the antimicrobial antisense therapeutic platform. VITRAVENE was a 21mer phosphorothioate oligo-2′-deoxynucleotide (PS-DNA; Figures 4, 6) that binds to the complementary mRNA sequence of major immediate-early region (IE2) proteins of human cytomegalovirus (CMV), thereby inhibiting replication of the virus. The drug was administered intravitreally to delay progression of CMV retinitis in AIDS patients. In immunocompromised individuals this disease leads to loss of retinal cells and eventually vision. In cell culture, the ASO was demonstrated to reduce immediate-early protein synthesis in CMV-infected dermal fibroblasts in a dose-dependent fashion. Fomivirsen also showed activity against drug-resistant mutants of the virus in vitro and combinations of fomivirsen with the antiviral drugs ganciclovir or foscarnet resulted in additive anti-CMV activity. Studies of the pharmacokinetic parameters of fomivirsen in non-human primates established half-lives of its elimination from the vitreous and retina of 22 and 78 h, respectively. This clearance occurred because of the distribution of the drug to other ocular tissues and some chain shortening was most consistent with exonuclease degradation. Fomivirsen was not detected in the plasma of either animals or patients, indicating that there was no appreciable systemic exposure to the oligonucleotide.

<span style=color:blue>VITRAVENE（fomivirsen）是首个获得FDA批准的反义治疗药物，也是迄今为止唯一一种上市的基于寡核苷酸的抗病毒药物。目前有多项不同阶段的临床试验正在评估寡核苷酸针对乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）靶点的疗效，并且对抗微生物的反义治疗平台仍然存在着持续的兴趣。VITRAVENE是一种21碱基磷酸硫酯寡聚-2'-脱氧核苷酸（PS-DNA；见图4、6），它与人巨细胞病毒（CMV）主要即刻早期区（IE2）蛋白的互补mRNA序列结合，从而抑制病毒的复制。该药物通过玻璃体内给药以延缓AIDS患者CMV视网膜炎的进展。在免疫功能受损的个体中，该疾病会导致视网膜细胞丧失，最终影响视力。在细胞培养中，该反义寡核苷酸被证明可以剂量依赖性地降低CMV感染皮肤成纤维细胞中即刻早期蛋白的合成。Fomivirsen还显示出对病毒耐药突变株的体外活性，并且与抗病毒药物甘西奇洛韦或福斯卡尼特的联合应用具有协同的抗CMV活性。对非人灵长类动物的Fomivirsen药代动力学参数的研究确定了其从玻璃体和视网膜中消除的半衰期分别为22小时和78小时。这种清除是由于药物分布到其他眼部组织以及某种链缩短，最符合外切酶降解的情况。Fomivirsen在动物和患者的血浆中均未检测到，表明该寡核苷酸几乎没有体内系统暴露。</span>

**图 6.**

![VITRAVENE chemistry and mode(s) of action. Top: ASO sequence and chemical modification; yellow bars indicate phosphorothioate moieties and CpG steps are marked with a red bar. Bottom: individual steps in the ASO’s mechanism of action from cellular uptake to target degradation.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig6.jpeg)



<center><span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>VITRAVENE的化学特性和作用模式。顶部：反义寡核苷酸（ASO）序列和化学修饰；黄色条表示磷酸硫酯基团，红色条表示CpG位点。底部：ASO作用机制的各个步骤，包括细胞内摄取到靶标降解。</span></center>

At the time VITRAVENE was approved, antisense drug discovery and the utility of ASOs as pharmaceutical agents were viewed with skepticism by many . The 21mer PS-DNA shares none of the features of a typical small-molecule drug; it carries 20 negative charges and is actually a mixture of 220*R*p- and *S*p-PS diastereoisomers (Figures and 7A). The main mechanism of action is by RNase H-mediated degradation (Figure 6); at higher concentration of the oligo binding to viral coat proteins was suggested, although this non-antisense mode of action did not contribute to its activity. Similarly, there is no evidence that VITRAVENE is cleared by oxidative metabolic pathways (i.e. P450 enzymes). Oligo PS-DNAs bind to plasma proteins (mainly albumin and α2-macroglobulin), and are cleared from plasma by dose-dependent distribution to various tissues and nuclease metabolism with only minor excretion in urine or feces.

<span style=color:blue>在VITRAVENE获得批准时，许多人对反义药物的发现以及ASO作为药物的实用性持怀疑态度。这种21mer PS-DNA没有典型小分子药物的特征；它带有20个负电荷，实际上是220个*R*p-和*S*p-PS对映异构体的混合物。其主要作用机制是通过RNase H介导的降解（图6）；在较高浓度下，该寡核苷酸与病毒外壳蛋白结合的机制也被提出，尽管这种非反义作用方式并未对其活性产生贡献。类似地，没有证据表明VITRAVENE通过氧化代谢途径（即P450酶）清除。寡核苷酸PS-DNA与血浆蛋白（主要是白蛋白和α2-巨球蛋白）结合，通过剂量依赖的分布到各种组织和核酸酶代谢从血浆中清除，只有少量通过尿液或粪便排出。</span>

**图 7.**

![(A) Phosphorothioates are first-generation ASO modifications. Structures of the phosphate (left), Sp-phosphorothioate (Sp-PS, center) and Rp-phosphorothioate (Rp-PS, right) backbones. R = H (DNA), R = OH (RNA), R = F (2′-F RNA), and R = OMe (2′-O-Me RNA). (B) First- and second-generation RNA modifications. PS (X = S) is important both for ASOs and SSOs and can be combined with 2′-modifications. PS, 2′-O-Me and 2′-F are initial RNAi modifications, and 2'-O-MOE is prominently represented in ASOs and SSOs. Advantages of RNA 2′-modifications are affinity, nuclease resistance and chemical and metabolic stability, and modulation of hydration and protein binding.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig7.jpeg)



<center><span style=background:#eef0f4;font-family:楷体;font-size:16px;text-align:center>(<span style=font-weight:bold>A</span>) 磷酸硫酯是第一代ASO修饰。左图为磷酸盐的结构，中图为*S*p-磷酸硫酯（*S*p-PS），右图为*R*p-磷酸硫酯（*R*p-PS）。其中R = H（DNA），R = OH（RNA），R = F（2'-F RNA），R = OMe（2'-*O-*Me RNA）。<br><span style=font-weight:bold>B</span>第一代和第二代RNA修饰。PS（X = S）对ASOs和SSOs都很重要，并且可以与2'-修饰结合使用。PS、2'-*O*-Me和2'-F是最早的RNAi修饰，而2'-*O*-MOE在ASOs和SSOs中占据重要地位。RNA 2'-修饰的优势包括亲和力、核酸酶抗性、化学和代谢稳定性，以及调节水合和蛋白结合。</span></center>

One of the attractive features of the PS modification compared to the parent phosphodiester-based oligonucleotides is the enhanced nuclease resistance. The susceptibility to attack by nucleases differs for the two stereoisomers. Thus, snake venom phosphodiesterase (SVPD, 3′-exonuclease) degrades the *R*p PS isomer more rapidly than the *S*p isomer. Crystal structures of DNA polymerase I Klenow fragment exonuclease in complex with short PS-modified oligos demonstrated that the *S*p-PS modification affords better protection. Accordingly, the sulfur atom of that isomer intrudes into the coordination sphere of one of the two metal ions bound at the active site. By comparison, the endonucleases DNase I, S1 and P1 all prefer the *S*p- over the *R*p-PS isomer.

<span style=color:blue>与磷酸二酯基寡核苷酸相比，PS修饰的一个吸引人的特点是增强的核酸酶抗性。两个立体异构体对核酸酶的敏感性不同。例如，蛇毒磷酸二酯酶（SVPD，3'-外切酶）比较快速地降解*R*p-PS异构体，而比较慢地降解*S*p-PS异构体。晶体结构显示，DNA聚合酶I Klenow片段外切酶与短的PS修饰寡核苷酸结合时，*S*p-PS修饰提供了更好的保护效果。因此，该异构体的硫原子侵入到活性位点结合的两个金属离子的配位球中。相比之下，内切酶DNase I、S1和P1都更倾向于*S*p-PS异构体而非*R*p-PS异构体。</span>

Unfortunately, in light of the fact that *S*p PS-DNA is more resistant to attack by 3′-exonuclease, this isomer forms thermodynamically less stable duplexes with complementary RNA than the *R*p isomer. Incorporation of PS modifications with mixed stereochemistry into a DNA reduces the melting temperature Tm of the duplex with RNA by about 1°C per modification relative to the parent hybrid. Since the reduction in stability is greater for PS-modified A:T pairs than G:C pairs, a high GC content of PS-DNA oligos may be desirable for biological applications. However, the demonstration that RNase H activity with PS-DNA:RNA hybrids exceeds considerably that vis-à-vis all-phosphodiester hybrid duplexes is perhaps more important in this regard.

<span style=color:blue>不幸的是，考虑到*S*p-PS-DNA更不易受到3'-外切酶的攻击，与*R*p异构体相比，该异构体与互补的RNA形成的双链结构在热力学上更不稳定。将混合立体化学结构的PS修饰引入到DNA中，相对于纯正的杂交结构，每个修饰会使与RNA形成的双链的解链温度Tm降低约1°C。由于PS修饰对A:T碱基对的稳定性降低大于G:C碱基对，因此在生物应用中，PS-DNA寡核苷酸具有较高的GC含量可能是可取的。然而，与所有磷酸二酯杂交双链相比，显示出PS-DNA:RNA杂交双链的RNase H活性明显增强，这方面可能更为重要。</span>

PS oligonucleotide-associated toxicities and immune-stimulation have been analyzed in detail. In the case of the VITRAVENE 21mer PS-ASO it is clear that the antiviral activity did not arise as result of immune stimulation by the two CpG motifs (Figure 6) in the sequence. Thus, methylation of the cytosines in the CpG dimers did not lead to a reduction in the antiviral activity and an ASO mechanism remains the most plausible mode of action by VITRAVENE . Ultimately, the drug was taken off the US market in 2006 as the development of highly active antiretroviral therapies led to a reduced number of CMV cases.

<span style=color:blue>PS寡核苷酸相关的毒性和免疫刺激已经被详细分析。对于VITRAVENE的21mer PS-ASO，明确的是其抗病毒活性并非由序列中的两个CpG结构（图6）引起的免疫刺激导致。因此，在CpG二聚体中的胞嘧啶进行甲基化并未导致抗病毒活性的降低，因此ASO机制仍然是VITRAVENE最合理的作用方式。最终，该药物在2006年从美国市场撤出，因为高效抗逆转录病毒治疗的发展导致CMV病例数量减少。</span>

## SECOND-GENERATION MODIFICATIONS 第二代修饰

### Conformational preorganization and gapmer approach 空间预组织和间隔核苷酸策略

The RNA 2′-hydroxyl group shifts the conformational equilibrium of the sugar ring to the so-called *North* or C3′-*endo* conformation. There is a linear correlation between the electronegativity of the 2′-substituent and the ratio between the *North*/*South* sugar conformations. Although C3′-*endo* is the pucker mode preferred by ribonucleotides, the sugar is by no means frozen and RNA nucleotides (e.g. in tRNA) adopt a *Southern* conformation on occasion. In 2′-*O*Me-RNA and 2′-F-RNA (Figure 7B) the gauche effect between 2′-substituent and O4′ is maintained and both exhibit a preference for the C3′-*endo* sugar conformation. These analogs paired opposite RNA increase the thermodynamic stability of the resulting duplex compared with native RNA. The methyl moiety in 2′-*O*Me-RNA points into the minor groove and the C3′–C2′–O2′–Me torsion angle is always in the antiperiplanar range. DNA sugars favor the *South* or C2′-*endo* conformation, but the conformational equilibrium can be shifted to the C3′-*endo* pucker by altering the gauche effect between O3′ and O4′. Thus, the 3′-methylene and N3′→P5′ phosphoramidate DNA analogs mimic RNA and prefer the C3′-*endo* sugar pucker.

<span style=color:blue>RNA的2'-羟基团将糖环的构象平衡转移到所谓的"北"或C3'-内型构象。2'-取代基的电负性与"北"/"南"糖构象比之间存在线性相关性。虽然C3'-内型是核糖核苷酸首选的褶曲方式，但糖并不是冻结的，RNA核苷酸（例如在tRNA中）偶尔也会采用"南"构象。在2'-*O*Me-RNA和2'-F-RNA（图7B）中，2'-取代基和O4'之间的手性效应得到保持，并且两者都倾向于C3'-内型糖构象。这些类似物与RNA相互配对时，与天然RNA相比，形成的双链具有更高的热力学稳定性。2'-*O*Me-RNA中的甲基基团指向小凹槽，C3'-C2'-O2'-Me扭转角始终在反位构型范围内。DNA糖偏好于"南"或C2'-内型构象，但可以通过改变O3'和O4'之间的手性效应将构象平衡转移到C3'-内型褶曲。因此，3'-亚甲基和N3'→P5'磷酸酰胺酯DNA类似物模拟RNA，并倾向于C3'-内型糖褶曲。</span>

In chimeric RNA-DNA oligonucleotides, ribonucleotides can conformationally dominate the DNA portion to various degrees. We and others found in crystal structures that a single or a few ribonucleotides can flip a 10mer DNA duplex into the A-form. It is possible that this effect is influenced by lattice forces and dehydration as well as sequence, as the degree of conformational dominance appears to be different in solution. Also, in the crystal structure of the duplex [d(CGCGAA)-U*U*-d(CGCG)]2 with 2′-*S*Me-U (U*), only underlined nucleotides adopt a C3′-*endo* sugar pucker. Neighboring 2′-deoxyadenosines retain a C2′-*endo* pucker and the RNA-like modified uridines in the center force just the 3′-adjacent cytidine into a *North* conformation. As a result of the sugar pucker switch from *South* to *North* and back to *South* due to the presence of the 2′-*S*Me substituents, the minor groove in the center of the duplex widens significantly relative to the parent DNA duplex. The EcoRI restriction endonuclease cleaves the all-DNA strand between G and A (bold font) in the recognition sequence 5′-**GA**ATTC-3′/3′-CTTA**AG**-5′. However, when either one of the Ts or both are replaced by 2′-*S*eMe-U endonuclease activity is completely abolished, thus demonstrating that nucleic acid-binding and/or processing proteins are sensitive to local changes in backbone geometry and duplex conformation.

<span style=color:blue>在嵌合的RNA-DNA寡核苷酸中，核糖核苷酸可以以不同程度对DNA部分产生构象上的优势。我们和其他研究人员在晶体结构中发现，少量核糖核苷酸可以将一个10碱基的DNA双链转变为A形构象。这种效应可能受到晶格力和脱水以及序列的影响，因为在溶液中构象优势的程度似乎是不同的。此外，在[d(CGCGAA)-U*U*-d(CGCG)]2的晶体结构中，使用2'-*S*Me-U（U*）替代的核苷酸仅有下划线下的核苷酸采用C3'-内型糖褶曲。相邻的2'-去氧腺苷保持C2'-内型褶曲，而中间的类似RNA修饰的尿苷使得3'-相邻的胞苷转为"北"构象。由于存在2'-*S*Me取代基，糖褶曲从"南"到"北"再到"南"的转变，使得双链中心的小凹槽相对于亲本DNA双链显著加宽。EcoRI限制内切酶在识别序列5'-**GA**ATTC-3'/3'-CTTA**AG**-5'中的G和A之间（粗体字）切割全DNA链。然而，当一个或两个胸腺嘧啶被2'-*S*eMe-U替代时，内切酶活性完全消失，从而证明核酸结合和/或处理蛋白对于背骨几何和双链构象的局部变化非常敏感。</span>

The nucleotide sugar pucker is also a key determinant of the catalytic efficiency with which DNA polymerases (pols) incorporate dNTPs into the growing chain, whereby preferences vary widely among different pols. DNA primer insertion and extension assays using dATP analogs with methanocarba bicyclo[3.1.0]hexane sugar scaffolds that lock the pucker either in the North C2′-*exo* or South C3′-*exo* forms (N-MC-dATP and S-MC-dATP, respectively) identified distinct behaviors by so-called Y-family error bypass pols. Interestingly, given that they are DNA pols, human pol *η*, *κ* and *ι* all preferably or exclusively incorporate N-MC-dATP. In the steady-state kinetic analysis, the efficiency (*k*cat/*K*m) relative to incorporation of dATP was decreased 4-fold (pols *η* and *κ*) and increased 5-fold (pol *ι*). Neither pol *κ* nor pol *ι* were able to incorporate S-MC-dATP, but the former could at least extend from the N-MC-dA nucleotide. Conversely, pol *η* was able to also incorporate S-MC-dATP, albeit with an 80-fold decreased efficiency relative to dATP, and to extend from both the N- and S-MC-dA nucleotides. As expected, HIV reverse transcriptase preferred N-MC-dATP and the efficiency of incorporation was unchanged relative to that of dATP.

<span style=color:blue>核苷酸糖褶皱也是决定DNA聚合酶（pol）催化效率的关键因素之一，这些酶将dNTPs插入到增长的链中，不同的pol在偏好方面存在广泛差异。使用将糖褶皱锁定在北C2'-外型或南C3'-外型形式（分别为N-MC-dATP和S-MC-dATP）的甲基卡巴碳桥[3.1.0]己烷糖支架的dATP类似物进行DNA引物插入和延伸实验，发现所谓的Y家族错误旁路聚合酶表现出不同的行为。有趣的是，尽管它们是DNA聚合酶，但人类pol *η*、*κ*和*ι*都更倾向于或专门插入N-MC-dATP。在稳态动力学分析中，相对于dATP的插入效率（*k*cat/*K*m）下降了4倍（pol *η*和*κ*），增加了5倍（pol *ι*）。无论是pol *κ*还是pol *ι*都无法插入S-MC-dATP，但前者至少能从N-MC-dA核苷酸延伸。相反，pol *η*也能够插入S-MC-dATP，尽管相对于dATP而言效率降低了80倍，并且能够从N-MC-dA和S-MC-dA核苷酸进行延伸。正如预期的那样，HIV逆转录酶更倾向于N-MC-dATP，其插入效率相对于dATP没有变化。</span>

The distinct behaviors of the DNA pols vis-à-vis nucleotides of opposite puckers were also seen with the B-family Dpo1 and Y-family Dpo4 pols from the archaeal hyperthermophile *Sulfolobus solfataricus*. Thus, the former inserts both the N- and S-MC-dATPs with relatively minor reductions in efficiency, whereas the latter only inserts N-MC-dATP. Dpo4 was then unable to extend; extensions by Dpo1 from the MC-dA nucleotides were inhibited in both cases relative to dA, whereby incorporation following S-MC-dA was slightly favored. The tolerance toward both fixed conformation nucleotide analogs exhibited by human pol *η* foreshadowed the enzyme's ability to incorporate ribonucleotide triphosphates relatively efficiently, act as a reverse transcriptase, accommodate RNA for strand extension, and bind to DNA–DNA, DNA–RNA and RNA–RNA duplexes with similar affinities.

<span style=color:blue>在古细菌超热嗜好菌*Sulfolobus solfataricus*的B家族Dpo1和Y家族Dpo4聚合酶中，对于具有不同糖褶皱的核苷酸，也观察到了不同的行为。因此，前者插入N-MC-dATP和S-MC-dATP时的效率略有降低，而后者仅插入N-MC-dATP。然后，Dpo4无法进行延伸；Dpo1在两种情况下从MC-dA核苷酸的延伸相对于dA受到抑制，而在插入S-MC-dA后稍微偏好于插入。人类pol *η*对于固定构象的核苷酸类似物的耐受性预示了该酶相对高效地插入核糖核苷酸三磷酸盐，作为逆转录酶的功能，容纳RNA进行链延伸，并与DNA-DNA、DNA-RNA和RNA-RNA双链具有类似的亲和力结合。</span>

RNase H also displays affinity for all three duplex types as well as for single strands, but it binds DNA–RNA hybrid and RNA duplexes ca. 60-fold more tightly than DNA duplexes and ca. 300-fold more tightly than single stranded nucleic acids. However, as indicated before the enzyme only processes the RNA strand opposite DNA, although it is noteworthy that RNase HI from the thermoacidophilic archaeon *Sulfolobus tokodaii* was reported to cleave RNA strands opposite either DNA or RNA. RNase H and Ago2—the former targeting RNA opposite antisense DNA, the latter RNA opposite antisense (guide) RNA—catalyze the same reaction, namely phosphodiester hydrolysis via a dual metal ion mechanism that results in formation of two strands, one with a free 3′-hydroxyl group and the other with a 5′-phosphate group  (Figure 8A). The PIWI domain that harbors the RNA endonuclease activity in Ago2 also adopts an RNase H-type fold (Figure 8B).

<span style=color:blue>RNase H对三种双链结构以及单链结构都表现出亲和力，但它与DNA-RNA杂交和RNA双链结构的结合强度约为DNA双链结构的60倍，单链核酸的结合强度约为300倍。然而，正如之前所提到的，该酶只处理与DNA相对的RNA链，尽管值得注意的是，来自热酸性嗜好古菌*Sulfolobus tokodaii*的RNase HI据报道能够切割与DNA或RNA相对的RNA链。RNase H和Ago2（前者靶向反义DNA对位的RNA，后者靶向反义（引导）RNA对位的RNA）催化相同的反应，即通过双金属离子机制进行磷酸二酯水解，形成两条链，一条具有自由的3'-羟基，另一条具有5'-磷酸基团（图8A）。在Ago2中承载RNA内切酶活性的PIWI结构域也采用了RNase H类型的折叠结构（图8B）。</span>

**图 8.**

![(A) Phosphodiester cleavage reaction catalyzed by RNase H and Ago2. (B) Overlay of the crystal structures of B. halodurans (Bh) RNase H (light-blue ribbon cartoon) bound to a DNA (light-blue carbon atoms)-RNA (pink carbon atoms) hybrid (PDB ID 1zbi), and human Ago2 (Piwi domain; tan ribbon cartoon) bound to a passenger strand (tan carbon atoms)-guide strand (brown carbon atoms) duplex (PDB ID 4w5t). Mg2+ ions seen in RNase H complex are green spheres and 2′-OH oxygens are red spheres. Only protein atoms were used to superimpose the two complexes: RNase H E66–G194; Piwi Q589–Y790. (C) Overlay of the crystal structures of BhRNase H (light-blue ribbon cartoon) bound to a DNA (light-blue carbon atoms)–RNA (pink carbon atoms) hybrid (PDB ID 1zbi) and BhRNase H bound to DNA dodecamer duplex (tan ribbon cartoon; PDB ID 3d0p). Mg2+ ions seen in the complex with the hybrid duplex are green spheres. Only protein atoms were used to superimpose the two complexes.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig8.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">(</span><span style="font-weight:bold">A</span><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">) RNase H和Ago2催化的磷酸二酯切割反应。</span><br>（<span style="font-weight:bold">B</span>)<span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">）重叠显示</span><span style="font-weight:bold">B. halodurans</span><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">（</span><span style="font-weight:bold">Bh</span><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">）RNase H（浅蓝色螺旋状线条）与DNA（浅蓝色碳原子）-RNA（粉色碳原子）杂交体（PDB ID 1zbi）和人类Ago2（Piwi结构域；棕褐色螺旋状线条）与载体链（棕褐色碳原子）-导向链（棕色碳原子）双链体（PDB ID 4w5t）的晶体结构。RNase H复合物中观察到的Mg2+离子为绿色球体，2'-OH氧原子为红色球体。仅使用蛋白质原子对两个复合物进行叠合：RNase H的E66-G194；Piwi的Q589-Y790。<br>（</span><span style="font-weight:bold">C</span><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">）重叠显示</span><span style="font-weight:bold">Bh</span><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">RNase H（浅蓝色螺旋状线条）与DNA（浅蓝色碳原子）-RNA（粉色碳原子）杂交体（PDB ID 1zbi）和Bh RNase H与DNA十二聚体双链体（棕褐色螺旋状线条；PDB ID 3d0p）的晶体结构。观察到与杂交双链体结合的Mg2+离子为绿色球体。仅使用蛋白质原子对两个复合物进行叠合。</span></center>

In the crystal structure of a bacterial RNase H bound to an RNA–DNA hybrid, the RNA strand is properly oriented at the active site with two Mg2+ ions coordinated by Asp and Glu residues and the scissile phosphate lined up to be attacked by the water nucleophile. Conversely, the complex of Ago2 with an siRNA duplex is not trapped in an active conformation, Mg2+ ions are absent, and the sense strand does not reach the active site (seed region complex). An overlay of the Ago2 Piwi domain and RNase H from the two complex structures demonstrates that the respective RNA strands exhibit different curvatures (Figure 8B) and exposes Ago2 loop regions that need to recoil for the scissile phosphate to move into the active site.

<span style=color:blue>在细菌RNase H与RNA-DNA杂交体的晶体结构中，RNA链在活性位点上以正确的方向定位，两个Mg2+离子由Asp和Glu残基配位，并使被水亲核试剂攻击的切割磷酸盐排列整齐。相反，Ago2与siRNA双链体的结构并未陷入活性构象，缺少Mg2+离子，而正义链未达到活性位点（种子区结合）。将Ago2 Piwi结构域和RNase H的两个复合物结构进行重叠显示，可以看到各自的RNA链呈现不同的曲率（图8B），并暴露出Ago2回路区域，这些区域需要收缩以使切割磷酸盐移动到活性位点。</span>

RNase H probes the width of the minor groove of the duplex it docks onto, whereby that groove in an RNA-DNA substrate is narrower and wider than the corresponding grooves in RNA and DNA duplexes, respectively. An overlay of crystal structures of *Bacillus halodurans* RNase H bound to an RNA-DNA substrate duplex and a DNA–DNA inhibitor duplex of the same length shows that the groove widths and strand curvatures in the two duplexes differ distinctly (Figure 8C). RNase H interacts directly with several 2′-hydroxyl groups of the RNA strand and the lack of these contacts in the complex with a DNA duplex precludes proper recognition and of course processing, even if the 2′-OH groups are not directly involved in cleavage. The importance of the 2′-OH interactions for substrate recognition and action by RNase H is further demonstrated by the observation that the enzyme does not cleave a 2′-F-RNA strand opposite DNA. The absence of metal ions at the RNase H active site in the structure of the complex with the 2′-F-RNA–DNA duplex further highlights the key role played by 2′-hydroxyls in the proper functioning of the enzyme.

<span style=color:blue>RNase H探测其所结合的双链体的次沟宽度，在RNA-DNA底物中，该沟比RNA和DNA双链体的相应沟窄或宽。将* Bacillus halodurans * RNase H结合于RNA-DNA底物双链体和长度相同的DNA-DNA抑制剂双链体的晶体结构进行重叠，显示两个双链体的沟宽和链曲率明显不同（图8C）。RNase H直接与RNA链的几个2'-羟基进行相互作用，而在与DNA双链体形成的复合物中缺乏这些接触，阻止了适当的识别和处理，即使2'-羟基不直接参与切割。进一步证明了2'-羟基与RNase H底物识别和作用的重要性，观察到该酶不会切割2'-F-RNA链与DNA相对应的序列。在与2'-F-RNA-DNA双链体形成的复合物的结构中，RNase H活性位点缺乏金属离子进一步凸显了2'-羟基在酶的正常功能中的关键作用。</span>

Importantly, 2′-F-RNA as antisense oligo paired to a complementary RNA abrogates cleavage of the latter by RNase H, as do all ASOs that adopt an A-form geometry. Thus, a uniform 2′-*O*-modification strategy cannot be applied with ASOs that are intended to elicit RNase H and act via degradation of the RNA target. It also sheds light on the origins of the inability of RNase H to cleave RNA opposite a DNA containing 4′-thio-2′-deoxynucleotides. The gapmer ASO design provides a solution to this conundrum: the central PS-DNA window promotes cleavage by RNase H and 2′-*O*-modified wings afford stability. The central region is typically between six and ten nucleotides long and the PS modification ensures metabolic stability and favorable biodistribution compared to native DNA. Evidence has been presented that RNase H enzymes prefer particular sequences, and it turns out that RNase H is exquisitely sensitive to conformational changes induced by chemical modifications in the strand opposite RNA. Two of only a handful of ASO modifications that are tolerated by RNase H are arabinonucleic acid (ANA) and 2′-deoxy-2′-fluoro-arabinonucleic acid (FANA). FANA nucleotides in a DNA duplex background were found early on to adopt an *Eastern* O4′-*endo* pucker and both ANA and FANA appear capable of mimicking the DNA strand geometry in a hybrid duplex with RNA that is recognized and processed by RNase H.

<span style=color:blue>2'-F-RNA或采用A形态几何构型的ASO，与互补的RNA形成配对时，会阻止RNase H对后者的切割，与所有采用A形态几何构型的ASO一样。因此，在旨在通过降解RNA靶点来引发RNase H作用的ASO中，无法采用统一的2'-O-修饰策略。这也揭示了RNase H无法切割与含有4'-硫基-2'-脱氧核苷酸的DNA相对的RNA的原因。gapmer ASO设计提供了解决这个难题的方案：中央的PS-DNA窗口促进了RNase H的切割，而2'-O-修饰的翼部分则提供了稳定性。中央区域通常由六到十个核苷酸组成，并且PS修饰确保了与天然DNA相比的代谢稳定性和有利的生物分布。已经提供了RNase H对特定序列的偏好的证据，事实证明RNase H对RNA对侧发生的化学修饰引起的构象变化非常敏感。RNase H所容忍的ASO修饰中的两个例子是阿拉伯核酸（ANA）和2'-脱氧-2'-氟阿拉伯核酸（FANA）。早期的研究发现，将FANA核苷酸嵌入DNA双链背景中可采用东方的O4'-内环糖曲线，而ANA和FANA似乎能够模拟与RNA形成杂交双链时的DNA链几何结构，从而被RNase H识别和加工。</span>

### 2′-Modifications and MOE 2'-修饰与甲氧基乙基

Nucleic acids bearing modifications at the 2′-*O*-position are among the best studied analogs in the antisense, siRNA and aptamer contexts, starting of course with the 2′-*O*-methyl modification. One of the reasons the 2′-position has proved so fertile for antisense applications is that modification at that site maintains and potentially enhances preorganization of the sugar for an A-type backbone conformation. Modification also affords chemical stability in that it precludes 2′-OH-mediated strand cleavage. Moreover, it should result in better protection against nuclease attack owing to the vicinity of the 2′-position to the adjacent phosphate.

<span style=color:blue>在反义核酸、siRNA和适配体研究中，带有2'-O位点修饰的核酸是最为广泛研究的类似物之一，当然，最早研究的是2'-O-甲基修饰。2'-位点在反义应用中被证明非常适合进行修饰的原因之一是该位置的修饰可以维持并潜在增强糖的预组织，使其形成A型骨架构象。修饰还可以提供化学稳定性，因为它可以避免2'-OH介导的链断裂。此外，由于2'-位点与相邻磷酸的接近性，它应该能更好地保护核酸免受核酸酶的攻击。</span>

Conformational preorganization produces entropy-based gains in pairing stability and recent work has shed light on the origins of the ca. 1°C increase in *T*m per modification seen with 2′-*O*-Me modified strands opposite RNA. Accordingly, orientations of the 2′-OH group that have the hydrogen directed toward the phosphate group are at the root of the rich tertiary structure of RNA in that this induces non-canonical backbone conformations. Conversely, the 2′-OH hydrogen directed toward the base prevents it from scanning the backbone, thereby stabilizing a canonical (A-form) strand conformation. 2′-*O*-Me modification mimics the latter situation as it replaces the hydrogen with a methyl group that points away from the backbone and towards the minor groove.

<span style=color:blue>构象预组织产生了配对稳定性的熵增益，最近的研究揭示了2'-O-甲基修饰链与RNA相对时每个修饰引起的*T*值约1°C增加的起源。因此，2'-OH基团朝向磷酸基团的定向是RNA丰富三级结构的根源，因为这会诱导非经典的骨架构象。相反，2'-OH基团朝向碱基可以阻止其扫描骨架，从而稳定规范（A型）链的构象。2'-O-甲基修饰模拟了后一种情况，因为它用甲基取代了氢原子，该甲基指向远离骨架并指向较小的凹槽。</span>

We examined the pairing stability and nuclease resistance of ten 2′-*O*-modifications, including smaller substituents such as propyl, butyl, allyl, 2-fluoroethyl (FET) and 2-(methoxy)ethyl (MOE), as well as bulky, e.g. 2-(benzyloxy)ethyl (BOE), and positively charged moieties, e.g. 2-(imidazol-1-yl)ethyl (IME) and 2-[(*N*,*N*-dimethylamino)oxy]ethyl (DMAOE). The nucleobase in most cases was thymine and the tested DNA ASOs contained between three and ten modified nucleotides. The FET, IME and DMAOE modifications stabilized the duplex with RNA most, up to ca. 1.5°C Δ*T*m per modified nucleotide. By comparison, the MOE modification (Figure 7B) resulted in a ca. 1°C/residue average gain in *T*m for the three sequences tested. Interestingly, the ASO with four and ten consecutive BOE modifications still afforded *T*m increases of 0.8°C/residue and 0.7°C/residue, respectively.

<span style=color:blue>我们研究了十种2'-O-修饰的碱基对稳定性和核酸酶的抵抗性，其中包括较小的取代基，如丙基、丁基、烯丙基、2-氟乙基（FET）和2-(甲氧基)乙基（MOE），以及庞大的取代基，例如2-(苄氧基)乙基（BOE），和带正电荷的取代基，例如2-(咪唑-1-基)乙基（IME）和2-[(*N*,*N*-二甲基氨氧基)]乙基（DMAOE）。大多数情况下，碱基是胸腺嘧啶，测试的DNA ASOs包含3到10个修饰的核苷酸。FET，IME和DMAOE修饰使与RNA形成的双链稳定性最大，每个修饰核苷酸可使*T*值增加约1.5°C。相比之下，MOE修饰导致三个序列的平均*T*值增益约为1°C/核苷酸。有趣的是，具有连续四个和十个BOE修饰的ASO分别仍然导致0.8°C/核苷酸和0.7°C/核苷酸的*T*值增加。</span>

However, perhaps somewhat unexpectedly given its bulky nature, BOE only provided very little protection against degradation by the 3′-exonuclease snake venom phosphodiesterase (SVPD). In fact, among the investigated modifications, only the 2′-*O*-propargyl modification was worse. The crystal structure of a 2′-*O*-BOE-modified duplex revealed that the phenyl rings were positioned relatively far away from the phosphate group. IME, DMAOE and MOE incorporated at the 3′-end were ranked 1–3 in terms of protection against SVPD attack. The higher resistance to nuclease degradation seen with the IME and DMAOE modifications is consistent with the zwitterionic nature of these analogs that may position a positive charge near the 3′-phosphate group. This is consistent with the observation in crystal structures that virtually all 2′-*O*-substituents were directed toward the 3′-termini of strands.

<span style=color:blue>然而，或许有些出乎意料的是，尽管BOE取代基体积庞大，但在面对3'-外切核酸酶蛇毒磷酸二酯酶（SVPD）的降解时却提供了非常有限的保护。事实上，在所研究的修饰中，只有2'-O-丙炔基修饰效果更差。2'-O-BOE修饰的双链结构的晶体结构显示苯环离磷酸基相对较远。以IME、DMAOE和MOE修饰的3'-末端为基础，对抗SVPD攻击的保护能力分别排名第1至第3位。IME和DMAOE修饰显示出更高的核酸酶降解抗性，这与这些类似物的带电性质相一致，可能使正电荷靠近3'-磷酸基。这与晶体结构中的观察结果一致，几乎所有2'-O-取代基都指向链的3'-末端。</span>

The MOE-modified nucleoside features extra conformational preorganization as a gauche effect not only dictates the C3′-*endo* sugar ring pucker but also governs the conformation of the ethylene glycol moiety in the 2′-substituent (Figure 9). A crystal structure of a DNA A-form duplex with a single 2′-*O*-MOE residue per strand confirmed that the substituents assume a *synclinal* (*sc*) conformation. In the crystal structure both MOE-modified nucleosides cradle a water molecule that is coordinated to O3′, O2′ and the outer oxygen atom of the substituent (Figure [9](javascript:;)). The structure of a duplex that contained modified residues with a 2′-*O*-methyl[(tri(oxyethyl)]-substituent (TOE) demonstrated that TOE moieties snake along the backbone, are well ordered and that torsion angles around C-C bonds in the substituent are all in the *sc* range. In addition to the water molecule associated with MOE substituents, TOE substituents stabilize a second water that coordinates to the two outermost oxygen atoms. Without the gauche effect, conformational preorganization is diminished as seen in the crystal structure of a duplex with incorporated 2′-*O*-ethoxymethylene (EOM)-modified residues. Unlike MOE- or TOE-modified residues that enhance the thermodynamic stability of a duplex, the EOM modification is destabilizing and the crystal structure showed local unstacking caused by EOM moieties.

<span style=color:blue>MOE修饰核苷酸具有额外的构象预组织，这是由于"不对称"效应不仅决定了C3′-*内扭*糖环的弯曲，还控制了2′-取代基中乙二醇部分的构象（图9）。一对一链的DNA A-型双链结构与单个2′-O-MOE残基的晶体结构证实了取代基呈现*协轴*(*sc*)构象。在晶体结构中，两个MOE修饰核苷酸包裹着一分子水，该水分子与O3′、O2′和取代基的外部氧原子形成配位键（图9）。另一个含有2′-O-甲基[(三(氧乙基)]取代基（TOE）的修饰残基的双链结构显示，TOE取代基沿着链的骨架排列，有良好的有序性，并且取代基中C-C键的扭转角度都在*sc*范围内。除了与MOE取代基相关联的水分子外，TOE取代基还稳定了第二个与两个最外层氧原子配位的水分子。如果没有"不对称"效应，构象预组织将减弱，这在含有2′-O-乙氧基亚甲基（EOM）修饰残基的双链结构的晶体结构中可见。与增强双链热力学稳定性的MOE或TOE修饰残基不同，EOM修饰是一种降解因素，晶体结构显示由于EOM取代基而导致的局部失序现象。</span>

**图 9.**

![Conformational preorganization by additive gauche effects in 2′-O-[(2-methoxy)ethyl]-RNA (MOE RNA).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig9.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;text-align:center">2′-*O*-[(2-甲氧基)乙基]-RNA（MOE RNA）中通过加性*不对称*效应实现的构象预组织。</span></center>

A subsequently determined crystal structure of a fully modified MOE–RNA duplex attested further to the importance of conformational preorganization as the underlying cause of the increased stability and nuclease resistance of this analogue . Of the 24 MOE substituents in the duplex 22 adopted the *sc*+ or *sc*− conformations and most of them trapped a water in a chelate-like fashion between substituent, sugar and phosphate. Thus, MOE modification can stabilize up to three first-shell water molecules per residue, resulting in extensive hydration networks in the minor groove and around backbones in MOE–RNA.

<span style=color:blue>随后确定的一个完全修饰的MOE-RNA双链的晶体结构进一步证实了构象预组织作为增加稳定性和核酸酶抗性的原因的重要性。在该双链中的24个MOE取代基中，有22个采用了*sc*+或*sc*−构象，并且其中大多数通过类似螯合的方式将水分子困住在取代基、糖基和磷酸根之间。因此，MOE修饰可以使每个残基稳定最多三个第一层水分子，从而在MOE-RNA的小沟和磷酸骨架周围形成广泛的水合网络。</span>

Oligonucleotides with zwitterionic 2′-*O*-(3-aminopropyl)-modified (AP, Figure 10) ribonucleotides at the 3′-end displayed extraordinary resistance against degradation by SVPD. To gain insight into the origins of this protective effect, we determined the crystal structure of an AP-modified oligo in complex with *E. coli* DNA polymerase I 3′-exonuclease Klenow fragment. Rather than just altering the orientation of the substrate strand relative to active site residues, the AP substituent knocked out a catalytic metal ion and engaged in a salt bridge to an aspartic acid side chain. MOE can deliver enhanced pairing stability and nuclease resistance but is no match for the aminopropyl modification in terms of warding off an attack by an exonuclease.

<span style=color:blue>在3'-末端带有带电性2'-*O*-(3-氨基丙基)修饰（AP，图10）核苷酸的寡核苷酸显示出极高的抗SVPD降解能力。为了了解这种保护效应的起源，我们确定了一个AP修饰寡聚物与大肠杆菌DNA聚合酶I 3'-外切酶Klenow片段的晶体结构。AP取代基不仅改变了底物链相对于活性位点残基的定位，还排除了一个催化金属离子并与天冬氨酸侧链形成了盐桥。MOE可以提供增强的配对稳定性和核酸酶抗性，但在抵御外切酶攻击方面无法与氨丙基修饰相媲美。</span>

**图 10.**

![img](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/gkad067fig10.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">带离子性取代基的2′-*O*修饰，包括2′-*O*-(3-氨基丙基) (AP)，2′-*O*-[2-(胍基)乙基] (GE) 和 2′-*O*-2-[2-(*N*,*N*-二甲基氨基)乙氧基]乙基 (DMAEOE)。2′-*O*-[2-(甲氨基)-2-羟乙基] (NMA)。</span></center>

To combine the conformational preorganization of MOE with the record nuclease resistance delivered by the AP substituent, we created the 2′-*O*-2-[2-(*N*,*N*-dimethylamino)ethoxy]ethyl] (DMAEOE) modification (Figure 10). Indeed, DMAEOE affords gains in *T*m per modified residue of up to 1.2°C even with stretches of 10 consecutive modified nucleotides in the strand opposite RNA. Consecutive placement of analogues with positively charged 2′-*O*-substituents, e.g. AP, typically creates Coulombic repulsion in the minor groove with adverse effects on stability. The DMAEOE modification constitutes an exception in this regard as conformational preorganization by the MOE portion prevents entanglement by protonated dimethylamino moieties. Indeed, the crystal structure of a DMAEOE-modified duplex confirmed the hydration motif previously seen with MOE and TOE substituents. Finally, the 2′-*O*-[2-(guanidinium)ethyl] (GE, Figure 10) modification boosted the stability of ASO-RNA duplexes by 2°C (Δ*T*m) per modification and the stability of triplexes with duplex DNA by between 2.5 and 4.1°C per modification. This analogue also showed exceptional nuclease resistance but, unlike the findings with DMAEOE, consecutive placement of GE-substituted residues was not tolerated and resulted in a slight loss in *T*m of –0.1°C per modified residue.

<span style=color:blue>为了将MOE的构象预组织与AP取代基提供的出色核酸酶抵抗性相结合，我们设计了2′-*O*-2-[2-(*N*,*N*-二甲基氨基)乙氧基]乙基 (DMAEOE) 修饰（图10）。事实上，DMAEOE 即使在与RNA相对的链中连续插入10个修饰核苷酸时，每个修饰残基的*T*<sub>*m* </sub>增益可高达1.2°C。连续放置具有带正电的2′-*O* 取代基的类似物，如 AP，通常在小沟中产生库伦斥力，对稳定性产生不利影响。然而，DMAEOE修饰在这方面是个例外，因为MOE部分的构象预组织防止了质子化二甲基氨基基团的纠缠。实际上，DMAEOE修饰双链的晶体结构证实了先前在MOE和TOE取代基中观察到的水合模式。最后，2′-*O*-[2-(胍基)乙基] (GE，图10)修饰使ASO-RNA双链的稳定性每个修饰增加2°C (*ΔT*<sub>*m*</sub>)，并使具有双链DNA的三链结构的稳定性每个修饰增加2.5到4.1°C。该类似物也显示出异常的核酸酶抵抗性，但与DMAEOE的研究结果不同，连续放置的GE取代残基不能被耐受，并导致每个修饰残基的*T*<sub>*m*</sub>轻微降低-0.1°C。</span>

### KYNAMRO, TEGSEDI and WAYLIVRA

Since the original synthesis and characterization in 1995, MOE–RNA has been the focus of numerous investigations regarding its clinical efficacy, culminating in the approval of three MOE–RNA/PS–DNA ASO gapmers, KYNAMRO (mipomersen) , TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) (Figure 11). The plasma pharmacokinetics (PK) following intravenous (i.v.) administration of an all-PS 5–10–5 ASO with MOE wings targeting human tumor necrosis factor α were characterized in mouse, rat, dog, monkey and human and found to exhibit quite rapid distribution with a half-life of between 15 and 45 min in all species. Subcutaneous injection of the ASO resulted in absorptions of 80–100%, and when the oligo was administered intrajejunally, bioavailability reached 10% compared to i.v. administration. In monkeys less than 1% of the ASO administered by i.v. at up to 5 mg/kg was excreted in urine, the high levels of plasma protein-bound oligo presumably preventing renal filtration. In all species elimination of the ASO from tissue was very slow (several days) and dependent on tissue and organ, whereby the highest concentrations were seen in kidney, liver, lymph nodes, spleen and bone marrow. In a further plasma PK study, tissue distribution and metabolism of three ASOs with a phosphodiester (PO) backbone, all-PS and MOE at both 5′- and 3′-end, or all-PS but with MOE only at the 3′-end were compared after i.v. infusion of a 10 mg/kg dose in monkeys. Plasma clearance was significantly higher for the PO oligos compared to the two PS ones and was attributed to reduced plasma protein binding and nuclease resistance.

<span style=color:blue>自从1995年首次合成和表征以来，MOE-RNA一直是许多临床研究的焦点，最终批准了三种MOE-RNA/PS-DNA ASO gapmer，分别是KYNAMRO（mipomersen）、TEGSEDI（inotersen）和WAYLIVRA（volanesorsen）（图11）。通过静脉注射给予针对人类肿瘤坏死因子α的全PS 5-10-5 ASO与MOE翅膀，对小鼠、大鼠、狗、猴和人体进行了血浆药代动力学（PK）研究，发现在所有物种中都表现出相当快速的分布，半衰期在15到45分钟之间。皮下注射ASO导致80-100%的吸收，而当寡核苷酸经肠内注射时，生物利用度相对于静脉注射达到10%。在猴子中，通过静脉注射给予高达5 mg/kg的ASO，不到1%的剂量在尿液中排出，高水平的血浆蛋白结合寡核苷酸可能阻止了肾脏过滤。在所有物种中，ASO从组织中的消除速度非常缓慢（几天），并且取决于组织和器官，其中最高浓度出现在肾脏、肝脏、淋巴结、脾脏和骨髓中。在进一步的血浆PK研究中，比较了具有磷酸二酯（PO）骨架、全PS和MOE在5'-和3'-端的ASO以及全PS但只在3'-端具有MOE的三种ASO在猴子中10 mg/kg剂量的静脉输注后的组织分布和代谢情况。与两种PS ASO相比，PO寡核苷酸的血浆清除率显著更高，这归因于减少的血浆蛋白结合和核酸酶抵抗性。</span>

**图 11.**

![Sequences of three approved gapmer ASO therapeutics, KYNAMRO, TEGSEDI and WAYLIVRA. All elicit RNase H and encompass a 5–10–5 motif with PS/MOE–RNA wings (green) and a central PS–DNA window (blue).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig11.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">三种已获批的间隙寡核苷酸（ASO）治疗药物KYNAMRO、TEGSEDI和WAYLIVRA的序列。它们均诱导RNase H活性，具有5-10-5的结构基序，包括PS/MOE-RNA翅膀（绿色）和中央的PS-DNA窗口（蓝色）。</span></center>

The ASO with MOE modification at both ends exhibited greatly enhanced nuclease resistance in plasma and tissues, whereas the one with MOE modification only at the 3′-end resisted degradation in plasma to a certain degree but displayed only moderate resistance in tissues. Urinary excretion was a major elimination pathway for the PO oligo, but accounted for only a minor role in the elimination of the two PS/MOE-modified ASOs. The in vitro metabolic stabilities of PO and all-PS ASOs with MOE wings were also studied in a whole liver homogenate from rat or human and the outcomes including the metabolites compared to in vivo half-lives. The metabolites identified in vitro were consistent with those from in vivo observations and the relative stabilities of PO and PS/MOE oligos were similar in vitro and in vivo. However, the in vitro assay had limited predictive value in terms of the differences in metabolic stability exhibited by individual MOE/PS oligos. The metabolic pathway inferred from analysis of the metabolites in the preincubated liver homogenates was consistent with an initial endonucleolytic attack in the middle of the central PS–DNA window, followed by 5′- and 3′-exonuclease action. Among all investigated analogues, MOE–RNA constitutes the most thoroughly investigated modification with extensive clinical trial data available.

<span style=color:blue>在血浆和组织中，两端均含有MOE修饰的ASO表现出极强的核酸酶抗性，而仅在3'-端含有MOE修饰的ASO在血浆中抵抗降解到一定程度，但在组织中只表现出中等的抗性。尿排泄是PO寡核苷酸的主要排除途径，但对两种PS/MOE修饰的ASO的排除作用只起到次要的作用。还研究了含有MOE翅膀的PO和全PS ASO在大鼠或人类整个肝脏均匀液中的体外代谢稳定性，将其结果与体内半衰期及代谢物进行比较。体外鉴定的代谢物与体内观察的代谢物一致，PO和PS/MOE寡核苷酸的相对稳定性在体内外相似。然而，体外测定对于MOE/PS寡核苷酸的代谢稳定性差异具有有限的预测价值。通过对预孵肝脏均匀液中的代谢物进行分析，推断出代谢途径，首先在中央PS-DNA窗口的中部进行内切核酸酶攻击，然后进行5'-和3'-外切核酸酶作用。在所有研究的类似物中，MOE-RNA是最经彻底研究的修饰，拥有广泛的临床试验数据。</span>

KYNAMRO targeted the mRNA of ApoB protein, reduced cholesterol and was approved for treatment of familial hypercholesterolemia. It was the first systemically delivered ASO that obtained market approval (2013). KYNAMRO was given by injection once a week and lowered LDL-C levels in patients, but adverse effects included hepatotoxicity and injection site reactions. JUXTAPID® (lomitapide), a small molecule drug that, like KYNAMRO, comes with a risk of hepatotoxicity, ultimately proved more successful commercially, perhaps, in part, due to its oral administration.

<span style=color:blue>KYNAMRO以靶向ApoB蛋白的mRNA为目标，降低胆固醇，并获得了治疗家族性高胆固醇血症的批准。它是第一个获得市场批准的系统给药ASO（2013年）。KYNAMRO每周注射一次，可降低患者的低密度脂蛋白胆固醇（LDL-C）水平，但不良反应包括肝毒性和注射部位反应。JUXTAPID®（洛美他派），一种小分子药物，与KYNAMRO一样，存在肝毒性风险，但在商业上取得了更大的成功，可能部分原因是其口服给药形式。</span>

TEGSEDI is an ASO that targets the transthyretin (TTR) 3′-UTR and thereby inhibits production of wild-type and mutant TTR proteins. TTR acts as the primary transporter of retinol-binding protein and is also a redundant transport protein for thyroxine. The protein forms a homo-tetramer but mutations in the TTR monomer – there are some 150 reported mutations – destabilize the tetrameric structure. Dissociation of the tetramer releases misfolded monomers that can associate to form toxic oligomers and amyloid fibrils. Deposition of these TTR amyloid fibrils is referred to as TTR amyloidosis (ATTR) and the hereditary form of the autosomal dominant disorder is called hATTR. The predominant manifestations of the disease are either polyneuropathy or cardiomyopathy.

<span style=color:blue>TEGSEDI是一种靶向甲状腺素转运蛋白（TTR）3'-非翻译区（3'-UTR）的ASO，从而抑制野生型和突变型TTR蛋白的产生。TTR是维生素A结合蛋白的主要运输蛋白，也是甲状腺素的冗余运输蛋白。该蛋白形成一个同源四聚体，但TTR单体中的突变（已报道约150种突变）会使四聚体结构不稳定。四聚体的解离释放出错误折叠的单体，可以聚集形成有毒寡聚体和淀粉样纤维。这些TTR淀粉样纤维的沉积被称为TTR淀粉样病变（ATTR），而遗传性的常染色体显性遗传疾病形式被称为hATTR。该疾病的主要表现为多发性神经病或心肌病。</span>

Therapeutic intervention for hATTR in the US prior to 2018 included liver transplantation, stabilizing the TTR tetramer (diflunisal), or reducing TTR deposition with a combination of doxycycline and tauroursodeoxycholic acid. The first siRNA for hATTR treatment, ONPATTRO was approved in 2018 for the treatment of the polyneuropathy of hATTR mediated amyloidosis in adults. The antisense oligonucleotide TEGSEDI was approved later in the same year for the same indication. The two drugs have different routes of administration, and different safety profiles. TEGSEDI is administered subcutaneously, whereas ONPATTRO is administered intravenously as an LNP formulation.

<span style=color:blue>2018年之前，美国对hATTR的治疗干预方法包括肝移植、稳定TTR四聚体（地氟尼索）或使用多西环素和牛磺胆酸组合减少TTR沉积。2018年，首个用于治疗hATTR的小干扰RNA（siRNA）药物ONPATTRO获得批准，用于治疗成年人hATTR介导的多发性神经病。同年稍后，用于同一适应症的反义寡核苷酸药物TEGSEDI也获得批准。这两种药物具有不同的给药途径和不同的安全性特点。TEGSEDI通过皮下给药，而ONPATTRO通过静脉注射作为LNP制剂给药。</span>

WAYLIVRA is an ASO that targets the 3′-untranslated region (3′-UTR) of apolipoprotein C III (apoC III) mRNA and was approved by the European Union to treat familial chylomicronemia syndrome (FCS) in 2019. FCS is a metabolic disorder, causes hypertriglyceridaemia that involves a functionally impaired lipoprotein lipase (LPL) and is associated with potentially fatal consequences such as pancreatitis. The disorder is characterized by chylomicronemia and hypertriglyceridemia resulting from LPL action. ApoC III inhibits LDL and increases the concentration of plasma triglyceride by lowering the hepatic uptake of triglyceride-rich lipoproteins while also raising hepatic secretion of triglycerides. The drug is administered by subcutaneous injection; adverse effects include mild injection site reactions, a decreased platelet count and thrombocytopenia. In further clinical trials the utility of WAYLIVRA was assessed for the treatments of hypertriglyceridemia, familial partial lipodystrophy and partial lipodystrophy. However, it doesn’t appear in the current pipeline and was replaced by the corresponding GalNAc conjugate.

<span style=color:blue>WAYLIVRA是一种靶向载脂蛋白C III（apoC III）mRNA的3'-非翻译区（3'-UTR）的反义寡核苷酸药物，于2019年获得欧盟批准，用于治疗家族性乳糜微粒血症综合征（FCS）。FCS是一种代谢性疾病，导致高甘油三酯血症，其中涉及功能受损的脂蛋白脂肪酶（LPL），并且与胰腺炎等潜在致命后果相关。该疾病的特征是由于LPL作用引起的乳糜微粒血症和高甘油三酯血症。apoC III通过降低肝脏对富含甘油三酯的脂蛋白的摄取而增加血浆甘油三酯浓度，同时抑制低密度脂蛋白（LDL）的作用并提高肝脏甘油三酯的分泌。该药物通过皮下注射给药；不良反应包括轻度注射部位反应、血小板计数降低和血小板减少症。在进一步的临床试验中，评估了WAYLIVRA在治疗高甘油三酯血症、家族性部分脂肪营养不良和部分脂肪营养不良方面的功效。然而，该药物目前不在当前的研发计划中，并被相应的GalNAc结合物所取代。</span>

## SPLICE SITE SWITCHING OLIGONUCLEOTIDES 剪接位点转换寡核苷酸

### SPINRAZA, MOE and spinal muscular atrophy SPINRAZA、MOE和脊髓性肌肉萎缩症

The ability to modulate alternative splicing is clearly of therapeutic value, given that this process is a major contributor to proteome diversity. Thus, some 70% of human genes are thought to undergo alternative splicing and up to half of all human genetic diseases may arise as a result of mutations that affect splicing. Unlike ASOs that are designed to elicit RNase H action, splice-switching oligonucleotides (SSOs) need to bind the target sequence with high affinity and sterically block and redirect the spliceosome (Figure 5). SSOs enable highly specific targeting of essential sequence elements such as splicing enhancers and silencers in pre-mRNA. The splicing of a pre-mRNA transcript can be redirected by various means that include exon exclusion, intron retention, exon shuffling, selection of alternative 5′- and 3′-splice sites, shifting of promoter and polyadenylation sites, and so forth. Using an oligo to do so would seem more achievable that identifying small molecules to orchestrate the splicing machinery. However, there are numerous ongoing efforts directed at the discovery of small molecule modulators of alternative splicing.

<span style=color:blue>调节剪接位点的能力在治疗中具有明显的价值，因为这一过程是蛋白质组多样性的主要贡献者。据认为，约70%的人类基因经历了选择性剪接，并且高达一半的人类遗传疾病可能是由影响剪接的突变引起的。与旨在引发RNase H作用的反义寡核苷酸（ASO）不同，剪接位点转换寡核苷酸（SSO）需要高亲和力地结合目标序列，并在立体上阻碍和重定向剪接体（图5）。SSO使得对前体mRNA中的剪接增强子和沉默子等关键序列元素具有高度特异性的靶向成为可能。通过不同的方式，如外显子排除、内含子保留、外显子重排、选择替代的5'-和3'-剪接位点、启动子和聚腺苷酸化位点的移动等，可以重定向前体mRNA的剪接。使用寡核苷酸来实现这一目的似乎比寻找小分子来编排剪接机制更可行。然而，目前有许多不断进行的工作致力于发现调节选择性剪接的小分子调节剂。</span>

All-PS, all-PS/MOE-wing and all-MOE oligonucleotides against human h-ras or rat PKCα were delivered to rats by intrathecal injection (IT) in order to reach the cerebrospinal fluid (CSF). The MOE–ASO remained intact both in spinal cord tissue and in the CSF for up to a day after injection. The ASO was taken up by neurons and glia alike and found to downregulate PKCα in the spinal cord. By comparison, the PS–ASO was considerably less stable and metabolites were detected only 30 minutes after IT administration. Data resulting from this study also indicated that IT injection using increased dosages might successfully deliver ASOs to dorsal root ganglia cells and thus enable downregulation of sensory neuron targets. The findings were also exciting because they indicated that the MOE chemistry might open the door to a pharmacological approach for treating neurodegenerative disorders.

<span style=color:blue>为了进入脑脊液（CSF），采用腰髓内注射（IT）将全磷酸盐（all-PS）、全磷酸盐/MOE翼（all-PS/MOE-wing）和全MOE寡核苷酸输送到大鼠体内，针对人h-ras或大鼠PKCα进行作用。在注射后的一天内，MOE-ASO在脊髓组织和CSF中仍保持完整。ASO被神经元和胶质细胞吸收，并发现在脊髓中下调PKCα的表达。相比之下，PS-ASO的稳定性明显较差，仅在IT给药后30分钟后检测到代谢产物。该研究的数据还表明，使用增加的剂量进行IT注射可能成功地将ASO输送到脊神经节细胞，从而使感觉神经元靶点下调。这些发现也令人兴奋，因为它们表明MOE化学可能为治疗神经退行性疾病打开了药理学途径。</span>

Indeed, in 2016 SPINRAZA (nusinersen), a fully modified 18mer PS/MOE–ASO (Figure 12) was approved by the US FDA for treatment of spinal muscular atrophy (SMA). SMA is a major genetic disorder associated with degeneration of alpha motor neurons and leading to progressive muscular weakness and atrophy. Infantile-onset SMA robs the individual of the ability to move, eat or breathe and was reported as the leading genetic cause of death for infants. The vast majority of SMA cases are due to mutations or deletions in the survival motor neuron 1 (*SMN1*) gene that result in reduced levels of SMN, a multifunctional protein that is required for survival of all animal cells. Humans possess two nearly identical copies of the *SMN* gene, *SMN1* and *SMN2*. However, unlike in *SMN1*, exon 7 of *SMN2* is predominantly skipped during splicing in most tissues, thereby resulting in an unstable and only partially functioning protein. SPINRAZA promotes inclusion of exon 7 in *SMN2* by blocking an intronic splicing silencer and thus increases the total amount of SMN protein produced  (Figure12).

<span style=color:blue>的确，2016年，美国FDA批准了SPINRAZA（nusinersen），一种完全修饰的18mer PS/MOE–ASO（图12），用于治疗脊髓性肌萎缩（SMA）。SMA是一种与α运动神经元退化相关的重大遗传疾病，导致渐进性肌肉无力和萎缩。婴儿早发型SMA使患者失去了运动、进食和呼吸的能力，并被报道为婴儿死亡的主要遗传原因。绝大多数SMA病例是由生存运动神经元1（*SMN1*）基因的突变或缺失导致SMN水平降低所致，SMN是一种多功能蛋白，对所有动物细胞的生存都是必需的。人类拥有两个几乎相同的*SMN*基因副本，*SMN1*和*SMN2*。然而，与*SMN1*不同，*SMN2*的第7外显子在大多数组织中在剪接过程中主要被跳过，从而导致产生不稳定且仅部分功能的蛋白质。SPINRAZA通过阻断一个内含子剪接抑制因子，促进了*SMN2*中第7外显子的包含，从而增加了产生的SMN蛋白的总量（图12）。</span>

**图 12.**

![Schematic representation of the SMN2 exon 7 (capital font)/intron 7 (small font) junction. SPINRAZA blocks the intronic splicing silencer N1 (ISS-N1) located within intron 7 of SMN2 pre-mRNA (purple arrow), thereby preventing the skipping of exon 7 and promoting production of stable SMN2 protein. SMN2 intron 7 contains several U-rich clusters that are contacted by glutamine-rich RNA binding protein TIA1 to stimulate exon inclusion. The 3′-terminal end of exon 7, ISS-N1 and TIA1 binding site are highlighted with boxes and intron GU dinucleotides are colored in red. The SPINRAZA SSO contains 5-methyl-C (C*) and is fully PS and 2′-O-MOE modified.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig12.jpeg)


<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">*SMN2*外显子7（大写字体）/内含子7（小写字体）交汇处的示意图。SPINRAZA阻断了位于*SMN2*前体mRNA内含子7中的内含子剪接抑制因子N1（ISS-N1）（紫色箭头），从而防止外显子7的跳跃剪接，并促进稳定的SMN2蛋白的产生。*SMN2*内含子7包含数个富含尿嘧啶（U）的簇，这些簇与富含谷氨酰（glutamine-rich）的RNA结合蛋白TIA1相互作用，以促进外显子的包含。外显子7的3'-端、ISS-N1和TIA1结合位点以方框标出，内含子中的GU二核苷酸以红色表示。SPINRAZA SSO含有5-甲基-C（C*），并且完全是磷酸盐（PS）和2'-O-甲基酰基己酸酯（2'-O-MOE）修饰。</span></center>

There is no doubt that SPINRAZA has had a fundamental impact on the treatment of SMA and the lives of infants and adolescents inflicted by this genetic disorder. Not only has treatment resulted in prolonged survival but it has led to dramatic improvements in motor development in children with early and late onset of the disease, such as the abilities to sit up or walk without support. Two additional drugs have been developed for the treatment of SMA. One is ZOLGENSMA® (onasemnogene abeparvovec-xioi), a gene therapy that replaces the defect *SMN1* gene that was approved by the US FDA in 2019 for use with all types of SMA in newborns and toddlers up to age 2 via a single i.v. administration. The other is an orally administered small molecule drug, EVRYSDI® (risdiplam), that acts like SPINRAZA at the level of splicing by modulating the *SMN2* pre-mRNA splicing pattern and increasing the amount of full-length functional SMN protein. The breakthrough with respect to treatment of a neurodegenerative disorder by an SSO has raised the prospect of successfully expanding oligonucleotide-based therapies to combatting neurological disorders. Examples are Huntington's disease and multiple sclerosis for which MOE-based oligonucleotides are currently being evaluated in various phase clinical trials.

<span style=color:blue>毫无疑问，SPINRAZA对SMA的治疗和受此遗传疾病影响的婴儿和青少年的生活产生了根本性的影响。治疗不仅延长了患者的生存期，还使早发型和晚发型患儿的运动发育出现了显著改善，例如能够在没有支持的情况下坐起或行走。另外还开发了两种用于SMA治疗的药物。一种是ZOLGENSMA®（onasemnogene abeparvovec-xioi），一种基因疗法，用于在新生儿和2岁以下的幼儿中替代缺陷的*SMN1*基因，2019年获得美国FDA批准，通过单次静脉注射使用，适用于所有类型的SMA。另一种是口服小分子药物EVRYSDI®（risdiplam），在剪接水平上像SPINRAZA一样通过调节*SMN2*前体mRNA的剪接模式并增加全长功能性SMN蛋白的数量来发挥作用。SSO在神经退行性疾病治疗方面的突破为成功扩大基于寡核苷酸的治疗到神经系统疾病领域带来了希望。目前，MOE基础的寡核苷酸正在对亨廷顿病和多发性硬化等疾病进行各个临床试验阶段的评估。</span>

### EXONDYS 51/VYONDYS 53, PMOs and Duchenne muscular dystrophy

Additional SSOs that received market approval are EXONDYS 51 (eteplirsen, 2016) and VYONDYS 53 (golodirsen, 2019) (Figure 3, Table 1), both used in the treatment of Duchenne muscular dystrophy (DMD) and targeting exon 51 and exon 53, respectively, of dystrophin pre-mRNA (Figure 13). The two exon-skipping therapies aim to produce shortened but functional dystrophin to increase the levels of the protein in muscle. Dystrophin is expressed in skeletal and cardiac muscle as well as in the brain and is key for strengthening and connecting muscle fibers. Unlike SMA, DMD is not a CNS disease but a fatal X-linked disorder that is caused by any of >2000 mutations that affect the *DMD* gene and result in the loss of functional dystrophin protein. Some 70% of patients exhibit single- or multi-exon deletions that result in aberrant expression of dystrophin or duplications, thus leading to progressive skeletal weakness, muscle wasting and cardiomyopathy. DMD patients show levels of dystrophin that are less than 3% of normal. Symptoms of DMD are not limited to motor difficulties such as getting up or climbing stairs, but also include developmental delay and behavioral issues in children as well as impaired growth, delayed puberty and gastrointestinal problems. Life-threatening respiratory and cardiac complications are common in the second or third decade of life. Delays in disease progression and improved life expectancy have been achieved with corticosteroid treatment, surgical intervention and preventive measures in regard to heart failure related to cardiomyopathy.

<span style=color:blue>其他获得市场批准的SSO还包括EXONDYS 51 (eteplirsen，2016)和VYONDYS 53 (golodirsen，2019)（图3，表1），两者均用于治疗杜氏肌营养不良（DMD），分别靶向dystrophin前体mRNA的exon 51和exon 53（图13）。这两种外显子跳跃疗法旨在产生缩短但具有功能的dystrophin，以增加肌肉中该蛋白质的水平。dystrophin在骨骼和心脏肌肉以及大脑中表达，并且对于加强和连接肌纤维至关重要。与SMA不同，DMD不是一种中枢神经系统疾病，而是一种致命的X连锁隐性遗传疾病，由影响*DMD*基因的2000多种突变之一引起，导致功能性dystrophin蛋白的丧失。约70%的患者表现出单个或多个外显子缺失，导致dystrophin异常表达或重复，从而导致进行性骨骼肌无力、肌肉萎缩和心肌病。DMD患者的dystrophin水平不到正常水平的3%。DMD的症状不仅限于运动困难，如起身或爬楼梯，还包括儿童发育迟缓和行为问题，以及生长受阻、青春期延迟和胃肠问题。在生命的第二或第三个十年，常见的危及生命的呼吸和心脏并发症。通过皮质类固醇治疗、外科干预和预防心力衰竭相关措施，已经延缓了疾病进展并改善了预期寿命。</span>

**图 13.**

![Phosphorodiamidate morpholino (PMO) SSOs that mediate skipping of additional exons for treatment of two types of Duchenne muscular dystrophy (DMD). (A) PMO structure. (B) Model of PMO conformation in a stretch of A-form RNA. Nucleotide sequence, 5′-modification and mode of action of PMO-SSOs (C) EXONDYS 51 and (D) VYONDYS 53.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig13.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">磷酸二酰胺基吗啉核苷酸（PMO）SSO，用于治疗两种类型的杜氏肌萎缩症（DMD）的额外外显子跳跃。（<span style=font-weight:bold>A</span>）PMO结构。（<span style=font-weight:bold>B</span>）PMO在A型RNA链中的构象模型。PMO-SSO的核苷酸序列、5′修饰和作用机制（<span style=font-weight:bold>C</span>）EXONDYS 51和（<span style=font-weight:bold>D</span>）VYONDYS 53。</span></center>

EXONDYS 51 and VYONDYS 53 are phosphorodiamidate morpholino oligonucleotides (PMOs), often referred to as morpholinos . Morpholinos possess a neutral backbone that is completely resistant to nucleases. However, like the phosphorothioates or the neutral methylphosphonates, the PMO modification generates a mixture of *R*p- and *S*p-diastereoisomers (Figure 13A). PMOs are water soluble and display good cell permeability without assistance from cellular factors, but hybridized to RNA they do not elicit RNase H. Although there is a large body of data regarding cell-based assays and in vivo applications of morpholinos, and protocols for solid-phase synthesis of PMO oligomers, e.g. , detailed biophysical data and in particular experimental structural information are missing.

<span style=color:blue>其他获得市场批准的SSO还包括EXONDYS 51 (eteplirsen，2016)和VYONDYS 53 (golodirsen，2019)（图3，表1），两者均用于治疗杜氏肌营养不良（DMD），分别靶向dystrophin前体mRNA的exon 51和exon 53（图13 A）。这两种外显子跳跃疗法旨在产生缩短但具有功能的dystrophin，以增加肌肉中该蛋白质的水平。dystrophin在骨骼和心脏肌肉以及大脑中表达，并且对于加强和连接肌纤维至关重要。与SMA不同，DMD不是一种中枢神经系统疾病，而是一种致命的X连锁隐性遗传疾病，由影响*DMD*基因的2000多种突变之一引起，导致功能性dystrophin蛋白的丧失。约70%的患者表现出单个或多个外显子缺失，导致dystrophin异常表达或重复，从而导致进行性骨骼肌无力、肌肉萎缩和心肌病。DMD患者的dystrophin水平不到正常水平的3%。DMD的症状不仅限于运动困难，如起身或爬楼梯，还包括儿童发育迟缓和行为问题，以及生长受阻、青春期延迟和胃肠问题。在生命的第二或第三个十年，常见的危及生命的呼吸和心脏并发症。通过皮质类固醇治疗、外科干预和预防心力衰竭相关措施，已经延缓了疾病进展并改善了预期寿命。</span>

We modeled a morpholino nucleotide into an RNA A-form oligonucleotide and achieved a virtually seamless fit. Specifically, inserting a morpholino residue maintains the puckers of 5′- and 3′-adjacent riboses and no significant alterations of backbone angles were necessary apart from a flip from *sc*− to *sc*+ for ζ in the 5′-ribonucleotide (Figure 13B). All three substituents of the morpholine chair (base, C5′, and 3′-phosphate) adopt an equatorial orientation and stacking is maintained. The model was built with the program UCSF Chimera and energy-minimized with the Amber14 force field, using steepest descent and conjugate gradient methods until convergence. A PMO nucleotide can just as easily be slipped into a DNA B-form backbone and accommodated without significant structural perturbation (not shown).

<span style=color:blue>我们将一个morpholino核苷酸模型插入了一个RNA A-型寡核苷酸，并实现了几乎无缝连接。具体而言，插入morpholino残基可以保持5'-和3'-相邻核糖的扭曲，并且除了在5'-核糖的ζ从*sc*−翻转到*sc*+之外，骨架角度没有显著的改变（图13B）。morpholine椅子的三个取代基（碱基、C5'和3'-磷酸酯基团）采用赤道方向，并且堆叠结构得以保持。该模型是使用UCSF Chimera程序构建的，并使用Amber14力场进行了能量最小化，采用最陡下降和偶联梯度方法直到收敛。一个PMO核苷酸可以轻松地滑入DNA B-型骨架中，并在没有显著结构扰动的情况下适应其中（未显示）。</span>

Considering that 5 out of the 16 oligonucleotide therapeutics approved to date are splice-shifting oligos (Figure 3) and that they have paved the road to treatments of devastating diseases for which there are no cures, certainly the development of SSOs should be seen as a success, despite the somewhat controversial FDA approval of EXONDYS 51. Several other targets, however, are being pursued in future treatments of DMD patients, among them therapies to counter muscle degeneration and fibrosis, reduce inflammation, bypass aberrant stop codons and modulate utrophin, a protein that is similar to dystrophin and may replicate some of its functions. Thus, other splice site-targeting drugs are currently undergoing clinical evaluation, and the exon 53 PMO-SSO therapeutic VILTEPSO® (viltolarsen) received FDA approval in 2020. The exon 45 PMO–SSO therapeutic AMONDYS 45® (casimersen) received FDA approval in 2021. In addition, CRISPR/Cas9-based gene replacement approaches may be pursued in the case of DMD treatment as with SMA before, and small-molecule drug discovery might result in the identification of new orally available therapeutics that effectively modulate *DMD* pre-mRNA splicing to boost dystrophin expression.

<span style=color:blue>考虑到迄今为止已批准的16种寡核苷酸治疗药物中有5种是剪接转换寡核苷酸（图3），它们为无可治愈的可怕疾病的治疗铺平了道路，尽管EXONDYS 51的FDA批准引起了一些争议，但SSO的开发应被视为成功。然而，在未来治疗DMD患者时，还有其他几个目标正在追求，其中包括对抗肌肉退化和纤维化的疗法、减少炎症、绕过异常终止密码子以及调节乌托芬（一种与肌酸激酶类似并可能复制其部分功能的蛋白质）。因此，其他靶向剪接位点的药物目前正在进行临床评估，外显子53的PMO-SSO治疗药物VILTEPSO®（viltolarsen）于2020年获得FDA批准。外显子45的PMO-SSO治疗药物AMONDYS 45®（casimersen）于2021年获得FDA批准。此外，在DMD治疗中，基于CRISPR/Cas9的基因替代方法可能会像在SMA中一样被追求，小分子药物的发现可能会找到新的口服可用药物，有效调节*DMD*前体mRNA的剪接以增加瘦肌蛋白的表达。</span>

## THIRD-GENERATION SUGAR MODIFICATION CHEMISTRIES

We reviewed the concept of conformational preorganization in one of the above sections and discussed various effects on the equilibrium between the C2′-*endo* (DNA-like) and C3′-*endo* (RNA-like) pucker modes of the sugars in the backbones of DNA and RNA. Particularly modifications targeting the 2′-position such as 2′-F, 2′-*O*-Me, 2′-*O*-MOE and 2′-*O*-substitution in general favor the A-form backbone geometry. The sugar ring flips between the North and South regions of the pseudorotation phase cycle and the Eastern region is only sparsely populated, FANA being the prime example of a modification that prefers the East O4′-*endo* pucker . However, without further constraints the pentose retains its ability to fluctuate conformationally, which typically results in an entropically unfavorable contribution to pairing stability opposite an RNA target.

<span style=color:blue>在上述的某个部分，我们回顾了构象预组织的概念，并讨论了对DNA和RNA骨架中糖的C2′-*endo*（类似DNA）和C3′-*endo*（类似RNA）脱氧核糖的平衡产生的各种影响。特别是针对2′位点的修饰，如2′-F、2′-*O*-Me、2′-*O*-MOE和2′-*O*的取代，通常有利于A型骨架几何结构。糖环在伪旋转相位周期中在北部和南部区域之间翻转，而东部区域只有稀疏的占据，FANA是更倾向于东部的O4′-*endo*脱氧核糖修饰的主要例子。然而，在没有进一步的约束条件下，脱氧核糖仍然保持着构象的波动性，这通常会导致与RNA靶标相对配对稳定性的熵不利贡献。</span>

Chemical modifications that could freeze or lock the sugar moiety in the nucleic acid backbone would offer the ultimate control of conformational preorganization. Bicyclic frameworks achieve just that, and so-called locked nucleic acid (LNA) has arguably become the most well-known representative of this class of analogues since its inception in 1997/1998 (Figure 14) . Bridging ribose O2′ and C4′ with a methylene group effectively locks the sugar moiety in the C3′-*endo* conformation. The concept to bridge various atoms of 2′-deoxyribose, ribose and other sugar stereoisomers and using various linker chemistries has given rise to a wealth of bridged nucleic acids (BNAs, see Figure 14 for a small selection) . As expected, pairing between an oligonucleotide containing LNA and either complementary DNA or RNA results in a strongly stabilized duplex - up to 10°C per modified nucleotide compared to the parent duplex. In principle, this renders LNA a promising modification for antisense applications, although the analogue could only be used in the wings of ASOs so as not to abolish RNase H activity. Indeed, LNA oligos show 5- to 10-fold increased potencies relative to MOE-ASOs in animal studies. However, in rodents, non-human primates and humans, LNA-ASO were found to cause renal and hepatic toxicities and adverse injection site reactions. Clinical trials with a number of LNA-ASOs against various targets as well as with an LNA anti-miRNA oligo (antagomir) are continuing.

<span style=color:blue>能够冻结或锁定核酸骨架中的糖基团的化学修饰将提供对构象预组织的终极控制。双环框架正是实现这一目标的方法，自1997/1998年以来，所谓的锁定核酸（LNA）可能已成为这类类似物中最为知名的代表（见图14）。通过用亚甲基桥接核糖O2′和C4′，可以有效地将糖基团锁定在C3′-*endo*构象中。通过在2′-脱氧核糖、核糖和其他糖立体异构体的不同原子之间桥接，并使用不同的连接化学手段，产生了丰富的桥接核酸（BNAs，见图14中的一小部分）。如预期的那样，含有LNA的寡核苷酸与互补的DNA或RNA之间的配对形成了强烈稳定的双链结构，相对于未修饰的双链结构，每个修饰核苷酸可使稳定温度提高高达10°C。原则上，这使得LNA成为一种有前景的反义应用修饰，尽管该类似物只能在ASO的翅膀部分使用，以免抑制RNase H的活性。实际上，在动物研究中，与MOE-ASO相比，LNA寡核苷酸显示出5至10倍增强的活性。然而，在啮齿动物、非人灵长类动物和人类中，发现LNA-ASO会导致肾脏和肝脏毒性以及不良的注射部位反应。对多个靶点的LNA-ASO以及LNA抗-miRNA寡核苷酸（antagomir）进行的临床试验仍在进行中。</span>

**图 14.**

![Structures of locked nucleic acid (LNA), bridged nucleic acids (BNAs), bicyclo-DNA (bcDNA), tricylco-DNA (tc-DNA) and North and South methanocarba nucleic acids (N-MC and S-MC, respectively). The preferred sugar puckers of the RNA and DNA analogs are given below the structural formulas.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig14.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">锁定核酸（LNA）、桥接核酸（BNAs）、双环-DNA（bcDNA）、三环-DNA（tc-DNA）以及北甲烷环核酸（N-MC）和南甲烷环核酸（S-MC）的结构如下图所示。RNA和DNA类似物的优选糖环构型在结构式下方给出。</span></center>

The LNA O2′-C4′ bridge allows for further chemical modification. The cEt BNA isomers feature methyl substituents at C4′ and the cMOE BNA isomers are the result of stitching together C4′ and the inner carbon of the ethyl moiety in the 2′-*O*-MOE substituent (Figure 14). Not only do these BNAs maintain the ability to stabilize duplexes relative to MOE-modified strands, but both cyclic analogs exhibit better resistance to 3′-exonuclease degradation than the parent MOE modification. Surprisingly, cEt BNA affords better protection than cMOE and crystal structures of modified duplexes and models of 3′-terminally modified strands bound to exonuclease point to a steric origin of the favorable resistance. Several clinical trials with cEt-modified oligonucleotides are underway. A carbocyclic analog of LNA (cLNA) with an exocyclic methylene group in place of the 2′-oxygen (methylene-cLNA) afforded similar pairing stability gains and mismatch discriminations as the parent LNA. The corresponding ASOs showed similar affinities but reduced toxicity relative to LNA. The methylene-cLNA modification was superior to Me-cLNA isomers, both in terms of affinity and ASO activity.

<span style=color:blue>LNA O2′-C4′桥能够进行进一步的化学修饰。cEt BNA异构体在C4′位置具有甲基取代基，而cMOE BNA异构体是通过将C4′和2′-*O*-MOE取代基中乙基部分的内部碳连接在一起形成的（见图14）。这些BNAs不仅相对于MOE修饰链能够保持稳定双链的能力，而且这两种环状类似物相对于原始的MOE修饰具有更好的抵抗3′-外切核酸酶降解的能力。令人惊讶的是，cEt BNA提供了比cMOE更好的保护效果，修改双链的晶体结构和3′端修饰链与外切核酸酶结合的模型表明有利的耐受性源于立体位阻效应。目前正在进行几项使用cEt修饰寡核苷酸的临床试验。LNA的环状类似物（cLNA）中，以2′-氧原子的位置具有外环亚甲基取代基（methylene-cLNA），其所提供的成对稳定性增益和错配区分能力与原始的LNA相似。相应的ASOs显示了与LNA相似的亲和力，但毒性降低。相对于Me-cLNA异构体，methylene-cLNA修饰在亲和力和ASO活性方面表现出更优越的特性。</span>

Bicyclic frameworks do not just allow one to freeze the sugar conformation in the C3′-*endo* mode, but judicious use of isomers and types of bridges has resulted in analogs that are limited to a DNA-like sugar pucker. Thus, α-*L*-LNA adopts solely the South-type C3′-*exo* pucker (Figure 14) , but nonetheless does not elicit RNase H when paired with RNA. The synthesis of bicyclo-DNA (bcDNA) represents a very early attempt to rigidify the DNA sugar-phosphate backbone. The analogue formed entropically favored duplexes and displayed a propensity for triplex formation, whereby the preferred sugar pucker was either C2′-*endo* or C1′-*exo*. Tricyclo-DNA (tcDNA) contains an additional cyclopropyl ring compared with bcDNA, but its sugar adopts a C3′-*endo* pucker instead. In the crystal structure of a DNA duplex with tcDNA residues, the cyclopropyl ring was positioned at the edge of the major groove. This observation helped rationalize the considerably increased nuclease resistance seen with tcDNA-modified oligos. Tricyclo-DNA was also extensively tested inside PS-modified ASO gapmers and found to exhibit robust antisense activity in the absence of hepatotoxicity.

<span style=color:blue>双环框架不仅可以将糖的构象冻结在C3′-*endo*模式下，而且通过适当选择异构体和桥接类型，可以得到限制在DNA样式糖构象的类似物。因此，α-*L*-LNA仅采用南型C3′-*exo*糖构象（见图14），但与RNA配对时并不引发RNase H反应。双环-DNA（bcDNA）的合成代表了刚性化DNA糖磷酸骨架的非常早期尝试。该类似物形成了熵上有利的双链结构，并具有三链结构形成的倾向，其中首选的糖构象为C2′-*endo*或C1′-*exo*。与bcDNA相比，三环-DNA（tcDNA）多了一个环丙基环，但其糖构象取代为C3′-*endo*。在含有tcDNA残基的DNA双链结构中，环丙基环位于主沟边缘。这一观察结果有助于解释tcDNA修饰寡核苷酸显示出显著增强的核酸酶抗性。三环-DNA也被广泛用于修饰了PS的ASO间隙探针内进行了大量测试，并且在没有肝毒性的情况下表现出强大的反义活性。</span>

Finally, the aforementioned methanocarbacyclic N-MC and S-MC sugar modifications also feature a cyclopropyl moiety, between C4′ and C7′ (replaces O4′) and C7′ and C1′, respectively (Figure 14). This rather simple measure locks the pucker in the North C2′-*exo* (N-MC) or South C3′-*exo* (S-MC) mode. The N-MC analogue was combined with the 2′-fluoro modification (2′-F-NMC), initially only at the level of thymidine. More recently all four nucleoside phosphoramidites have been prepared and incorporated into siRNAs to evaluate the activity of this modification in the context of RNAi.

<span style=color:blue>最后，前述的甲基环丙基 N-MC 和 S-MC 糖修饰也具有环丙基基团，分别位于 C4′ 和 C7′（取代 O4′）以及 C7′ 和 C1′ 之间（见图14）。这种相对简单的措施将糖构象锁定在北向 C2′-*exo*（N-MC）或南向 C3′-*exo*（S-MC）模式。N-MC 类似物与 2′-氟修饰（2′-F-NMC）结合，最初仅在胸腺嘧啶水平上进行。最近，已制备了所有四种核苷酸磷酰胺酯，并将其合并到 siRNA 中，以评估该修饰在 RNAi 环境中的活性。</span>

## RNAi THERAPEUTICS: DOUBLE-STRANDED MECHANISM OF ACTION RNAi治疗：双链作用机制

### A natural defense and regulatory system 一种天然的防御和调控系统

The most obvious difference between ASOs and small interfering RNAs (siRNAs) as embodied by current oligonucleotide therapeutics is that the former are single-stranded and the latter double-stranded (Figure 4). The origin of the double-stranded nature of siRNA is not entirely clear. It may be rooted in the archaeal ancestry of the eukaryotic Argonaute (eAgo) proteins or a consequence of a subsequently acquired mode of action during the assembly of the eukaryotic RNA interference (RNAi) machinery from prokaryotic sources. Thus, all cell-based life forms rely on defense systems that provide protection against viruses or transposable elements. The actual mechanism involves a DNA- or RNA-based guide that directs a nuclease (slicer) to destroy the target, whereby specificity is conferred by base complementarity between guide and target.

<span style=color:blue>当前核酸药物中的短寡核苷酸（ASO）和小干扰RNA（siRNA）的最明显区别在于前者是单链结构，而后者是双链结构（图 4）。siRNA的双链性质的起源尚不完全清楚。它可能源于真核生物阿尔卡纳酶（eAgo）蛋白的古菌祖先，或者是在真核生物RNA干扰（RNAi）机制的组装过程中从原核源头后续获得的一种作用模式。因此，所有细胞生命形式都依赖于提供对抗病毒或可转座元件的保护的防御系统。实际的机制涉及DNA或RNA为基础的导向物，将核酸酶（切割酶）定向破坏目标，其中导向物和目标之间的碱基互补性赋予了特异性。</span>

A ribozyme would represent the primordial version of this defense mechanism in that the catalytic RNA combines guide and nuclease. Because host and parasite have co-evolved since the earliest stages of cellular life, defense mechanisms must have emerged simultaneously as part of the diversification of host cells and given rise to the host-parasite arms race that is a central element in the evolution of life. The prokaryotic Ago system (pAgo) is the direct predecessor of eAgo and constitutes the core of proteins and domains that underlie DNA- or RNA-guided innate immunity. Proteins containing MID, PIWI and/or PAZ domains (Figures 8 and 15A) and potentially associated with other nucleases, helicases and nucleic acid-binding proteins served RNA guide processing, maturation and amplification and the subsequent recognition and destruction of targets.

<span style=color:blue>在这种防御机制中，核酸酶可以被视为原始版本，因为催化RNA结合了导向物和核酸酶的功能。由于宿主和寄生体在细胞生命的早期阶段就共同进化，防御机制必须同时出现作为宿主细胞多样化的一部分，并导致了宿主-寄生体的军备竞赛，这是生命进化的一个核心元素。原核生物中的阿尔卡纳酶系统（pAgo）是真核生物阿尔卡纳酶（eAgo）的直接前身，它构成了在DNA-或RNA引导下的固有免疫中起核心作用的蛋白质和结构域。包含MID、PIWI和/或PAZ结构域的蛋白质（图8和图15A）以及潜在与其他核酸酶、解旋酶和核酸结合蛋白相关的蛋白质，用于RNA导向物的处理、成熟和扩增，以及随后对目标的识别和破坏。</span>

**图 15.**

![(A) Crystal structure at 2.5 Å resolution of human Ago2 in complex with a guide (red)-passenger (blue) strand siRNA duplex (PDB ID 4w5t) (217). Individual enzyme domains are colored differently and are labeled; N-terminal and linker domains are colored in different shades of gray. The MID domain harbors the binding site for the 5′-phosphate group of the guide strand that is colored in black, highlighted in ball-and-stick mode and marked with a red P. The PIWI RNA endonuclease domain (‘slicer’) cleaves the targeted mRNA opposite guide siRNA. The PAZ domain binds to the 3′-terminal overhang of the guide strand. Dashed lines indicate missing portions of either protein or RNA, e.g. nucleotides 15 to 19 of the guide strand. The arrow points to the sharp kink between base pairs arising from AS6 and AS7. (B) Cryo EM structure at 3.3 Å resolution of Drosophila Dicer-2:R2D2 heterodimer in complex with a guide (red)-passenger (blue) strand siRNA duplex and a piece of double-stranded RNA, dsRNA (PDB ID 7v6c) (290). Individual Dicer-2 and R2D2 domains are colored differently and are labeled (R2D2 RBD, RNA binding domain and CTD, C-terminal domain). Regions in Dicer-2 outside the helicase, RNase III and platform-PAZ domains are colored in light gray, and dashed lines indicate missing portions in the protein chains.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig15.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">(<span style=font-weight:bold>A</span>) 人类Ago2与引导（红色）-乘客（蓝色）链siRNA双链复合物的晶体结构，分辨率为2.5 Å（PDB ID 4w5t）。各个酶结构域以不同的颜色进行标记；N末端和连接区域以不同的灰色阴影进行标记。MID结构域含有引导链5'-磷酸基团的结合位点，以黑色表示，在球棒模式下突出显示，并用红色P标记。PIWI RNA内切酶结构域（“切割酶”）在引导siRNA相对于靶向mRNA的位置进行切割。PAZ结构域结合于引导链的3'-末端突出部分。虚线表示蛋白质或RNA的缺失部分，例如引导链的核苷酸15至19。箭头指向由AS6和AS7引起的碱基对之间的急剧弯曲。<br>(<span style=font-weight:bold>B</span>) Drosophila Dicer-2：R2D2异二聚体与引导（红色）-乘客（蓝色）链siRNA双链和一段双链RNA（dsRNA）的低温电镜结构，分辨率为3.3 Å（PDB ID 7v6c）。Dicer-2和R2D2各自的结构域以不同的颜色进行标记（R2D2 RBD，RNA结合域和CTD，C末端域）。Dicer-2中螺旋酶、RNase III和平台-PAZ结构域之外的区域以浅灰色进行标记，虚线表示蛋白链中的缺失部分。</span></center>

The eAgo system features additional components such as Dicer (Figure 15B) with a helicase domain of archaeal origin and RNase III domains of bacterial origin as well as RNA-dependent RNA polymerase (RdRp) of phage origin that emerged from a predecessor DdRp and is concerned with siRNA amplification in eukaryotes. Dicer is the endoribonuclease that processes double-stranded RNA (dsRNA) into siRNA (hence the double-stranded nature of fragments), and pre-microRNA into miRNA. In eukaryotic cells, the RNAi machinery sets up the innate immunity response and the piwiRNA branch constitutes the distinct type of adaptive immunity. In the evolution of the eukaryotic RNAi machinery, the prokaryotic CRISPR/Cas system that represents adaptive immunity in the lower organisms was thus discarded. Not only is the eAgo system inherently more complex than its pAgo predecessor, but it exclusively uses RNA guides and chiefly targets RNA, a change that was presumably triggered by the transition from the prokaryotic world of viruses mainly governed by DNA to a eukaryotic virosphere that is dominated by RNA viruses.

<span style=color:blue>eAgo系统具有额外的组分，例如具有古菌起源的螺旋酶结构域和具有细菌起源的RNase III结构域的Dicer（图15B），以及具有噬菌体起源的RNA依赖性RNA聚合酶（RdRp），它起源于前体DdRp，并参与真核生物中的siRNA扩增。Dicer是内切核酸酶，可将双链RNA（dsRNA）处理成siRNA（因此片段具有双链性），并将前体微小RNA处理成微小RNA。在真核细胞中，RNAi机制建立了先天免疫响应，而piwiRNA分支构成了独特类型的适应性免疫。在真核RNAi机制的演化过程中，代表低级生物中适应性免疫的原核CRISPR/Cas系统被舍弃。eAgo系统不仅固有比其pAgo前体更复杂，而且仅使用RNA引导，并主要靶向RNA，这种变化可能是由于从主要由DNA主导的原核病毒世界过渡到以RNA病毒为主导的真核生物病毒界。</span>

The discovery of RNAi as the agent of gene silencing in *C. elegans* and later the demonstration that short dsRNA fragments could be used to silence genes in mammalian cells without triggering an immune response was greeted with excitement, as it offered a path to a new therapeutic approach by hitchhiking on a natural defense and regulatory machine. Andrew Z. Fire and Craig C. Mellow were jointly awarded the 2006 Nobel Prize in Physiology or Medicine for their discovery of RNA interference - gene silencing by double-stranded RNA. However, the challenges encountered with early clinical trials echoed those with ASOs a decade before and included toxicity related to immune stimulation, problems with delivery and insufficient therapeutic efficacy .

<span style=color:blue>在线虫C. elegans中发现RNAi作为基因沉默的机制，随后证明可以使用短的双链RNA片段在哺乳动物细胞中沉默基因而不引发免疫反应，这一发现令人兴奋，因为它为一种新的治疗方法提供了可能，通过利用天然的防御和调控机制。安德鲁·Z·费尔（Andrew Z. Fire）和克雷格·C·梅洛（Craig C. Mellow）因其发现RNA干扰-双链RNA引起的基因沉默而共同获得了2006年诺贝尔生理学或医学奖。然而，早期临床试验中遇到的挑战与10年前ASO的问题相似，包括与免疫刺激相关的毒性、递送问题和治疗效果不足。</span>

However, RNAi established itself very quickly as a powerful tool in cell-based assays, using either transfection or vector-based delivery in combination with high-throughput screens to knockdown gene expression to ferret out their function and for target validation. As well, existing ASO modification chemistries could be applied immediately to siRNAs and tested. Although effective for downregulating genes in vitro, unmodified siRNAs are quickly degraded in vivo and protective steps need to be taken to prevent degradation by nucleases. Unlike natural noncoding RNAs that are composed mostly of native ribonucleotides and sparsely modified, RNAi therapeutics require extensive chemical modification.

<span style=color:blue>然而，RNAi迅速成为细胞基因分析的有力工具，在转染或基于载体的递送方式结合高通量筛选中使用，以降低基因表达并揭示其功能和进行靶点验证。此外，现有的ASO修饰化学方法可以立即应用于siRNA并进行测试。虽然在体外能有效下调基因表达，但未修饰的siRNA在体内很快被核酸酶降解，因此需要采取保护措施来防止降解。与主要由天然核苷酸组成且稀疏修饰的自然非编码RNA不同，RNAi治疗需要进行广泛的化学修饰。</span>

Shared features between ASOs and siRNAs contrast with clear differences. As pointed out above, siRNAs are 21mer duplexes that consist of the paired guide (antisense, AS) and passenger (sense, S) strands (Figure 4). Although activity based on the guide strand alone (ss-siRNA) has been demonstrated, the use of duplex constructs remains much more common. The nuclease in RNAi-mediated cleavage of target mRNA is Ago2, whereby the PIWI domain that adopts an RNase H-like fold harbors the endonuclease (Figure 8). Deviating architectures of RNase H and Ago2 create fundamentally different protein interactions with ASO and guide RNA that direct degradation of their respective targets. Among the Ago family of proteins, Ago2 is the only one that possesses endonuclease activity. Other family members are involved in miRNA-mediated pathways of post-transcriptional regulation.

<span style=color:blue>ASO和siRNA之间存在一些共同特征，但也存在明显的差异。正如上面指出的那样，siRNA是由成对的导向链（反义链，AS）和乘客链（正义链，S）组成的21碱基双链结构（图4）。虽然单独使用导向链（ss-siRNA）已经被证明具有活性，但双链结构的使用更为普遍。RNAi介导的靶mRNA裂解的核酸酶是Ago2，其中采用RNase H样折叠的PIWI结构域具有内切酶活性（图8）。RNase H和Ago2的不同结构决定了它们与ASO和导向RNA的蛋白质相互作用的根本差异，从而指导了它们各自目标的降解。在Ago蛋白家族中，Ago2是唯一具有内切酶活性的成员，其他成员参与miRNA介导的转录后调控途径。</span>

The various steps of RNA interference using an exogenous siRNA are depicted in Figure 16. Following delivery and cellular uptake, (i) the siRNA duplex is loaded into RISC Ago2, (ii) the passenger strand is peeled off the guide strand and discarded, (iii) after which the target mRNA is accommodated opposite the guide siRNA, (iv) prompting cleavage of the former by Ago2 and (v) removal of the sliced target and initiation of the next round of endo-nucleolytic cleavage. The illustration in Figure 16 highlights another difference between guide siRNA and ASO, namely a 5′-phosphate group in the former that is important for recognition and stable binding of the guide as well as discriminating between guide and passenger strands (Figure 15A).

<span style=color:blue>图16展示了使用外源siRNA进行RNA干扰的各个步骤。在递送和细胞摄取之后，（i）siRNA双链结构被加载到RISC Ago2中，（ii）乘客链从导向链上剥离并丢弃，（iii）之后，目标mRNA与导向siRNA相互配对，（iv）促使Ago2剪切目标mRNA，（v）移除剪切的目标mRNA并启动下一轮内切剪切。图16中的插图突出了导向siRNA和ASO之间的另一个差异，即导向siRNA具有重要的5'-磷酸基团，该基团对于识别和稳定结合导向链以及区分导向链和乘客链起着重要作用（图15A）。</span>

**图 16.**

![(A) Individual steps of RNA interference directed by exogenously delivered siRNA: (1) RISC loading, (2) passenger strand removal, (3) binding of mRNA target, (4) target cleavage, and (5) release of cleavage products and pairing with the next target to begin a new round of cleavage. Guide siRNA, passenger siRNA, and mRNA target are colored in red, blue and black, respectively. The Ago2 MID domain is highlighted in green and red and gray dots mark the 5′-terminal phosphate and 3′-terminal TT overhang, respectively. (B) The phosphodiester cleavage reaction catalyzed by Ago2.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig16.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">(<span style=font-weight:bold>A</span>) 外源siRNA引导的RNA干扰的各个步骤：(1) RISC加载，(2) 乘客链剥离，(3) 与mRNA目标结合，(4) 目标剪切，(5) 释放剪切产物并与下一个目标配对，开始新一轮剪切。导向siRNA、乘客siRNA和mRNA目标分别以红色、蓝色和黑色表示。Ago2 MID结构域以绿色和红色突出显示，灰色圆点标记5'-端磷酸基团和3'-端TT末端突出。</span></center>

The presence of two strands and the lack of proper discrimination between them can trigger an off-target effect (OTE). An OTE can arise from a passenger strand directing cleavage of a complementary target, i.e. sense-mediated silencing. Alternatively, downregulation of an mRNA target is based on partial complementarity between siRNA and mRNA target, also referred to as seed-mediated silencing (the seed region entails nucleotides 2–8 of the guide strand). Other OTEs are the induction of type I interferons and inflammatory cytokines (immune stimulation) and upregulation of miRNA-controlled genes as a result of a saturation of the RNAi machinery . Shortened passenger strands as well as blunt-end siRNA designs were introduced to counter the likelihood of OTEs.

<span style=color:blue>存在两条链和缺乏正确鉴别它们之间的区别可能会引发离靶效应（OTE）。OTE可以源自乘客链引导对互补靶点的剪切，即正义介导的沉默。另外，mRNA靶点的下调基于siRNA与mRNA靶点之间的部分互补性，也称为种子介导的沉默（种子区域包括导向链的核苷酸2-8）。其他OTE包括诱导I型干扰素和炎性细胞因子（免疫刺激）以及miRNA调控基因的上调，这是由于RNAi机制的饱和所致。为了减少OTE的可能性，人们引入了缩短的乘客链以及带有钝端的siRNA设计。</span>

Compared to ASOs, the double-stranded nature of siRNAs also creates unique challenges for delivery that need to be addressed with tailored approaches for formulation and new modification/conjugation chemistries. Not unexpectedly, single-stranded ASO and siRNA duplexes exhibit divergent pharmacokinetic and pharmacodynamic profiles. To make siRNAs into drugs, chemical modification strategies need to consider both the guide and the passenger strand, thus precluding a uniform modification design seen, for example, with SSO therapeutics such as SPINRAZA or EXONDYS 51.

<span style=color:blue>将siRNA与ASO相比，siRNA双链结构的特性也为传递提出了独特的挑战，需要针对性地进行配方和新的修饰/偶联化化学策略。预料之中的是，单链ASO和siRNA双链在药代动力学和药效动力学特性上表现出差异。为将siRNA转化为药物，化学修饰策略需要同时考虑引导链和载客链，这使得无法像SPINRAZA或EXONDYS 51等SSO药物一样采用统一的修饰设计。</span>

### Initial RNA modifications: PS, 2′-*O*-Me and 2′-F 初始RNA修饰：PS、2'-O-Me和2'-F

We discussed in detail the benefits of the phosphorothioate and 2′-*O*-modifications for ASOs and SSOs. They include nuclease protection, conformational preorganization and enhanced pairing strength (2′-*O*-mods.), low toxicity and favorable pharmacokinetic and pharmacodynamic behavior (PS, MOE). In a study dating back almost a decade, we compared the in vitro and in vivo efficacies of various 2′-modifications in siRNA against Factor VII, an established endogenous target system. In both the guide (AS) and passenger (S) strands every pyrimidine ribonucleotide was replaced with the 2′-F, 2′-*O*-Me, 2′-*O*-MOE or LNA analogues. Relative levels of Factor VII protein were measured in mice on day 2 and up to three weeks after administering 2, 3 or 5 mg/kg of F/F, OMe/OMe, MOE/MOE, LNA/LNA, OMe/F, MOE/F or LNA/F (S/AS strands) siRNA in a lipid formulation. Factor VII amounts resulting from treatment with the F/F combination were >3-fold lower than those seen with the second ranked siRNA, LNA/F and ca. 10-fold reduced relative to the levels measured for OMe/OMe, MOE/MOE and LNA/LNA.

<span style=color:blue>我们详细讨论了磷酸硫酯和2'-O-修饰对ASO和SSO的益处。这些益处包括核酸酶保护、构象预先组织和增强配对强度（2'-O-修饰）、低毒性以及良好的药代动力学和药效动力学特性（PS、MOE）。在将近十年前的一项研究中，我们比较了针对凝血因子VII的siRNA中不同2'-修饰在体外和体内的疗效。在引导链（AS）和载客链（S）上，每个嘧啶核苷酸被2'-F、2'-O-Me、2'-O-MOE或LNA类似物所取代。在小鼠体内，给予2、3或5 mg/kg F/F、OMe/OMe、MOE/MOE、LNA/LNA、OMe/F、MOE/F或LNA/F（S/AS链）的siRNA脂质配方后，测量了第2天和至少三周内因子VII蛋白的相对水平。F/F组合处理后的因子VII水平比第二高的LNA/F siRNA低3倍以上，并且相对于OMe/OMe、MOE/MOE和LNA/LNA的水平降低了约10倍。</span>

The overall ranking was as follows: F/F < LNA/F < OMe/F < MOE/F ≈ MOE/MOE ≈ OMe/OMe ≈ LNA/LNA. The F/F siRNA also outperformed the parent duplex (OH/OH) in terms of silencing and was non-immunostimulatory, unlike OH/OH that stimulated IFN-α and TNF-α. The melting temperature (*T*m) of the F/F duplex was about 20°C above that of the parent duplex, but LNA/LNA and MOE/MOE as well as LNA/F and MOE/F duplexes were all more stable than F/F. The increased stability of the F/F duplex is chiefly enthalpy-based which points to improved stacking and/or H-bonding interactions because of fluorine modification. Indeed, we subsequently demonstrated using solution NMR and thermodynamic assays with RNA hairpins that featured 2′-F-modified overhangs at the 3′-end that the fluorine modification strengthens both Watson-Crick H-bonds and base stacking.

<span style=color:blue>整体排序如下：F/F < LNA/F < OMe/F < MOE/F ≈ MOE/MOE ≈ OMe/OMe ≈ LNA/LNA。与OH/OH相比，F/F siRNA在基因沉默方面表现出色，并且不具有免疫刺激性，而OH/OH会刺激IFN-α和TNF-α的产生。F/F双链的熔化温度（Tm）比母体双链高约20°C，但LNA/LNA、MOE/MOE以及LNA/F和MOE/F双链都比F/F更稳定。F/F双链的增加稳定性主要基于焓，这表明氟修饰改善了叠合和/或氢键作用。事实上，我们随后通过使用溶液核磁共振和热力学测定，针对具有2'-F修饰的RNA发夹结构，特别是在3'-端具有氟修饰的突出部分，证明了氟修饰强化了Watson-Crick氢键和碱基叠合。</span>

Fluorine is smaller than the 2′-hydroxyl group, hydrophobic and typically lacks the ability to participate in H-bonds. This is definitely the case in the RNA minor groove as we showed using crystallographic data and osmotic stressing assays  (Figure 17). However, organic fluorine leads somewhat of a double life and there have been observations where it does act as an H-bond acceptor. The poor hydration in the minor groove precludes the need for de-solvation of 2′-F-modified siRNA upon transport and uptake and may have an impact on cellular trafficking and endosomal release. One limitation of the 2′-F modification is the limited protection against nuclease degradation it affords compared to other 2′-modifications such as 2′-*O*-Me and 2′-*O*-MOE. Moreover, at high concentrations 2′-F nucleotides are recognized, although somewhat poorly, by human RNA polymerases.

<span style=color:blue>氟原子比2'-羟基基团要小，具有疏水性，并且通常缺乏参与氢键的能力。我们使用晶体学数据和渗透压应激实验（图17）证明了这一点，尤其是在RNA的小凹槽中。然而，有时有观察到有机氟会作为氢键受体发挥作用。小凹槽中的贫水化情况消除了在转运和摄取过程中需要对2'-F修饰的siRNA进行去溶剂化的需求，并可能对细胞转运和内体释放产生影响。2'-F修饰的局限性之一是相对于其他2'-修饰（如2'-*O*-Me和2'-*O*-MOE），它对核酸酶降解的保护作用有限。此外，在高浓度下，2'-F核苷酸会被人类RNA聚合酶识别，尽管识别效果不佳。</span>

**图 17.**

![Effects of chemical modification on the water structure around RNA. Minor groove hydration in (A) RNA and (B) 2′-F-RNA. RNA 2′-hydroxyl groups serve as bridge heads for tandem water bridges across the minor groove (89). Introduction of fluorine (highlighted in green) abolishes H-bonds between 2′-substituent and water, as apparent by altered distances and shifted water molecules. (291,294). Water molecules are gray spheres, H-bonds are thin solid lines and selected distances are indicated by dashed lines.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig17.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">化学修饰对RNA周围水结构的影响。(<span style=font-weight:bold>A</span>) RNA和(<span style=font-weight:bold>B</span>) 2'-F-RNA中的小凹槽贫水化。RNA中的2'-羟基基团作为小凹槽中串联水桥的桥头。氟原子的引入（绿色高亮显示）破坏了2'-取代基与水之间的氢键，通过距离的改变和水分子的偏移可观察到。水分子用灰色球体表示，氢键用细实线表示，选择的距离用虚线表示。</span></center>

A design principle that emerged as a solution to these shortcomings is to combine 2′-F and 2′-*O*-Me modified nucleotides in fully modified siRNAs. An example of the successful application of this approach is GIVLAARI (givosiran), an siRNA approved by the US FDA in 2019 for treatment of acute hepatic porphyria (Figures 1 and 18). GIVLAARI also contains pairs of PS modifications at the 5′- and 3′-ends of the guide siRNA as well as PS modifications on the first and second phosphates in the passenger siRNA as well as the triantennary GalNAc linker at its 3′-end to facilitate uptake (vide infra).

<span style=color:blue>将2'-F和2'-O-Me修饰的核苷酸结合在完全修饰的siRNA中成为解决这些缺点的设计原则。成功应用该方法的一个例子是GIVLAARI（givosiran），这是一种在2019年获得美国FDA批准用于治疗急性肝性卟啉病的siRNA（图1和图18）。GIVLAARI还包含在引导siRNA的5'-和3'-末端的PS修饰对以及旅客siRNA中第一个和第二个磷酸基的PS修饰，以及三糖基GalNAc连接剂位于其3'-末端以促进摄取（见下文）。</span>

**图 18.**

![Guide and passenger strand sequences and modifications in the five RNAi therapeutics that have received market approval to date. (A) ONPATTRO, (B) GIVLAARI, (C) OXLUMO, (D) LEQVIO and (E) AMVUTTRA. Ribo-, 2′-deoxyribo-, 2′-O-Me- and 2′-F-nucleotides are depicted as circles colored in red, blue, black and green, respectively. GIVLAARI, OXLUMO, LEQVIO and AMVUTTRA feature PS modifications (orange bars) and a triantennary GalNAc conjugate at the 3′-terminal end of the passenger strand.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig18.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">迄今为止获得市场批准的五种RNAi治疗药物的引导链和旅客链的序列和修饰。(<span style=font-weight:bold>A</span>) ONPATTRO, (<span style=font-weight:bold>B</span>) GIVLAARI, (<span style=font-weight:bold>C</span>) OXLUMO, (<span style=font-weight:bold>D</span>) LEQVIO和(<span style=font-weight:bold>E</span>) AMVUTTRA。核糖核苷酸（Ribo-）、2'-脱氧核糖核苷酸（2'-deoxyribo-）、2'-*O*-Me核苷酸和2'-F核苷酸分别以红色、蓝色、黑色和绿色的圆圈表示。GIVLAARI、OXLUMO、LEQVIO和AMVUTTRA在旅客链的3'-末端具有PS修饰（橙色条）和三糖基GalNAc偶联物。</span></center>

As mentioned above, MOE modification of siRNA strands did not result in favorable in vitro or in vivo efficacies against the Factor VII targe. The modification is sterically quite demanding in the minor groove and a model of a modified RNA duplex bound to Piwi protein revealed clashes between protein side chains and MOE substituents at the protein-siRNA interface. Conversely the small fluorine substituent is well tolerated and mimics 2′-hydroxyl groups in the complex with the parent duplex. Thus, it is the only 2′-modification that is tolerated at the second position of the guide strand (AS2), where Ago2 forces the RNA to make a tight turn. We also used the crystal structure of human Ago2 in complex with miR-20a to build a model with 2′-*O*-MOE substituents attached to all residues of the guide strand seed region (AS2–AS8). The model exposed clashes between all MOE moieties and Ago2 side chains, indicating that the MOE modification is likely too bulky to be accommodated at many sites in the siRNA guide and passenger strands. An MOE-modified residue was introduced at the first position of the guide strand (AS1), but the crystal structure of the complex with Ago2 did not reveal an interaction between the 2′-*O*-substituent and MID domain residues.

<span style=color:blue>如上所述，MOE修饰的siRNA链对于Factor VII靶点的体外或体内疗效不佳。这种修饰在次要沟槽中的空间要求较高，在与Piwi蛋白结合的修改RNA双链模型中，蛋白质侧链与MOE取代基在蛋白质-siRNA界面存在冲突。相反，较小的氟取代基能够很好地容忍，并在与母体双链的复合物中模拟2'-羟基基团。因此，它是唯一能够容忍在引导链第二位置（AS2）的2'-修饰，Ago2迫使RNA产生紧密转向。我们还利用人类Ago2与miR-20a复合物的晶体结构，构建了一个模型，其中引导链种子区（AS2-AS8）的所有残基都附有2'-*O*-MOE取代基。该模型显示所有MOE基团与Ago2侧链之间存在冲突，表明MOE修饰可能过于庞大，无法适应siRNA引导链和旅客链中的许多位点。在引导链的第一个位置（AS1）引入了一个MOE修饰残基，但与Ago2的结晶结构并未显示2'-*O*-取代基与MID结构域残基之间的相互作用。</span>

Another modification at that site, 2′-*O*-[2-(methylamino)-2-oxoethyl] (2′-*O*-NMA), in combination with a 5′-(*E*)-vinylphosphonate ((*E*)-VP) moiety, a metabolically stable phosphate mimic (Figure 19), improved RISC loading and showed robust siRNA-mediated gene silencing. A structural model of 5′-terminal guide strand residues with 5′-(*E*)-VP/2′-*O*-NMA-U at AS1 bound to Ago2 was consistent with an H-bond between the NMA substituent and the side chain of Gln-548 that together with Asn-551 stabilizes the tight turn in the guide strand at that site.

<span style=color:blue>在该位置上的另一种修饰是2'-*O*-[2-(甲基氨基)-2-氧代乙基]（2'-*O*-NMA），结合具有代谢稳定性的磷酸盐模拟物5'-(*E*)-乙烯基膦酸酯((*E*)-VP)（见图19），改善了RISC的装载并展示了强大的siRNA介导的基因沉默作用。将5'-(*E*)-VP/2'-*O*-NMA-U与AS1处的5'-端引导链残基结合于Ago2的结构模型与NMA取代基和Gln-548的侧链之间的H键相一致，Gln-548与Asn-551一起稳定了引导链在该位点的紧密转向。</span>



**图 19.**

![Structures of the phosphate analog E-vinylphosphonate (E-VP, left), (S)-GNA (center), and the amide backbone linkage (AM1, right).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig19.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">磷酸盐模拟物<span style=font-style:italic>E</span>-乙烯基膦酸酯（<span style=font-style:italic>E</span>-VP，左图），（<span style=font-style:italic>S</span>）-GNA（中图），和酰胺骨架连接（AM1，右图）的结构。</span></center>

### Conformational flexibility and reduced off-target effects: GNA

We touched upon off-target effects (OTEs) in the siRNA introductory section and discussed the various origins and types of OTEs, including silencing of genes due to passenger strand activity and RNAi-mediated silencing caused by matching sequences between guide-strand seed region and non-targeted RNAs. Careful selection of target sequence and region, avoidance of non-Ago2 mediated silencing involving guide-strand seed pairing opposite non-targeted sequences (activation of miRNA pathway of silencing) and reduced dosage combined with chemical modification to modulate seed pairing can all reduce OTEs. The latter idea was inspired by a kink between nucleotides AS6 and AS7 in the siRNA seed region in the structures of Ago2 complexes bound either to miRNA or guide/passenger strand seed duplexes (Figure 15A). The wrinkle in the RNA chain causes local unstacking and appears to be promoted by an isoleucine side chain that inserts itself between AS6 and AS7 nucleobases. Moreover, the RNA backbone at the site of the kink is characterized by closely spaced phosphate groups, whereby potential Coulombic repulsion is relieved by adjacent arginine residues.

<span style=color:blue>我们在siRNA的介绍部分提到了非特异性作用效应（OTEs），并讨论了各种OTEs的起源和类型，包括由于乘客链活性引起的基因沉默，以及由导引链种子区与非靶向RNA之间匹配序列导致的RNAi介导的沉默。通过仔细选择目标序列和区域、避免非Ago2介导的沉默、减少剂量以及化学修饰来调节种子区的配对，都可以减少OTEs。后一种思路受到了siRNA种子区中AS6和AS7核苷酸之间的弯曲现象的启发，该现象在结合miRNA或导引链/乘客链种子双链结构的Ago2复合物中观察到（图15A）。RNA链的弯曲导致局部非叠加，并且似乎由一支异亮氨酸侧链插入AS6和AS7核苷酸之间所促进。此外，弯曲部位的RNA磷酸骨架具有密集排列的磷酸基团，邻近的精氨酸残基可以缓解潜在的库仑斥力。</span>

Incorporation of an (*S*)-glycol nucleic acid (GNA, Figure 19) residue or GNA base pair at the site of the kink resulted in favorable in vitro and in vivo silencing activity of the modified siRNA relative to the parent duplex (ca. 2-fold gain in potency). GNA is the simplest phosphate-based nucleic acid, lacks a cyclic sugar moiety and its backbone is shortened by a bond compared to DNA and RNA. GNA is chiral and the pairing behavior is quite unusual. GNA self-pairing is of the Watson-Crick type, but base pairs are inverted—like in left-handed Z-DNA—inside the (*S*)-GNA right-handed duplex with a backbone geometry that resembles the A-form. Paired opposite RNA—only (*S*)-GNA pairs with RNA but not (*R*)-GNA—GNA does not alter its inverted base orientation. Thanks to its shorter backbone (*S*)-GNA mimics the kinked RNA conformation between AS6 and AS7, thereby mitigating OTEs. First, GNA conformationally preorganizes the RNA backbone for the kinked conformation that is sculpted by Ago2 after loading. Second, the conformationally flexible GNA residue incorporated into RNA lowers the thermodynamic stability of modified duplexes and depresses the affinity of pairing between guide siRNA seed region and matching sequences of non-targeted RNAs. This work demonstrated the benefits of structure-based and regiospecific chemical modification of siRNAs.

<span style=color:blue>在弯曲点的位置引入(*S*)-甘醇核酸（GNA，见图19）残基或GNA碱基对相对于母体双链的修饰siRNA表现出有利的体外和体内沉默活性（效力增加约2倍）。GNA是最简单的基于磷酸的核酸，不含有环糖基团，其骨架相对于DNA和RNA而言缩短了一条化学键。GNA是手性的，其碱基配对行为非常不寻常。GNA自身的配对是属于Watson-Crick型，但碱基对是倒置的——就像左手Z-DNA一样——在(*S*)-GNA右手双链内，其骨架几何形状类似A型。与RNA相配对时，只有(*S*)-GNA与RNA配对，而不是(*R*)-GNA。GNA不改变其倒置的碱基取向。由于其较短的骨架，(*S*)-GNA模拟了AS6和AS7之间弯曲的RNA构象，从而减轻了OTEs。首先，GNA在构象上预组织了RNA骨架，使其形成由Ago2负载后塑造的弯曲构象。其次，结构具有构象灵活性的GNA残基降低了修饰双链的热力学稳定性，并降低了导引siRNA种子区与非靶向RNA匹配序列之间的配对亲和力。这项研究展示了基于结构和区域特异性的化学修饰对siRNA的益处。</span>

There are many other design strategies to combat RNAi OTEs and improve siRNA potency. A recent example is the blockage of 5′-phosphorylation of the passenger strand by a 5′-morpholino modification. This modification results in improved antisense strand selection and RNAi activity. When the morpholino moiety is placed at the 5′-end of the guide strand it triggers complete loss of activity. Morpholino modification makes the sense strand siRNA a more effective passenger and can be combined with the (*E*)-VP moiety instead of phosphate at the 5′-end of the guide strand (Figure 19). The interaction between the 5′-phosphate and a strongly positively polarized binding pocket on the MID domain is probably key to loading and discrimination between guide and passenger strand. The (*E*)-VP but not the (*Z*)-VP modification mimics the 5′-phosphate bound to MID and affords enhanced potency by precluding dephosphorylation and repeated phosphorylation in cellular environments. The enhanced stability and activity afforded by the (*E*)-VP phosphate analog is particularly important for ss-siRNA efficacy.

<span style=color:blue>有许多其他的设计策略可以应对RNAi的OTEs并提高siRNA的效力。最近的一个例子是通过5'-morpholino修饰阻断载体链的5'-磷酸化。这种修饰导致改善了反义链的选择和RNAi活性。当morpholino基团位于导引链的5'-末端时，会导致完全失去活性。Morpholino修饰使正义链的siRNA成为更有效的载体，并且可以与(*E*)-VP基团结合在导引链的5'-末端，取代磷酸酯（见图19）。5'-磷酸与MID结构域上强正极化的结合口袋之间的相互作用可能对导引链和载体链的加载和区分起关键作用。(*E*)-VP但不是(*Z*)-VP修饰模拟了结合到MID的5'-磷酸酯，并通过阻止细胞环境中的脱磷酸化和重复磷酸化来提供增强的效力。(*E*)-VP磷酸酯类似物提供的增强稳定性和活性对于ss-siRNA的疗效尤为重要。</span>

Finally, yet another way for reducing potential OTEs was demonstrated with a neutral amide modification (Figure 19) that replaces the RNA phosphate group. Amides are well tolerated at many sites in the backbone of guide and passenger strands and were found to emulate interactions between the negatively charged phosphate group and protein side and main chain atoms . However, the amide moiety is not a suitable mimic of the phosphate at the site of a sharp turn between the AS1 and AS2 residues of guide siRNA bound to Ago2. Thus, an amide linkage incorporated at the corresponding site in passenger siRNA, between S1 and S2, can prevent off-target activity by the sense strand.

<span style=color:blue>最后，还有一种减少潜在OTEs的方法是通过中性酰胺修饰（见图19）取代RNA的磷酸酯基团。酰胺在导引链和载体链的骨架中的许多位置上都能很好地耐受，并且发现它们模拟了磷酸酯基团与蛋白质侧链和主链原子之间的相互作用。然而，酰胺基团不适合模拟导引siRNA与Ago2结合时AS1和AS2残基之间的锐角转折点处的磷酸酯。因此，在载体siRNA的相应位置上引入酰胺连接，即S1和S2之间，可以阻止正义链的非特异性活性。</span>

### The first RNAi therapeutic: ONPATTRO 第一个 RNAi 治疗药物：ONPATTRO

In 2018, ONPATTRO® (patisiran) received approval in the US and Europe for the treatment of the hereditary disease transthyretin-mediated amyloidosis in adults. (hATTR) (Figures 1and 3, Table 1). As pointed out above, the PS/MOE-modified ASO gapmer TEGSEDI (inotersen) was granted approval by the EC and subsequently by the FDA in the same year. Both therapeutics target the 3′-UTR of *TTR* mRNA but are administered via different routes, namely intravenously and subcutaneously, respectively .

<span style=color:blue>2018年，ONPATTRO®（patisiran）在美国和欧洲获得批准，用于成人遗传性转甲状腺激素介导的淀粉样变性病（hATTR）的治疗（图1和图3，表1）。正如上文所指出的，经过PS/MOE修饰的ASO gapmer TEGSEDI（inotersen）在同一年获得欧洲委员会的批准，并随后获得了美国食品药品监督管理局的批准。这两种治疗药物的靶点都是*TTR* mRNA的3'-非翻译区（3'-UTR），但给药途径有所不同，分别为静脉注射和皮下注射。</color>

ONPATTRO features 21mer guide and passenger strands with deviating modification patterns (Figure 18A). They share the use of 2′-deoxythymidines at the 3′-ends and 2′-*O*-Me modification of selected pyrimidine nucleotides. However, in the guide only two uridines are 2′-modified as compared to five uridines and four cytidines in the passenger strand. 2′-*O*-Me modification affords increased nuclease resistance at sites that were found to be prone to strand cleavage. TEGSEDI and ONPATTRO exhibited somewhat different safety profiles in phase 3 clinical trials, whereby thrombocytopenia, renal dysfunction or elevated levels of liver enzymes were not observed with administration of ONPATTRO. ONPATTRO is delivered in a lipid nanoparticle (LNP) formulation and in order to minimize potential proinflammatory effects, patients are pretreated with H1 and H2 antihistamines, an analgesic and a glucocorticoid. LNP formulation is not unique to ONPATTRO, as 10 other LNP drugs have been given the green light by regulatory agencies over the last 30 years. However, ONPATTRO is the only oligonucleotide therapeutic so far that employs LNPs for delivery (Figures 2B and 20).

<span style=color:blue>ONPATTRO具有21碱基的引导链和过客链，并具有不同的修饰模式（图18A）。它们共享在3'-末端使用2'-脱氧胸苷和选择性嘧啶核苷酸的2'-*O*-Me修饰。然而，在引导链中，只有两个尿嘧啶核苷酸进行2'-修饰，而在旅行链中有五个尿嘧啶核苷酸和四个胞嘧啶核苷酸进行2'-修饰。2'-*O*-Me修饰可增强易受链断裂的位点的核酸酶抗性。在3期临床试验中，TEGSEDI和ONPATTRO显示出略有不同的安全性特征，其中在使用ONPATTRO时未观察到血小板减少、肾功能障碍或肝酶水平升高。ONPATTRO采用脂质纳米粒（LNP）制剂进行传递，并且为了最小化潜在的促炎作用，患者在治疗前接受H1和H2抗组胺药物、镇痛药和糖皮质激素预处理。LNP制剂并不是ONPATTRO独有的，过去30年中已经有其他10种LNP药物获得了监管机构的批准。然而，ONPATTRO是迄今为止唯一一种使用LNP进行传递的寡核苷酸治疗药物（图2B和20）。</span>

**图 20.**

![Platforms for delivery of functional siRNAs to liver: LNPs vs. GalNAc-siRNA conjugates.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig20.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">用于将功能性siRNA传递到肝脏的平台：LNP与GalNAc-siRNA偶联物。</span></center>

The success with LNP formulation built on the initial breakthroughs with systemic delivery of modified siRNA by i.v. in mice and systemic delivery in a liposomal formulation to non-human primates. Although LNP formulation had been developed for delivery of small molecule drugs, those concepts did not yield viable formulations for clinical use of the much larger and negatively charged siRNAs. Ultimately, it took several breakthroughs to optimize LNPs with the ability to encapsulate the siRNA duplex and deliver it to the cytoplasm of hepatocytes in vivo. One of these was the identification of ionizable cationic lipids that are positively charged at acidic pH but neutral at physiological pH to prevent toxic effects due to immune stimulation triggered by positively charged systems. Another was the use of PEG lipids with C14 acyl chains for incorporation into the surface of LNPs to generate diameters in the 20–100 nm range and minimize interactions between PEG and target cells that could hamper delivery. Lastly, a large number of ionizable lipids was screened and evaluated initially in rodents and subsequently in non-human primates in the search for a chemistry that would afford optimal potency (Figure 21A). And so ONPATTRO became the first RNAi therapeutic to be brought to market, 20 years after the discovery of RNA interference.

<span style=color:blue>在利用LNP（脂质纳米粒子）制剂进行全身性递送修饰siRNA的初始突破之后，LNP制剂在小鼠中经静脉注射和非人灵长类动物中的脂质体制剂进行全身性递送方面取得了成功。尽管LNP制剂已经被用于小分子药物的递送，但这些概念并没有产生可用于临床应用的体积更大且带有负电荷的siRNA的制剂。最终，需要进行多次突破来优化LNPs，使其能够封装siRNA双链并将其递送到体内肝细胞的细胞质中。其中之一是识别出具有在酸性pH下呈正电荷但在生理pH下呈中性的离子化阳离子脂质，以防止由正电荷系统引发的免疫刺激导致的毒性作用。另一个突破是使用具有C14酰基链的PEG脂质，用于将其纳入LNPs表面，以生成直径在20-100 nm范围内，并最大限度减少PEG与目标细胞之间的相互作用，以防止递送受阻。最后，对大量离子化脂质进行了筛选和评估，最初在啮齿动物中，随后在非人灵长类动物中，以寻找能够提供最佳效力的化学成分（图21A）。因此，ONPATTRO成为第一个RNAi治疗药物，距离RNA干扰的发现已经有20年的时间。</span>

**图 21.**

![(A) LNP multi-component formulation for efficient systemic delivery of the RNAi therapeutic ONPATTRO to hepatocytes. (B) LNP multi-component formulation for intramuscular administration of mRNA vaccines COMIRNATY and SPIKEVAX.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig21.jpeg)


<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">(<span style=font-weight:bold>A</span>) LNP多组分制剂，用于有效递送RNAi治疗药物ONPATTRO至肝细胞。</span><br><span style="background:#eef0f4;font-family:楷体;font-size:16px;">(<span style=font-weight:bold>B</span>) LNP多组分制剂，用于COMIRNATY和SPIKEVAX mRNA疫苗的肌肉注射给药。</span></center>

### GIVLAARI and acute hepatic porphyria GIVLAARI与急性肝卟啉症

GIVLAARI® (givosiran) is used in the treatment of acute hepatic porphyria (AHP) in adults and was the second RNAi therapeutic to receive approval by the FDA. AHP are rare inherited, metabolic disorders of heme biosynthesis that lead to build-up of porphyrins which negatively affects skin or the nervous system, with some patients experiencing serious and potentially life-threatening attacks. Symptoms of an attack include chest and abdominal pain, vomiting, constipation, and high blood pressure and heart rate. Treatment options depend on the type of porphyria and a patient's symptoms. Avoiding sunlight helps with porphyria of the skin and the treatment of an attack may involve intravenous application of heme or glucose solution. The disease can be inherited from one parent or both and be of the autosomal dominant, autosomal recessive or X-linked dominant types.

<span style=color:blue>GIVLAARI®（givosiran）用于治疗成年人的急性肝卟啉症（AHP），是第二个获得FDA批准的RNAi治疗药物。AHP是罕见的遗传代谢性疾病，影响血红素生物合成，导致卟啉物质的积累，进而对皮肤或神经系统产生负面影响，部分患者可能出现严重且潜在危及生命的发作。发作症状包括胸痛、腹痛、呕吐、便秘、高血压和心率增快。治疗选择取决于卟啉症的类型和患者的症状。对于皮肤型卟啉症，避免阳光暴晒有助于缓解症状，而发作的治疗可能包括静脉注射血红素或葡萄糖溶液。该疾病可以从一个或两个父母遗传，并可属于常染色体显性遗传、常染色体隐性遗传或X连锁显性遗传类型。</span>

AHP arises from an autosomal dominant loss-of-function of one of three enzymes in the heme biosynthesis pathways, namely the third (leading to acute intermittent porphyria), sixth (leading to hereditary coproporphyria) or seventh enzyme (leading to variegate porphyria). A fourth rarer type stems from an autosomal recessive inheritance. As a consequence of these disorders, precursors such as δ-aminolevulinic acid and porphobilinogen are being accumulated, eventually triggering AHP attacks. Notable individuals who were speculated to have suffered from porphyria include King George III and Vincent van Gogh, although in the case of the former this was debunked. A definitive diagnosis of porphyria in the case of the artist remains elusive, and various origins of his symptoms and mental health state have been put forth, including schizoaffective disorder and lead poisoning.

<span style=color:blue>AHP起因于血红素生物合成途径中三个酶之一的常染色体显性失活，即第三酶（导致急性间歇性卟啉症），第六酶（导致遗传性卟胆卟啉症）或第七酶（导致杂色卟啉症）。第四种更罕见的类型源于常染色体隐性遗传。由于这些疾病，δ-氨基乙酸和卟胆原等前体物质会积累，最终触发AHP发作。被猜测曾经患有卟啉症的知名人物包括乔治三世国王和文森特·梵高，尽管对于前者的猜测已经被证实是错误的。关于艺术家患有卟啉症的明确诊断至今仍然难以确定，人们提出了各种关于他症状和心理健康状态起源的理论，包括情感性精神障碍和铅中毒等。</span>

GIVLAARI targets aminolevulinate synthase 1 (*ALAS1*) mRNA and is composed of fully chemically modified 23mer and 21mer siRNA guide and passenger strands, respectively. The 3′-end of the passenger siRNA is linked to a triantennary N-acetylgalactosamine- (GalNAc-) containing ligand (Figure 18B）. Except for the passenger terminus that is conjugated to the GalNAc ligand, the remaining termini are PS-modified at the last two bridging phosphates. The siRNA duplex contains 28 2′-*O*-Me modified nucleotides and 16 2′-F modified nucleotides, such that the modification chemistries in the guide siRNA are nearly balanced (12 2′-*O*-Me and 11 2′-F residues). The two analogs alternate along nearly the entire length of the guide; in the passenger strand the alternating mode is limited to the central 11mer (Figure 18B).

<span style=color:blue>GIVLAARI靶向δ-氨基乙酸合成酶1（*ALAS1*）mRNA，由完全化学修饰的23碱基和21碱基的siRNA引导链和过客链组成。过客链的3'-末端连接着一个三支化的乙酰半乳糖胺（GalNAc）配体（图18B）。除了被动链末端与GalNAc配体结合外，其余的末端在最后两个桥联磷酸酯处都被PS修饰。siRNA双链包含28个2'-*O*-Me修饰的核苷酸和16个2'-F修饰的核苷酸，因此在引导链的修饰化学结构中几乎达到平衡（12个2'-*O*-Me和11个2'-F残基）。这两种模拟物几乎沿着引导链的整个长度交替出现；而在过客链中，交替模式仅限于中央的11碱基（图18B）。</span>

GalNAc conjugation chemistry requires no formulation and offers a delivery concept that is entirely different from i.v. administration of LNP-encapsulated siRNA (Figure 20). GalNAc-siRNA conjugates allow targeted delivery to liver thanks to GalNAc sugars being recognized by the asialoglycoprotein receptor carbohydrate recognition domain (ASGPR-CRD). ASGPR is predominantly expressed on the surface of hepatocytes but only exists in small quantities on extra-hepatic cells. This enables specific, receptor-mediated hepatocyte delivery of therapeutics for the treatment of hepatic afflictions while reducing risk of off-target effects. Galactose and GalNAc are sugars that ASGPR binds with high affinity, whereby the particular isomeric form, branching and galactose linkers, among others, influence ligand-receptor binding. Once docked to ASGPR, the receptor facilitates internalization of the conjugated siRNA by clathrin-mediated endocytosis.

<span style=color:blue>GalNAc偶联化学不需要制剂，并提供了一种与i.v.注射LNP封装siRNA完全不同的传递概念（图20）。GalNAc-siRNA偶联物能够通过GalNAc糖与无糖型糖蛋白受体碳水化合物识别结构域（ASGPR-CRD）结合，实现靶向肝脏的传递。ASGPR主要表达在肝细胞表面，但在肝外细胞中只存在少量。这使得治疗剂可以通过特异性的受体介导的肝细胞传递，用于治疗肝脏疾病，同时降低非靶效应的风险。半乳糖和GalNAc是ASGPR高亲和力结合的糖分子，其中特定的异构形式、支链和半乳糖连接部分等因素影响配体与受体的结合。一旦与ASGPR结合，受体通过衬膜蛋白介导的内吞作用促进偶联siRNA的内化。</span>

GIVLAARI is administered subcutaneously once a month and exhibited a half-life of six hours, whereby metabolites were primarily eliminated in urine. Adverse events during clinical trials included nausea, injection site reactions, rash, increase in serum creatinine, and transaminase elevations. An immunogenic effect was observed in one patient (of 111) during placebo-controlled and open-label clinical studies.

<span style=color:blue>GIVLAARI以皮下注射的方式每月一次给药，并表现出半衰期为六小时，代谢产物主要通过尿液排泄。临床试验期间的不良事件包括恶心、注射部位反应、皮疹、血清肌酐增高和转氨酶升高。在安慰剂对照和开放标签的临床研究中，有一个患者（111名患者中）观察到免疫原性效应。</span>

### OXLUMO and primary hyperoxaluria type 1 OXLUMO与一型原发性高草尿酸症

Primary hyperoxaluria 1 (PH1) is a rare genetic disorder that results in increased hepatic oxalate production. Debilitating and life-threatening clinical manifestations include kidney stones, kidney failure and systemic oxalosis. Novel therapeutic approaches aimed at lowering oxalate levels and minimizing renal damage and focused on different targets range from cell-, gene- and protein-based therapies to small molecule inhibitors and oxalate-degrading enzymes and bacteria. Substrate reduction therapy is a potentially successful strategy to treat inborn metabolic diseases. Thus, inhibiting the biosynthetic pathway to production of the main precursor of oxalate should in principle be therapeutically beneficial to PH1 patients.

<span style=color:blue>一型原发性高草酸尿症（PH1）是一种罕见的遗传性疾病，导致肝脏产生过多的草酸。该疾病会出现严重且危及生命的临床表现，包括肾结石、肾衰竭和全身性草酸沉积症。针对降低草酸水平、减少肾脏损伤的新型治疗方法涉及不同的靶点，包括细胞、基因和蛋白质治疗、小分子抑制剂以及降解草酸的酶和细菌。底物减少疗法是治疗先天代谢病的一种潜在成功策略。因此，原则上抑制草酸的主要前体物质的生物合成途径对于PH1患者在治疗上应该具有益处。</span>

RNAi offers an attractive approach for addressing an unmet need to treat PH1 with high efficacy and sufficient durability. Lumasiran is an siRNA that targets the mRNA of the hydroxyacid oxidase 1 (*HAO1*) gene that encodes glycolate oxidase (GO), thereby precluding the conversion of glycolate to glyoxylate, the main precursor of oxalate. This siRNA was approved by the US FDA in 2020 as OXLUMO for treatment of PH1, to lower urinary and plasma oxalate levels in pediatric and adult patients. GO lies upstream from alanine-glyoxylate aminotransferase (AGT) that normally metabolizes glyoxylate to glycine in liver peroxisomes. AGT deficiency due to genetic mutations in PH1 patients means that glyoxylate is not efficiently converted to glycine. Rather, glycine is oxidized to oxalate by cytosolic lactate dehydrogenase (LDH), causing urinary oxalate excretion to spike. As a consequence of the poor solubility of oxalate, it can crystallize in the form of calcium oxalate and aggregate into kidney stones or cause inflammation and nephrocalcinosis. With OXLUMO silencing *HAO1* mRNA, glyoxylate buildup is minimized and glycolate instead excreted in urine without resulting in kidney damage or toxic effects.

<span style=color:blue>RNAi为治疗一型原发性高草酸尿症（PH1）提供了一种具有高效和持久性的有吸引力的方法。Lumasiran是一种针对羟基酸氧化酶1（*HAO1*）基因的mRNA的siRNA，该基因编码甘酸氧化酶（GO），从而阻断了甘酸转化为草酸的过程，草酸是草酸的主要前体物质。这种siRNA在2020年获得美国FDA批准，以OXLUMO的名义用于治疗PH1，降低儿童和成人患者的尿液和血浆草酸水平。GO位于正常情况下在肝脏过氧化物体中将草酸转化为甘氨酸的丙氨酰-草酰基转氨酶（AGT）之上。PH1患者由于遗传突变导致AGT缺乏，使得草酰基不能有效地转化为甘氨酸。相反，甘氨酸会被细胞质中的乳酸脱氢酶（LDH）氧化为草酸，导致尿液中草酸的排泄增加。由于草酸溶解度较差，它会以草酸钙的形式结晶并聚集成肾结石，或引起炎症和肾脏钙化。通过沉默*HAO1* mRNA，OXLUMO能够最小化草酰基的积累，使甘酸代替草酰基在尿液中排泄，而不会导致肾脏损伤或毒性效应。</span>

Like GIVLAARI, OXLUMO features fully modified 23mer and 21mer siRNA guide and passenger strands, respectively (Figure 18C). The 3′-end of the latter is linked to the triantennary GalNAc-containing ligand. Also, except for that passenger terminus, the three remaining termini are PS-modified at the last two bridging phosphates. In a double-blind phase 3 lumasiran trial, 39 PH1 patients aged 6 and older were randomly assigned in a 2:1 ratio to receive either the drug or placebo subcutaneously for a period of six months; afterwards all patients would receive lumasiran for a period of up to 54 months. It was found that the reduction in the 24-hour urinary oxalate excretion was 53.5% greater for patients on lumasiran compared to those receiving placebo during the six-month trial. Patients on lumasiran had normal or near-normal urinary oxalate levels at six months. Lumasiran treatment also resulted in substantially reduced plasma oxalate levels, thereby providing support for its mechanism of action. Patients in the lumasiran group showed elevated levels of plasma and urinary glycolate which is expected on the basis of the inhibition of GO enzyme production by the drug. In a separate case study of a teenage PH1 patient, lumasiran was found to consistently and rapidly reduce plasma oxalate and urinary excretion to normal or almost normal levels for 18 months. This patient did not develop new kidney stones and required no further urological interventions.

<span style=color:blue>与GIVLAARI类似，OXLUMO的构成包括完全修饰的23mer和21mer的siRNA导向链和旅客链（图18C）。后者的3'端与三支GalNAc含有的配体连接。另外，除了旅客链末端外，其余三个末端的最后两个桥接磷酸根都被PS修饰。在一个双盲的III期lumasiran试验中，随机选取了39名年龄在6岁及以上的PH1患者，以2:1的比例分配到接受药物或安慰剂的皮下注射治疗组，在为期六个月的时间内进行治疗；之后，所有患者将接受长达54个月的lumasiran治疗。研究发现，在为期六个月的试验期间，与安慰剂组相比，接受lumasiran治疗的患者的24小时尿草酸排泄量减少了53.5%。在六个月时，接受lumasiran治疗的患者的尿草酸水平正常或接近正常水平。lumasiran治疗还显著降低了血浆草酸水平，从而支持其作用机制。lumasiran组的患者显示出血浆和尿液中甘酸水平升高，这是由于药物抑制了GO酶的产生。在一项关于一名青少年PH1患者的单独病例研究中，发现lumasiran能够持续快速地将血浆草酸和尿液排泄物降至正常或接近正常水平，持续时间达18个月。该患者未出现新的肾结石，并且不需要进一步的泌尿学干预措施。</span>

### LEQVIO: the first ‘millions of people’ global RNAi therapeutic? LEQVIO：首个"百万人"级全球RNAi治疗药物？

Inclisiran is an siRNA targeting proprotein convertase subtilisin-kexin type 9 (*PCSK9*) mRNA for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) to lower low-density lipoprotein cholesterol (LDL-C). Hypercholesterolemia is characterized by elevated levels of LDL-C that carries a risk of premature ASCVD. In two phase 3 trials, inclisiran was found to significantly lower LDL-C in adults compared to those who received placebo with an acceptable safety profile. Inclisiran (300 mg dose) or matching placebo were given by subcutaneous injection on days 1, 90, 270 and 450, whereby the two primary endpoints were the % change from baseline in the LDL-C level on day 510 and the % change from baseline in the LDL-C level between days 90 and 540. The minor common side effects include injection site reactions such as pain, redness and swelling. The twice-yearly dosing regimen constitutes a major advantage of inclisiran compared to a monoclonal antibody against PCSK9 protein that also reduces LDL-C but needs to be administered every two to four weeks. Inclisiran was given approval under the brand name LEQVIO in the EU and the US in 2021 and 2022, respectively (Figure 3).

<span style=color:blue>Inclisiran是一种靶向前蛋白转化酶枯草杆菌蛋白酶9（PCSK9）mRNA的siRNA，用于治疗杂合性家族性高胆固醇血症（HeFH）或临床动脉粥样硬化性心血管疾病（ASCVD），以降低低密度脂蛋白胆固醇（LDL-C）水平。高胆固醇血症以升高的LDL-C水平为特征，存在患早发动脉粥样硬化性心血管疾病的风险。在两个3期试验中，与接受安慰剂的成年人相比，Inclisiran显著降低了LDL-C水平，并具有可接受的安全性。Inclisiran（300毫克剂量）或相应的安慰剂于第1天、第90天、第270天和第450天通过皮下注射给予，其中两个主要终点是第510天时与基线相比的LDL-C水平变化百分比，以及第90天至第540天期间与基线相比的LDL-C水平变化百分比。常见的轻微副作用包括注射部位反应，如疼痛、红肿等。与针对PCSK9蛋白的单克隆抗体相比，Inclisiran每半年一次的给药方案具有重要优势，后者也可以降低LDL-C，但需要每两到四周进行一次给药。Inclisiran在2021年和2022年分别在欧盟和美国以商标名LEQVIO获得批准（图3）。</span>

Like GIVLAARI, LEQVIO features 2′-F and 2′-*O*-Me modification chemistry with pairs of PS moieties at the 5′- and 3′-ends of the 23mer guide strand and at the 5′-end of the 21mer passenger strand. The latter consists mainly of 2′-*O*-Me nucleotides (just two 2′-F nucleotides in the 5′-half and a central 2′-deoxynucleotide; Figure 18D). The 3′-end of the passenger is tethered to the triantennary GalNAc conjugate. Phase 3 trials of the drug were completed by The Medicines Company and Novartis subsequently acquired The Medicines Company and inclisiran in 2019. Compared to the majority of currently approved nucleic acid therapeutics that are used in the treatment of rare genetic disorders, LEQVIO targets both elevated LDL-C (in patients with the disease HeFH) and ASCVD due to elevated LDL-C, a condition that affects millions of patients worldwide. Thus, the drug will likely become the first ‘millions-of-people’ global RNAi therapeutic.

<span style=color:blue>与GIVLAARI类似，LEQVIO采用了2'-F和2'-*O*-Me修饰化学结构，其中23个核苷酸的导引链的5'-端和3'-端以及21个核苷酸的旅行链的5'-端均配对有磷酸甘露糖胺（PS）基团。后者主要由2'-*O*-Me核苷酸组成（在5'-半部分只有两个2'-F核苷酸和一个中央的2'-去氧核苷酸；图18D）。旅行链的3'-端与三支GalNAc偶联物相连。该药物的3期临床试验由The Medicines Company完成，随后Novartis于2019年收购了The Medicines Company和inclisiran。与目前大多数用于治疗罕见遗传疾病的核酸治疗药物相比，LEQVIO针对的是同时存在高LDL-C（HeFH患者）和由高LDL-C引起的ASCVD的情况，这是一种影响全球数百万患者的疾病。因此，该药物有望成为首个面向“百万人群体”的全球RNAi治疗药物。</span>

### AMVUTTRA, a second-generation siRNA therapeutic for hATTR-mediated amyloidosis AMVUTTRA，第二代siRNA hATTR淀粉样变性病治疗药物

AMVUTTRA® (vutrisiran) is a transthyretin-directed siRNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. AMVUTTRA has the same sequence as the failed investigational drug revusiran but with different chemistry to provide extended metabolic stability of the drug (revusiran clinical development was voluntarily stopped in 2016). AMVUTTRA uses GalNAc-conjugation for efficient delivery into hepatocytes and further follows the design of GIVLAARI and OXLUMO for having enhanced metabolic stability (ESC chemistry with additional terminal PS modification, Figure 18E). AMVUTTRA received FDA approval in June of 2022. It is the fifth siRNA-based drug reaching approval status in five years (Figure 3). Compared to the first-generation ONPATTRO, it offers the benefit of infrequent dosing, i.e. 25 mg administered by subcutaneous injection once every three months, without the need for IV premedications to reduce infusion-related reactions.

<span style=color:blue>AMVUTTRA®（vutrisiran）是一种转甲状腺素定向siRNA药物，用于治疗成年人遗传性转甲状腺素介导的淀粉样变性引起的多发性神经病变。AMVUTTRA与失败的研究药物revusiran具有相同的序列，但具有不同的化学结构，以提供药物的长期代谢稳定性（revusiran的临床开发于2016年自愿停止）。AMVUTTRA利用GalNAc偶联技术实现高效递送至肝细胞，并采用GIVLAARI和OXLUMO的设计思路以提高药物的代谢稳定性（采用增强型代谢稳定性（ESC）化学结构，并额外进行了末端PS修饰，图18E）。AMVUTTRA于2022年6月获得FDA批准。它是在五年内获得批准的第五种siRNA药物（图3）。与一代药物ONPATTRO相比，AMVUTTRA具有不经常给药的优势，即每三个月一次皮下注射25毫克，无需进行静脉前用药以减少输注相关反应。</span>

## DELIVERY PLATFORMS 递送平台

### Lipid nanoparticles 脂质纳米粒

The first two siRNA therapeutics to receive market approval, ONPATTRO and GIVLAARI, use entirely different delivery systems, LNP carrier versus triantennary carbohydrate conjugate to target ASGPR, respectively (Figure 20). Both approaches serve to deliver the siRNA duplex to the cytoplasm of hepatocytes in vivo. The development of efficient delivery systems is key to the success of oligonucleotide therapeutics and remains a very active area of research. Several excellent reviews of the oligonucleotide delivery field have been published in recent years and the interested reader may turn to these for more in-depth discussions of the various challenges and strategies being pursued to address them including oral delivery.

<span style=color:blue>获得市场批准的第一批siRNA药物ONPATTRO和GIVLAARI使用了完全不同的递送系统，分别为LNP载体和三支糖链偶联物以靶向ASGPR（图20）。这两种方法都用于将siRNA双链递送到体内肝细胞的细胞质中。高效的递送系统的开发对寡核苷酸治疗药物的成功至关重要，并且仍然是一个非常活跃的研究领域。近年来已经发表了一些对寡核苷酸递送领域进行了出色综述的文章，感兴趣的读者可以参考这些综述以获取更深入的讨论，了解应对挑战的各种策略，包括口服递送。</span>

Briefly, a first hurdle to overcome is getting the oligo to the particular tissue of therapeutic interest. The obstacles tissues have erected that need to be scaled include the vascular endothelial barrier, the reticuloendothelial system, renal excretion and its effects both on pharmacokinetics and biodistribution, as well as the blood-brain barrier. Receptor-mediated targeting may allow cell-specific delivery and internalization of the oligos. Examples of receptor families are integrins, G protein-coupled receptors, receptor tyrosine kinases, Toll-like receptors, scavenger receptor, folate receptor, and, as mentioned before, ASGPR. But after reaching cell surface and internalization by endocytosis, an oligonucleotide remains separated from the cytosol and thus its ultimate target if it cannot escape the endosome. Therefore, understanding the intracellular trafficking machinery and breaching the endosomal barrier critically affect the design and clinical success of oligonucleotide therapeutics. There are many other delivery approaches besides the aforementioned LNPs and GalNAc conjugates for targeting ASGPR, but because they proved successful first in the clinic, we will limit the discussion to these two in this review and perspective article.

<span style=color:blue>克服的第一个障碍是将寡核苷酸送达到特定的治疗目标组织。需要克服的障碍包括血管内皮屏障、网状内皮系统、肾脏排泄以及对药代动力学和生物分布的影响，以及血脑屏障。受体介导的靶向可能实现寡核苷酸的细胞特异性递送和内吞。一些受体家族的例子包括整合素、G蛋白偶联受体、受体酪氨酸激酶、Toll样受体、清道夫受体、叶酸受体，以及前面提到的ASGPR。但是，在达到细胞表面并通过内吞作用内化之后，如果寡核苷酸不能逃脱内体，它将与细胞质和最终目标分离。因此，了解细胞内的运输机制和突破内体屏障对寡核苷酸治疗药物的设计和临床成功至关重要。除了前面提到的脂质体纳米粒和GalNAc偶联物以靶向ASGPR之外，还有许多其他递送方法。但是，由于它们在临床中取得了成功，本文将限制讨论这两种递送方法。</span>

LNPs represent important delivery systems for siRNA therapeutics and the particular lipids and lipoids used in the multi-component formulation of the carrier for ONPATTRO are shown in Figure 21A. The second generation ionizable amino-lipid heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate (DLin-MC3-DMA) afforded increased potency compared to first generation benchmark LNPs. In the positively charged state this lipid interacts with negatively charged lipids, thereby disrupting the bilayer membrane and allowing release of the siRNA from the endosome into the cytoplasm. Another key component is the PEG lipid mPEG2000-C14 glyceride that is associated with the surface of the LNP and influences the diameter of the particle in a concentration-dependent manner. PEG lipids can dissociate from the LNP and bind to lipoprotein particles in plasma which facilitates interactions between the unshielded LNP and target cells and thus enables uptake. Two additional components of the LNP are 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC) and cholesterol (Figure 21A). It was recently shown that DSPC-cholesterol resides in the outer layers when the LNP is empty, i.e. not containing the siRNA. However, once siRNAs are loaded into the system, DSPC-cholesterol becomes internalized together with siRNA, thus suggesting that they act as helper lipids and are key to stable encapsulation of the RNA cargo.

<span style=color:blue>脂质体纳米粒（LNPs）是siRNA药物的重要递送系统，ONPATTRO的载体的多组分配方中使用的特定脂质和脂质类物质如图21A所示。第二代离子化氨基脂质heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate（DLin-MC3-DMA）与第一代基准LNP相比具有更高的效力。在带正电的状态下，该脂质与带负电的脂质发生相互作用，从而破坏双层膜，并允许siRNA从内体释放到细胞质中。另一个关键组分是PEG脂质mPEG2000-C14甘油酯，它与LNP的表面相关，并以浓度依赖的方式影响粒子的直径。PEG脂质可以从LNP中解离，并结合到血浆中的脂蛋白粒子上，从而促进未被屏蔽的LNP与靶细胞之间的相互作用，从而实现摄取。LNP的另外两个组分是1,2-二硬脂酸-sn-甘油-3-磷酰胆碱（DSPC）和胆固醇（图21A）。最近的研究表明，在LNP为空的情况下，DSPC-胆固醇存在于外层。然而，一旦siRNA被加载到系统中，DSPC-胆固醇会与siRNA一起内化，这表明它们起到辅助脂质的作用，并且对于稳定封装RNA荷载至关重要。</span>

The mechanistic model of LNP-mediated delivery of ONPATTRO into hepatocytes entails the following steps. (i) PEG lipids are released from the particle surface. (ii) Endogenous apolipoprotein E (ApoE) is recruited to the LNP surface. (iii) ApoE promotes trafficking of LNPs through fenestrated endothelium and subsequent binding to lipoprotein receptors on the surface of hepatocytes. (iv) Internalization of LNPs via endocytosis. (v) The low pH in the endosome results in protonation of DLin-MC3-DMA. (vi) Interactions between positively charged DLin-MC3-DMA and negatively charged endogenous lipids destabilize the endosomal membrane. (vii) siRNA is released into the cytoplasm of hepatocytes and loaded into Ago2-RISC.

<span style=color:blue>ONPATTRO通过LNP介导的递送机制进入肝细胞，包括以下步骤：（i）PEG脂质从粒子表面释放出来。（ii）内源性载脂蛋白E（ApoE）被招募到LNP表面。（iii）ApoE促进LNPs通过有孔内皮细胞的运输，并随后结合到肝细胞表面的脂蛋白受体上。（iv）通过内吞作用将LNPs内化。（v）内体液泡中的低pH使DLin-MC3-DMA质子化。（vi）正电荷的DLin-MC3-DMA与负电荷的内源性脂质之间的相互作用破坏内体液泡膜。（vii）siRNA释放到肝细胞的细胞质中，并加载到Ago2-RISC中。</span>

### Asialoglycoprotein receptor and GalNAc conjugates 去唾液酸糖蛋白受体和 GalNAc 偶联物

Chemical modification of oligonucleotides affects their physical-chemical properties and we discussed the effects of PS modification on pairing stability, nuclease resistance, protein binding, cellular uptake and pharmacokinetics and pharmacodynamics. Moreover, uptake and biodistribution of single-stranded ASOs and double-stranded siRNAs used alone versus in the presence of a carrier, e.g. LNPs, are obviously quite different and siRNAs face bigger hurdles with respect to delivery. Conjugation of a chemically modified oligonucleotide to a ligand potentially offers a strategy to overcome the challenges facing delivery of a polyanion of molecular weight >10 kDa across a cell membrane.

<span style=color:blue>寡核苷酸的化学修饰会影响其物理化学性质，我们已经讨论了磷酸酯（PS）修饰对配对稳定性、核酸酶抗性、蛋白结合、细胞摄取以及药代动力学和药效学的影响。此外，单链反义寡核苷酸（ASO）和双链小干扰RNA（siRNA）在单独使用和与载体（例如LNPs）共同使用时的摄取和生物分布显然是不同的，siRNA在传递方面面临着更大的障碍。将化学修饰的寡核苷酸与配体结合可能是克服将分子量大于10 kDa的多阴离子通过细胞膜传递的挑战的一种策略。</span>

In pioneering work dating back >30 years, Letsinger and colleagues reported the synthesis, properties and activity of cholesteryl-conjugated oligos targeted against several HIV proteins in cell culture. The cholesterol moiety was tethered to the 3′-end of the oligos and significantly increased their antiviral potencies. The hydrophobic cholesterol conjugation was also shown to improve interactions between siRNA and plasma lipoproteins, uptake and tissue distribution. Cholesterol promotes enhanced association of oligos with low-density or high-density lipoproteins (LDL or HDL, respectively).

<span style=color:blue>在30多年前的开创性研究中，Letsinger及其同事报告了合成、性质和活性与几种HIV蛋白靶向的胆固醇偶联寡核苷酸在细胞培养中的研究。胆固醇部分被连接到寡核苷酸的3'-末端，显著增强了其抗病毒效能。疏水性的胆固醇偶联还改善了siRNA与血浆脂蛋白的相互作用、摄取和组织分布。胆固醇促进了寡核苷酸与低密度脂蛋白（LDL）或高密度脂蛋白（HDL）的增强结合。</span>

Although hepatic targeting is most commonly pursued with cholesterol-conjugated siRNAs, delivery of siRNA to muscle and other extrahepatic tissues has also been demonstrated with cholesterol conjugation chemistry. A comprehensive study compared fifteen different lipid-conjugation chemistries with regards to siRNA tissue distribution and efficacy. In general, the hydrophobicity of the conjugate correlated with the degree of clearance and the distribution between liver and kidney. One notable finding was that several of the conjugates afforded accumulation of siRNA in extra-hepatic tissues such as muscle, lung, heart and adrenal glands. Moreover, cholesterol was inferior to several of the tested conjugates in promoting siRNA distribution to extra-hepatic tissues. This suggests that the chemical nature of the lipid conjugate plays an important role in enabling and maximizing siRNA delivery to organs other than liver. Current efforts directed at the development and clinical use of siRNA-bioconjugates have recently been reviewed. The bioconjugation platform for siRNA delivery is rapidly expanding and besides the abovementioned lipids, conjugates tethered to RNA termini include peptides, receptor ligands, aptamers, antibodies, and CpG oligos.

<span style=color:blue>虽然胆固醇偶联siRNA通常用于肝脏靶向，但也已经通过胆固醇偶联化学方法将siRNA传递到肌肉和其他肝外组织中。一项综合研究比较了15种不同的脂质偶联化学方法在siRNA组织分布和效果方面的差异。总体而言，偶联物的疏水性与清除程度和肝脏与肾脏之间的分布相关。一个值得注意的发现是，其中几种偶联物导致siRNA在肌肉、肺、心脏和肾上腺等肝外组织中的积累。此外，胆固醇在促进siRNA分布到肝外组织方面不如其他被测试的偶联物。这表明脂质偶联物的化学性质在实现和最大化siRNA传递到肝脏以外器官中起着重要作用。最近对siRNA生物偶联物的开发和临床应用进行了综述。siRNA传递的生物偶联平台正在迅速扩展，除了上述脂质偶联物外，还包括与RNA末端相连的肽、受体配体、适配体、抗体和CpG寡核苷酸。</span>

The triantennary GalNAc conjugate tethered to the 3′-terminus of the GIVLAARI siRNA passenger strand enables efficient ASGPR-mediated delivery of the therapeutic to hepatocytes. ASGPR is abundantly expressed in hepatocytes and congregates on the cell surface in coated pits. The receptor can form a trefoil composed of ASGPR1 and ASGPR2 subunits (called H1 and H2, respectively, in the human system), whereby the former features a carbohydrate recognition domain (CRD; Figure 22). Crystal structures of H1-CRD alone and bound to either lactose or a bicyclic bridged ketal that efficiently binds to ASGPR were determined. In addition, the crystal structure of a mannose binding protein mutant in complex with GalNAc provided insight into the preferential binding of ASGPR-CRD to this sugar compared with galactose  (Figure 22).

<span style=color:blue>三叉状的GalNAc偶联物与GIVLAARI siRNA载体链的3'-末端相连，实现了通过ASGPR介导的有效治疗物传递到肝细胞。ASGPR在肝细胞中丰富表达，并在细胞表面聚集于包被窝。该受体可以形成由ASGPR1和ASGPR2亚单位组成的三叉形结构（在人体系统中分别称为H1和H2），其中前者具有碳水化合物识别结构域（CRD；图22）。已确定了H1-CRD单独和与乳糖或有效结合ASGPR的双环桥酮结合时的晶体结构。此外，一个与甘露糖结合蛋白突变体与GalNAc结合形成的晶体结构揭示了相比于半乳糖，ASGPR-CRD与甘露糖的优先结合性（图22）。</span>

**图 22.**

![GalNAc conjugates for optimal hepatic delivery. The cartoon in the center shows siRNA–GalNAc conjugate binding and internalization by ASGPR, RISC loading and formation of functional RISC, mRNA target recognition and catalytic cleavage, and initiation of a new cycle. Panels around the simplified schematic of a hepatocyte depict, from the upper right and moving in a counterclockwise fashion: (i) The triantennary GalNAc conjugate L96. (ii) The crystal structure of ASGPR-H1-CRD (PDB ID 1DV8 (342)); Ca2+ ions are green, three disulfide bridges are highlighted in yellow, and the blue arrow points to the GalNAc binding site. (iii) The crystal structure of mannose binding protein (MBP) QPDWGH mutant bound to GalNAC (PDB ID 1BCH (343)); GalNAc carbon atoms are black and the ASGPR-H1-CRD is superimposed on one of the MBP-CRDs; note the central coiled-coil stalk that stabilizes the trimer. (iv) A model of GalNAc bound to ASGPR-H1-CRD based on the structure of the complex with lactose (PDB ID 5JPV (323)); the GalNAc oxygen attached to the L96 spacer is highlighted in magenta.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig22.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">为了实现最佳的肝脏传递，采用GalNAc偶联物。中间的示意图显示了siRNA-GalNAc偶联物与ASGPR的结合和内吞，RISC的装载和功能RISC的形成，mRNA靶标的识别和催化性切割，以及新循环的开始。简化的肝细胞示意图中的面板，从右上角开始并按逆时针方向移动：(i) 三叉状的GalNAc偶联物L96。(ii) ASGPR-H1-CRD的晶体结构（PDB ID 1DV8）；Ca2+离子为绿色，三个二硫键用黄色突出显示，蓝色箭头指向GalNAc结合位点。(iii) 蔗糖结合蛋白（MBP）QPDWGH突变体与GalNAC结合的晶体结构（PDB ID 1BCH）；GalNAc碳原子为黑色，并将ASGPR-H1-CRD与MBP-CRD之一进行了重叠；请注意用于稳定三聚体的中央螺旋丝杆。(iv) 基于与乳糖的复合物结构（PDB ID 5JPV），给出了与ASGPR-H1-CRD结合的GalNAc模型；突出显示与L96间隔物相连的GalNAc氧原子为洋红色。</span></center>

The carbohydrate binding site is shallow and exposed to solvent and this may explain why multiple subunits are needed to confer sufficient binding affinity and selectivity for the GalNAc sugar. Manoharan and coworkers designed modified siRNAs with trivalent GalNAc conjugates tethered to the 3′-end of the passenger strand. Careful optimization of the chemistry connecting the terminus of the passenger to the linker, the linker chemistry, and the spacers in the triantennary portion of the conjugate resulted in the current ‘L96’ design (Figure 22). Thus, the 3′-terminal phosphate is attached to a prolinol sugar and a C12-spacer connects via amide moieties prolinol sugar on one side and trivalent spacer and GalNAc sugars on the other. In the L96 conjugate, the spacers also contain two amide groups that interrupt the carbon chain and provide some polarity and conformational rigidity.

<span style=color:blue>糖结合位点是浅层且暴露于溶剂中，这可能解释了为什么需要多个亚单位才能赋予足够的结合亲和力和选择性来与GalNAc糖发生作用。Manoharan和他的同事设计了将三糖基GalNAc偶联物连接到乘客链的3'-端的修饰siRNA。通过仔细优化连接乘客链末端的化学结构、连接物的化学结构以及三糖基部分的间隔物，得到了目前的"L96"设计（图22）。因此，3'-末端的磷酸根与脯氨醇糖和C12间隔物通过酰胺基团相连，其中一侧是脯氨醇糖，另一侧是三糖基间隔物和GalNAc糖。在L96偶联物中，间隔物还含有两个酰胺基团，中断了碳链并提供了一定的极性和构象刚性。</span>

The GalNAc conjugation chemistry for ASGPR-mediated hepatic delivery and successfully applied in the case of GIVLAARI to treat acute hepatic porphyria is now also being tested with other siRNAs and ASOs currently in the clinic. A recent review listed no fewer than 9 siRNAs and 12 ASOs with GalNAc conjugates in preclinical, phase 1 or phase 2 trials.

<span style=color:blue>ASGPR介导的肝脏传递所采用的GalNAc偶联化学方法已成功应用于GIVLAARI治疗急性肝性卟啉症，并正在测试其他目前正在临床试验中的siRNA和ASO。最近的一篇综述列出了不少于9个siRNA和12个ASO，它们采用了GalNAc偶联物在临床前、一期或二期试验中进行研究。</span>

## THE APTAMER APPROACH 适配体方法

Nucleic acid aptamers are single-stranded, folded RNA or DNA oligonucleotides that bind molecular targets (small molecules, proteins or nucleic acids) with high specificity and affinity. Aptamers against diverse targets can be identified from oligonucleotide libraries of sufficient sequence complexity by a process called ‘systematic evolution of ligands by exponential enrichment’ . They hold great potential in therapeutics as highly specific modulators of gene function as well as in diagnostics. As in the case of ASOs and siRNAs, native RNA and DNA aptamers are unsuitable for applications in biological systems because of rapid degradation *in vitro* and *in vivo*. They also have poor pharmacokinetic properties as putative therapeutics *in vivo*. Importantly, searching only sequence space often yields aptamers that are limited in specificity and particularly in affinity. Beyond sequence space, it is therefore necessary to explore the chemical and structure space to identify more mature functional aptamers.

<span style=color:blue>核酸适配体是单链折叠的RNA或DNA寡核苷酸，具有高度特异性和亲和力，可与小分子、蛋白质或核酸等分子靶点结合。通过一种称为“指数富集下的适配体系统进化”的过程，可以从具有足够序列复杂性的寡核苷酸文库中鉴定出针对不同靶点的适配体。它们在基因功能的高度特异性调节和诊断方面具有巨大潜力。与ASO和siRNA的情况类似，由于在*体外*和*体内*快速降解，原生RNA和DNA适配体不适用于生物系统中的应用。它们在*体内*作为潜在的治疗药物也具有较差的药代动力学特性。重要的是，仅在序列空间中搜索通常会得到具有限特异性和亲和力的适配体。因此，除了序列空间外，还有必要探索化学和结构空间以寻找更成熟的功能性适配体。</span>

MACUGEN (pegaptanib) was the first RNA-based therapeutic approved by the US FDA (2004, Figures 2and 3) and is the only aptamer among oligonucleotide drugs that have reached the market to date. The 27-nucleotide aptamer targets VEGF for the treatment of wet age-related macular degeneration. It is composed entirely of 2′-F and 2′-*O*-Me modified nucleotides except for two residues (Figure 23A). Vascular endothelial growth factor (VEGF) is a prominent drug target and extensive studies confirmed a role for VEGF in ocular neovascular diseases and demonstrated that VEGF165 is the isoform largely responsible for pathological ocular neovascularization. Although both VEGF165 and VEGF121 are effective mitogens for human umbilical vein endothelial cells, pretreatment of cells with active ingredient inhibited proliferative responses only to VEGF165. These findings are consistent with photo-crosslinking experiments that demonstrated that binding of pegaptanib to VEGF involves a close contact with Cys-137 of VEGF165. This residue is contained within the 55-amino-acid heparin-binding domain (HBD) of VEGF (Figure 23B) which is not present in VEGF121.

<span style=color:blue>MACUGEN（pegaptanib）是美国FDA批准的第一种RNA类药物（2004年，图2和3），也是迄今为止进入市场的寡核苷酸药物中唯一的适配体。这种由27个核苷酸组成的适配体针对VEGF，用于治疗湿性年龄相关性黄斑变性。除了两个残基外，它完全由2'-F和2'-*O*-Me修饰的核苷酸组成（图23A）。血管内皮生长因子（VEGF）是一个重要的药物靶点，广泛的研究证实了VEGF在眼部新生血管性疾病中的作用，并表明VEGF165是主要导致病理性眼部新生血管化的亚型。虽然VEGF165和VEGF121对人脐静脉内皮细胞具有促增殖作用，但用活性成分对细胞进行预处理仅抑制对VEGF165的增殖反应。这些发现与光交联实验一致，该实验表明pegaptanib与VEGF的结合涉及与VEGF165的Cys-137的密切接触。这个残基位于VEGF的55个氨基酸的肝素结合区域（HBD）内（图23B），而VEGF121中则没有这个结构域。</span>



**图 23.**

![Aptamers that target VEGF. (A) Secondary structure and chemical modification of MACUGEN for treatment of wet age-related macular degeneration (AMD). Ribo-, 2′-deoxyribo-, 2′-O-Me- and 2′-F-nucleotides are depicted as circles colored in pink, black, blue and green, respectively. (B) NMR solution structure of the VEGF heparin binding domain (HBD) comprising Ala-111 to Arg-165 (PDB ID 1KMX (372)). The backbone is traced with a ribbon colored in gray, and disulfide bridges as well as side chains that show the largest chemical shifts upon aptamer binding (373) are depicted in ball-and-stick mode and are colored in yellow and cyan, respectively. Red arrows point to residues U14 and Cys-137 that could be photo-crosslinked in the RNA aptamer-VEGF165 complex (355). (C) Secondary structure of an all-2′-O-Me modified VEGF aptamer (361). Incorporation of a PS2 modification (yellow sphere; structure shown on the right) at either site boosts the Kd 1000-fold to ca. 1 pM (368). Both aptamers bind exclusively to the VEGF-HBD.](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig23.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">VEGF的靶向适配体。（<span style=font-weight:bold>A</span>）用于湿性年龄相关性黄斑变性（AMD）治疗的MACUGEN的二级结构和化学修饰。核糖基、2'-脱氧核糖基、2'-<span style=font-style:italic>O</span>-Me和2'-F-核苷酸分别以粉色、黑色、蓝色和绿色表示为圆形。（<span style=font-weight:bold>B</span>）VEGF肝素结合区域（HBD）的NMR溶液结构，由Ala-111到Arg-165（PDB ID 1KMX）组成。主链用灰色表示的螺旋追踪，二硫键以及在适配体结合时显示最大化学位移的侧链以球棍模式表示，并分别以黄色和青色表示。红色箭头指向U14和Cys-137残基，这些残基可能在RNA适配体-VEGF165复合物中发生光交联。（<span style=font-weight:bold>C</span>）全2'-<span style=font-style:italic>O</span>-Me修饰的VEGF适配体的二级结构。在任意一个位点上引入PS2修饰（黄色球体；右侧显示的结构）可使<span style=font-style:italic>K</span>d增加1000倍，达到约1 pM。这两种适配体仅与VEGF-HBD结合。</span></center>


Exploration of sequence space using SELEX resulted in the initial anti-VEGF RNA aptamer. Subsequent trial-and-error exploration of the ‘chemical space’ to optimize the RNA sequence resulted in the high-affinity pegaptanib aptamer with a *K*d of 49 pM. One limitation of the incorporation of 2′-F modified nucleotides was that only the pyrimidines were commercially available at the time. Hence the use of the 2′-*O*-Me modification chemistry for purine residues (Figure 23A). Another important modification concerns PEGylation at the 5′-end that confers drug-like properties to the aptamer for uptake and biodistribution; MACUGEN was administered by intravitreal injection. In principle, a certain amount of chemical modification can be built into the selection process, as in the case of a procedure to identify all-2′-*O*-Me RNA aptamers against VEGF (Figure 23C). Such aptamers bound VEGF with equilibrium dissociation constants of 1–4 nM and were reasonably stable to degradation in serum. However, these affinities are significantly worse than the pM value for MACUGEN. Because pM binding affinities are highly desirable for increased potency in a therapeutic use this difference is noteworthy. For comparison, LUCENTIS® (ranibizumab), a monoclonal antibody-based therapeutic for wet AMD has a VEGF binding affinity of 140 pM. Antibody-based approaches have become the most prescribed therapies for AMD treatment and have all but replaced MACUGEN.

<span style=color:blue>通过SELEX对序列空间的探索得到了最初的抗VEGF RNA适配体。随后通过“化学空间”的试错探索优化了RNA序列，得到了具有49 pM的高亲和力的pegaptanib适配体。2'-F修饰核苷酸的一个限制是当时仅有嘧啶类可供商业使用。因此，使用2'-*O*-Me修饰化学对嘌呤残基进行修饰（图23A）。另一个重要的修饰涉及PEG化在5'-末端，使适配体具有类似药物的特性，用于摄取和生物分布；MACUGEN通过眼内注射给予患者。原则上，一定程度的化学修饰可以纳入选择过程中，例如通过一种识别VEGF的全2'-*O*-Me RNA适配体的过程（图23C）。这些适配体与VEGF结合的平衡解离常数为1-4 nM，并在血清中相对稳定。然而，这些亲和力明显不及MACUGEN的pM级别。因为pM级别的结合亲和力在治疗中增加药效方面非常理想，这种差异值得注意。作为对比，作为湿性AMD的单克隆抗体治疗药物的LUCENTIS®（ranibizumab）具有140 pM的VEGF结合亲和力。基于抗体的方法已成为AMD治疗中使用最广泛的疗法，并且几乎已经取代了MACUGEN。</span>

Many approaches have been utilized to try and improve aptamer affinity including chemical modification. Thus, selection of aptamers against interleukin-6 (IL-6) from a library of DNA molecules containing 40 random positions and 5-(*N*-benzylcarboxamide)-2′-deoxyuridine (BndU) or 5-[*N*-(1-naphthylmethyl)carboxamide]-2′-deoxyuridine (NapdU) replacing dT furnished candidates of improved binding (10-fold; relative to DNA) and inhibition (20-fold), but overall modest affinity (*K*d = 0.2 nM) and potency (IC50 = 0.2 nM). Further post-SELEX modification placing 2′-*O*-Me at certain sites improved the affinity minimally. Moreover, this selection process approach to enhance the hydrophobic contributions to the aptamer-protein target interface is laborious, expensive, and limited to modifications tolerated by the polymerases employed.

<span style=color:blue>为了提高适配体的亲和力，人们采用了许多方法，包括化学修饰。例如，通过从包含40个随机位点和5-（*N*-苄基甲酰胺）-2'-脱氧尿嘧啶（BndU）或5-[*N*-（1-萘甲基）甲酰胺]-2'-脱氧尿嘧啶（NapdU）的DNA分子库中选择针对白细胞介素-6（IL-6）的适配体，得到了亲和力改善（相对于DNA，提高了10倍）和抑制效果增强（提高了20倍）的候选物，但总体亲和力（*K*d = 0.2 nM）和效力（IC50 = 0.2 nM）仍然相对较低。进一步在SELEX之后的修饰中引入2'-*O*-Me在特定位点上略微提高了亲和力。此外，这种选择过程中用于增强适配体-蛋白质靶标界面的疏水性贡献的方法费时、费钱，并且受到所使用的聚合酶所容忍的修饰的限制。</span>

We demonstrated that a single phosphorodiothiate (PS2) modification can boost the affinity of RNA aptamers against VEGF and thrombin 1000-fold and tighten the binding affinity to 1–2 pM (Figure 23C). Comparison of crystal structures for complexes between thrombin and the native and PS2-modified RNA aptamers and subsequent calculations identified three components that underlie the remarkable change in binding affinity enabled by a single PS2 modification. (i) A hydrophobic patch (phenylalanine, Phe) at the floor of a slight depression on the surface of the protein target. (ii) Local flexing of the RNA backbone that moves the PS2 moiety significantly closer to the edge of the phenyl ring compared to the native phosphate-Phe pair. (iii) An electric field generated by pairs of lysines and arginines that surround the hydrophobic patch and result in polarization of the sulfur that interacts with Phe.

<span style=color:blue>我们证明了单个磷酸二酯硫（PS2）修饰能够将针对VEGF和凝血酶的RNA适配体的亲和力提高1000倍，并将结合亲和力提高到1-2 pM的水平（图23C）。通过比较凝血酶与天然和PS2修饰的RNA适配体之间的复合物的晶体结构和随后的计算，我们确定了导致单个PS2修饰引发的亲和力显著改变的三个组分：（i）位于蛋白质靶标表面轻微凹陷处的疏水性区域（苯丙氨酸，Phe）；（ii）RNA骨架的局部弯曲使得PS2基团与苯环边缘的距离明显缩短，相比天然磷酸-Phe对；（iii）由赖氨酸和精氨酸成对产生的电场环绕疏水性区域，并导致与Phe相互作用的硫原子极化。</span>

One disadvantage of the VEGF system in regard to optimization of aptamer affinity and selectivity is that, unlike for other aptamers including the anti-thrombin RNA, the 3D structures of VEGF165 and those of the native and chemically modified anti-VEGF RNA aptamers are not known. Thus, structural information regarding the components of the complex is limited to the NMR solution structure of the VEGF-HBD. Moreover, it was demonstrated by NMR that the secondary structures of the aptamer are maintained between the complexes with VEGF165 and VEGF-HBD (55 residues) .

<span style=color:blue>在优化aptamer的亲和力和选择性方面，与其他aptamer（包括抗凝血酶RNA）不同的是，VEGF系统存在一个不利因素，即VEGF165及其天然和化学修饰的抗VEGF RNA aptamer的三维结构尚未知晓。因此，关于复合物组分的结构信息仅限于VEGF-HBD的NMR溶液结构。此外，NMR实验证明aptamer在与VEGF165和VEGF-HBD（55个残基）形成复合物时，其二级结构得以保持。</span>

A recent exciting development is SELEX with adapted polymerases and xeno nucleic acids (XNAs) . Aptamers based on 2′-F-arabinonucleic acid (FANA), (3′→2′)-*L*-α-threofuranosyl nucleic acid (TNA) and other XNAs are highly resistant to degradation and offer the prospect of expanded function and fold space. About a dozen aptamer therapeutic candidates are currently being evaluated in clinical trials. It is to be hoped that MACUGEN will not remain the only clinically approved aptamer for long.

<span style=color:blue>在核酸药物研发领域中，使用适应的聚合酶和异构核酸（XNAs）的SELEX技术是最近的一项令人激动的进展。基于2'-F-阿拉伯核酸（FANA）、（3'→2'）-L-α-噻吕糖核酸（TNA）和其他XNAs的寡核苷酸适配体在抵抗降解方面具有高度稳定性，并为扩展功能和结构空间提供了可能性。目前大约有十几个适配体治疗候选药物正在进行临床试验评估，这表明适配体作为治疗药物的潜力与日俱增。希望MACUGEN不会长期成为唯一获得临床批准的适配体。</span>

## A HEPATITIS B VACCINE OLIGONUCLEOTIDE ADJUVANT: CpG 1018 AND HEPLISAV-B® 乙型肝炎疫苗寡核苷酸佐剂：CpG 1018 和 HEPLISAV-B®

HEPLISAV-B is a recombinant vaccine that prevents hepatitis B liver infection caused by hepatitis B virus (HBV). It is composed of a 0.5 mL aqueous mixture of 20 μg of hepatitis B surface antigen (HBsAg) derived from Hansenula polymorpha with 3 mg of CpG 1018, an oligonucleotide adjuvant Toll-like receptor 9 (TLR9) agonist. The vaccine received US FDA approval in 2017 for use in adults ≥ 18 years. HEPLISAV-B is given by intramuscular injection in a 2-dose regimen spaced one month apart. CpG 1018 is a 22mer oligo-2′-deoxynucleotide phosphorothioate (PS-DNA) of sequence 5′-ps-d(TG AC TG TG AA**CG**TT**CG** AG AT GA)-3′ with two CpG steps (boldface) and a palindromic section (underlined). The mechanism of action of this adjuvant oligo is quite different from those presented thus far and including ASOs, SSOs, siRNAs and aptamers (Figure 3).

<span style=color:blue>乙肝疫苗HEPLISAV-B®使用了一种寡核苷酸佐剂CpG 1018，该疫苗是一种预防由乙型肝炎病毒（HBV）引起的乙型肝炎肝脏感染的重组疫苗。它由20μg来自Hansenula polymorpha的乙型肝炎表面抗原（HBsAg）与3mg的CpG 1018组成，后者是一种寡核苷酸佐剂，能激活Toll样受体9（TLR9）。该疫苗于2017年获得美国FDA批准，适用于18岁及以上的成年人。HEPLISAV-B®通过肌肉注射，分两次注射，间隔一个月。CpG 1018是一种22核苷酸磷酸硫酸酯修饰的寡聚-2'-脱氧核苷酸（PS-DNA），序列为5'-ps-d(TG AC TG TG AA**CG**TT**CG** AG AT GA)-3'，其中包含两个CpG位点（粗体标记）和一个回文结构（下划线标记）。这种佐剂寡聚体的作用机制与前述的ASOs、SSOs、siRNAs和适配体有很大的区别（见图3）。</span>

The presence of the CpG motif is central to its mode of action and underlies the adjuvant's role as a TLR9 agonist. In eukaryotic DNAs CpG dinucleotides are present at lower frequency than in the prokaryotic DNA sequences. Moreover, the frequency of methylation at CpG sites is higher in eukaryotic DNA than in the DNA of microbes. Differential CpG-methylation affords a molecular basis for TLR9 to distinguish self from non-self DNA in the host's defense immune response to microbial infections and thereby potential therapeutic applications of (unmethylated) agonistic CpG-containing oligonucleotides . Thus, CpG 1018 was used in combination immunotherapy with rituximab to treat patients with non-Hodgkin lymphoma. Conversely, ASOs have 5MeC rather than C, primarily to avoid any immune-stimulation when present along with G, but also to increase the binding affinity to the target RNA by 0.5°C/mod. The structural basis for a CpG-containing oligo to act as agonist (or antagonist in the methylated form) is depicted in Figure 24.

<span style=color:blue>CpG基序的存在对其作用方式至关重要，并构成了该佐剂作为TLR9激动剂的基础。在真核DNA中，CpG二核苷酸的频率比原核DNA序列中低。此外，真核DNA中CpG位点的甲基化频率比微生物DNA高。不同的CpG甲基化为TLR9提供了在宿主的免疫防御应答中区分自身DNA和非自身DNA的分子基础，因此有潜在的治疗应用前景（甲基化）激动性含CpG寡核苷酸。因此，CpG 1018与利妥昔单抗联合免疫疗法用于治疗非霍奇金淋巴瘤患者。相反，ASOs中的C位点被5MeC取代，主要是为了避免在存在G时产生任何免疫刺激，同时也提高了与靶向RNA的结合亲和力（每个甲基引起0.5°C的亲和力提高）。CpG寡核苷酸作为激动剂（或甲基化形式下的拮抗剂）的结构基础如图24所示。</span>

**图 24.**

![Structural basis of CpG recognition by TLR9 in the crystal structure of the DNA-receptor complex (PDB ID 3wpe (412)). (A) Close-up view of the interaction between the CpG step and TLR9. The C5-methyl of cytosine (carbon highlighted in yellow) is not present in the crystal structure. It was added to show contacts with neighboring polar moieties (thin solid lines) that reduce the affinity of an antagonist, i.e. an mCpG-containing oligo, by ca. threefold relative to the corresponding CpG-containing agonist oligo. Views of the DNA-TLR9 complex with the molecular surface of the receptor colored according to (B) Coulombic potential (blue, positively polarized, and red, negatively polarized) and (C) hydrophobicity potential (orange, most hydrophobic and purple, least hydrophobic).](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/m_gkad067fig24.jpeg)

<center><span style="background:#eef0f4;font-family:楷体;font-size:16px;">TLR9在DNA受体复合物的晶体结构中识别CpG的结构基础（PDB ID 3wpe）。(<span style=font-weight:bold>A</span>) CpG步骤与TLR9之间相互作用的近距离视图。甲基化的Cytosine的C5位点（以黄色突出显示的碳原子）在晶体结构中不存在。它被添加以显示与邻近极性基团（细实线）的接触，这些接触与相应的CpG含有激动剂寡核苷酸相比，降低了拮抗剂（即含有mCpG的寡核苷酸）的亲和力约三倍。DNA-TLR9复合物的视图，其中受体的分子表面按照(<span style=font-weight:bold>B</span>) 库仑势（蓝色表示正极化，红色表示负极化）和(<span style=font-weight:bold>C</span>) 疏水性势（橙色表示最疏水，紫色表示最亲水）进行着色。</span></center>

The following are the principal actions of CpG 1018 in combination with HBsAg in the HEPLISAV-B vaccine against HBV infection: (i) Activation of plasmacytoid dendritic cells (pDCs) for secretion of interferons (IFNs) and cytokines. (ii) Conversion of pDCs into efficient antigen-presenting cells such that they present processed HBsAg peptides to CD4+ T cells. (iii) Promotion of T cell differentiation to functional helper T cells via pDC-derived IFNs and cytokines. Multiple signals to B cells specific for intact HBsAg are then provided by the antigen-specific helper T cells, resulting in the generation of antibody responses that afford protective immunity to HBV.

<span style=color:blue>CpG 1018与HBsAg在HEPLISAV-B疫苗中对抗HBV感染的主要作用包括：(i) 激活浆细胞样树突状细胞（pDCs），促使其分泌干扰素（IFNs）和细胞因子。 (ii) 将pDCs转化为高效的抗原呈递细胞，从而向CD4+ T细胞呈递经过处理的HBsAg肽段。 (iii) 通过pDC源性的IFNs和细胞因子促进T细胞分化为功能性辅助T细胞。然后，特异性抗原辅助T细胞向HBsAg特异性B细胞提供多重信号，从而产生对HBV的保护性免疫应答。</span>

CpG 1018 exerts its biological actions locally at the injection site and draining lymph nodes. These stimulatory actions decline quite rapidly, such that biomarkers of 1018 activity return to baseline values within a week. At the doses that CpG 1018 is administered in HEPLISAV-B, the adjuvant is cleared from circulation within a couple of hours. Hence the oligonucleotide does not reach levels that would result in systemic TLR9-mediated immune stimulation. Therefore, it is the long-lived antibody responses and T and B cell memory that make up the durable effects of HEPLISAV-B immunization. Once these responses that are highly specific for the HBs antigen itself are generated, the continuing presence of either antigen or CpG 1018 adjuvant is no longer needed.

<span style=color:blue>CpG 1018在注射部位和引流淋巴结处发挥其生物作用。这些刺激性作用迅速下降，因此1018活性的生物标志物在一周内恢复到基线水平。在HEPLISAV-B中使用的CpG 1018剂量下，佐剂从循环中清除的时间只需几个小时。因此，寡核苷酸不会达到导致全身TLR9介导的免疫刺激的水平。因此，持久的HEPLISAV-B免疫效果是由长期存在的抗体应答和T、B细胞记忆所构成的。一旦产生了高度特异性的HBs抗原特异性应答，不再需要持续存在的抗原或CpG 1018佐剂。</span>

## COMIRNATY AND SPIKEVAX: mRNA VACCINES COMIRNATY与SPIKEVAX: mRNA 疫苗

With many thousands of prescription drug products approved for marketing in the US alone, and small molecule compounds constituting the largest share among them, oligonucleotide therapeutics occupy niches. But SSOs and siRNAs have enabled breakthrough treatments for rare genetic disorders that have proven difficult targets for small molecules. In fact, both ASOs and siRNAs are in development or approved for at least several rare disorders, giving these patients options to participate in clinical research and access to treatment choices for the first time.

<span style=color:blue>在仅美国市场上，已经批准上市的处方药品数量超过几千种，其中小分子化合物占据了最大份额，而寡核苷酸治疗药物则在特定领域占据了一席之地。然而，SSOs和siRNAs为罕见的遗传性疾病提供了突破性的治疗方法，这些疾病对于小分子化合物而言往往是难以攻克的靶点。事实上，ASOs和siRNAs已经在开发中或已经获得批准用于治疗至少数种罕见疾病，为这些患者提供了参与临床研究和获得治疗选择的机会，这也是他们首次获得这些选择。</span>

The traditional competition between antibody- and oligo-based therapeutics looks to increasingly become a synergistic partnership if mRNA vaccines live up to their immense promise. Thus, the ever-expanding RNA therapeutic toolbox includes molecules that range from those controlling gene expression (ASO, SSO, siRNA), regulation (antagomirs), proinflammatory effects (ssRNA and dsRNA) and recognizing proteins and receptors (aptamers) to RNA immunotherapeutics, such as mRNA vaccines that encode antigens of interest as well as self-amplifying RNAs. Provided the proteins encoded by mRNA vaccines elicit a robust neutralizing antibody response, the traditional antibody vs. oligo therapeutic ‘100m dash’ is being transformed into a ‘400m relay’, with RNA doing the early legwork and antibodies carrying the baton over the finishing line. Thus, early evidence in the development of a SARS-CoV-2 mRNA vaccine looked promising and the program received fast track designation by the US FDA on 12 May 2020. As well a preliminary account of a phase 1, dose-escalation, open-label trial with mRNA-1273 that included 45 healthy adults reported vaccine-induced anti-SARS-CoV-2 immune responses in all participants and an absence of trial-limiting safety concerns. A timeline of COVID-19 vaccine news and updates from the early days to the FDA-authorized emergency use of the Moderna SPIKEVAX® and Pfizer-BioNTech COMIRNATY® COVID-19 vaccines in children down to 6 months of age can be found here: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#authorized-vaccines.

<span style=color:blue>传统上，抗体类和寡核苷酸类治疗药物之间存在竞争关系，但随着mRNA疫苗兑现其巨大的潜力，二者之间的关系将越来越趋向于合作伙伴关系。因此，不断扩大的RNA治疗工具箱包括了一系列分子，涵盖了基因表达调控（ASO，SSO，siRNA），调节（antagomirs），促炎作用（ssRNA和dsRNA），以及识别蛋白质和受体（aptamers）的分子，还包括编码感兴趣抗原和自放大RNA等RNA免疫治疗药物。如果mRNA疫苗所编码的蛋白质能引发强效的中和抗体反应，传统的抗体与寡核苷酸治疗的“百米冲刺”正在转变为“400米接力赛”，其中RNA负责早期工作，而抗体在终点线上接力完成。因此，在SARS-CoV-2 mRNA疫苗的开发早期，有迹象表明该计划前景看好，并于2020年5月12日获得美国FDA的快速通道认可。此外，一项针对mRNA-1273的Ⅰ期剂量递增、开放标签试验的初步报告显示，在包括45名健康成年人的试验参与者中，疫苗诱导了针对SARS-CoV-2的免疫反应，并且没有出现限制试验的安全问题。关于COVID-19疫苗新闻和更新的时间线，从早期到FDA授权紧急使用Moderna SPIKEVAX®和Pfizer-BioNTech COMIRNATY® COVID-19疫苗适用于6个月以上儿童的情况，请参阅此处的链接：https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#authorized-vaccines。</span>

The two FDA-approved mRNA COVID-19 vaccines, Moderna's SPIKEVAX and Pfizer-BioNTech's COMIRNATY are generally effective and safe. Chemical modification, i.e. the use of N1-methyl-pseudouridine in place of U (Figure 2A), reduces the intrinsic immune stimulation potential of exogenous mRNAs. Moreover, refined delivery strategies, LNP technology in the case of both the Moderna and Pfizer-BioNTech vaccines (Figure 21B), are crucial and indispensable instruments in the development and clinical implementation of mRNA vaccines. Stay tuned – the future of RNA therapeutics is finally here!

<span style=color:blue>两种经FDA批准的mRNA COVID-19疫苗，Moderna的SPIKEVAX和Pfizer-BioNTech的COMIRNATY，一般来说是有效和安全的。化学修饰，即在U的位置使用N1-甲基伪尿苷（见图2A），降低了外源mRNA的固有免疫刺激潜力。此外，在现代和Pfizer-BioNTech疫苗中采用了LNP技术（见图21B）的改进递送策略，在mRNA疫苗的开发和临床应用中是至关重要且不可或缺的工具。敬请关注- RNA治疗的未来终于来临了！</span>

## CONCLUSIONS AND FUTURE OUTLOOK 结论和未来展望

This article was written to celebrate a milestone in the 30-odd years nucleic acid chemistry, modification and drug discovery saga, the approval of the first 18 nucleic acid-based therapeutics (Figure 3, Table 1). Those following the evolution of the blueprint to turn oligos into drugs from the very first hours will remember the ups and downs the field experienced over the years and countless occasions that led doubters to predict the premature end of the pursuit to create ASO therapeutics. Enter RNAi and more apparent challenges to protect double-stranded siRNA against nuclease attacks and facilitate uptake and tissue-specific delivery. Chemical modification played a crucial role in overcoming these, and just five backbone chemistries make up the oligo drugs that were brought to market since 1998. That three of them - 2′-F, 2′-*O*-Me and PS - were the first nucleoside and nucleotide modifications explored by chemists in the 1960s is quite astonishing.

<span style=color:blue>本文旨在庆祝核酸化学、修饰和药物发现领域30多年的里程碑，即首批18种核酸药物的获批（见图3、表1）。那些一直关注将寡核苷酸转化为药物的发展蓝图的人会记得这个领域多年来经历的起伏，以及无数次让怀疑者预言ASO治疗的过早终结的情况。随着RNAi的出现，保护双链siRNA免受核酸酶攻击、促进其摄取和组织特异性递送变得更加困难。化学修饰在克服这些问题中起到了至关重要的作用，自1998年以来，市场上推出的寡核苷酸药物仅使用了五种骨架化学结构。其中，2′-F、2′-*O*-Me和PS这三种修饰是化学家在上世纪60年代首次探索的核苷酸和核苷修饰，这一事实相当令人惊讶。</span>

The current success and positive outlook for oligonucleotide therapeutics with dozens of candidates in late-stage clinical trials should not prevent one from looking beyond the apparent magic of the 2′-F, 2′-*O*-Me, 2′-*O*-MOE, PS and PMO modifications. Although it seems unlikely that a silver bullet has been missed among the expanding universe of modifications that have been synthesized to date, many need to be looked at more closely and may pave the road to more potent therapeutics. In this review we discussed many modifications beyond the clinically successful ones pointed out above. For example, LNA and cEt-BNA modifications are being evaluated in various modalities and results will be forthcoming. It is also important to point out the commercial and business considerations from biotechnology firms which are evaluating such chemistries and limiting their evaluation to selected few for various proprietary and economic reasons. Yet another mentioned chemistry, GNA, has entered clinical trials in an RNAi therapeutic as an efficient off-target mitigator.

<span style=color:blue>目前，寡核苷酸药物在临床试验的晚期阶段有数十个候选药物取得了成功并展现了积极的前景，但这并不应阻止我们超越2′-F、2′-*O*-Me、2′-*O*-MOE、PS和PMO等修饰的显而易见的成功。尽管在迄今为止合成的各种修饰物中，很难说是否有一种灵丹妙药被忽视了，但许多修饰物需要更仔细地研究，可能为更强效的治疗药物铺平道路。在本综述中，我们讨论了许多超越上述临床成功修饰的修饰物。例如，LNA和cEt-BNA修饰正在不同的疗法中进行评估，结果将会陆续公布。同时，还要指出生物技术公司在商业和业务考虑方面对这些化学修饰进行评估，并基于各种专有和经济原因将其限制在少数几种修饰上。另外提到的GNA修饰已作为高效的副靶位缓解剂进入了RNAi治疗的临床试验阶段。</span>

Probably the most important breakthrough in the successful launch of two RNAi therapeutics concerns delivery using LNPs or conjugation chemistry for receptor-mediated uptake and tissue-specific targeting. LNPs validated the RNAi platform (ONPATTRO) and a new delivery platform. Further, the latter validated the mRNA vaccine platform. Regarding the conjugates, GalNAc-containing LEQVIO that lowers LDL-cholesterol (LDL-C) by targeting *PCSK9* mRNA for the treatment of HeFH or atherosclerotic cardiovascular disease (ASCVD) and received regulatory approval in 2021/22, represents a game changer. ASCVD is the greatest health burden worldwide with an estimated 22 million deaths/year expected by 2040. In clinical studies, inclisiran siRNA provided durable, potent and consistent LDL-C lowering over 18 months with a safety profile similar to placebo. With maintenance dosing every 6 months, LEQVIO offers a potentially more convenient option compared to approved monoclonal antibody (mAb) options (REPATHA and PRALUENT) that are dosed every 2–4 weeks. Thus, RNAi treatment has become more similar to a ‘flu shot’ taken a couple of times per year, but in this case to prevent development or progression of ASCVD. Successful hepatic delivery by targeting ASGPR with GalNAc conjugation chemistry as applied with GIVLAARI, OXLUMO, LEQVIO and AMVUTTRA points the way to using other receptor/ligand pairs in order to enable future delivery of oligo therapeutics to various tissues.

<span style=color:blue>在两种RNAi治疗药物成功上市方面，可能最重要的突破涉及使用脂质体纳米粒（LNPs）或结合化学反应进行受体介导摄取和组织特异性靶向。LNPs验证了RNAi平台（ONPATTRO）和一种新的递送平台。后者进一步验证了mRNA疫苗平台。至于共轭物，通过靶向*PCSK9* mRNA降低低密度脂蛋白胆固醇（LDL-C）的GalNAc-LEQVIO药物在2021/22年获得了监管批准，代表了一种革命性的突破。动脉粥样硬化性心血管疾病（ASCVD）是全球最大的健康负担，预计到2040年将有约2200万人死于该病。在临床研究中，inclisiran siRNA在18个月内提供了持久、强效和一致的LDL-C降低效果，安全性与安慰剂相似。每6个月维持剂量的LEQVIO相比每2-4周剂量的已批准单克隆抗体（mAb）选项（REPATHA和PRALUENT），提供了一种更方便的选择。因此，RNAi治疗变得更类似于每年接种几次流感疫苗，但这种情况是为了预防或延缓ASCVD的发展。通过使用GalNAc共轭化学反应以靶向ASGPR成功进行肝脏递送，如GIVLAARI、OXLUMO、LEQVIO和AMVUTTRA，为利用其他受体/配体对以实现将寡核苷酸治疗药物递送到各种组织指明了方向。</span>

Beyond the LNP and GalNAc platforms, new approaches are being assessed for delivery to extrahepatic tissues. A lipid-conjugated siRNA for CNS applications and an antibody-conjugated siRNA for muscle delivery have entered clinical studies. Additional ligands and delivery platforms are on the horizon. Future challenges and available opportunities for nucleic acid-based medicines have been recently addressed.

<span style=color:blue>除了LNP和GalNAc平台，还在评估用于向肝脏之外组织递送的新方法。一种用于中枢神经系统应用的脂质共轭siRNA和一种用于肌肉递送的抗体共轭siRNA已进入临床研究。其他配体和递送平台也在不断涌现。关于核酸药物的未来挑战和可用机会最近已得到探讨。</span>

## ACKNOWLEDGEMENTS 致谢

We thank our colleague Dhrubajyoti Datta for help with figures and references. We thank our colleagues Cindy Courtney, Jen Backo, Tim Long and Kevin Fitzgerald for their valuable comments. We are grateful to all our colleagues across the various disciplines who tirelessly contributed over the past several decades to the creation of the oligonucleotide-based medicines described herein. We especially acknowledge the vision, courage, and tenacity of Stanley T. Crooke (Isis-Ionis Pharmaceuticals) and John Maraganore (Alnylam Pharmaceuticals). Finally, we dedicate this review and perspective article to pioneers in the nucleic acid structure, chemistry and modification fields: Rosalind Franklin (100th birth anniversary on 25 July 2020), Robert L. Letsinger (100th birth anniversary on 31 July 2021), Har Gobind Khorana (100th birth anniversary on 9 January 2022), and Fritz Eckstein (on the occasion of his 90th birthday on 7 September 2022).

<span style=color:blue>我们感谢我们的同事Dhrubajyoti Datta对图表和参考文献的帮助。我们感谢我们的同事Cindy Courtney、Jen Backo、Tim Long和Kevin Fitzgerald对本文的宝贵评论。我们衷心感谢各个领域的同事们在过去几十年中对本文所描述的基于寡核苷酸的药物的不懈贡献。特别感谢Stanley T. Crooke（Isis-Ionis Pharmaceuticals）和John Maraganore（Alnylam Pharmaceuticals）的远见、勇气和韧性。最后，我们将这篇综述和展望文章献给核酸结构、化学和修饰领域的先驱者：罗莎琳德·弗兰克林（2020年7月25日诞辰100周年）、罗伯特·L·莱辛格（2021年7月31日诞辰100周年）、哈·戈宾德·科拉纳（2022年1月9日诞辰100周年）以及弗里茨·埃克斯坦（2022年9月7日90岁生日）。</span>

## FUNDING 资助

Alnylam Pharmaceuticals. The open access publication charge for this paper has been waived by Oxford University Press – *NAR* Editorial Board members are entitled to one free paper per year in recognition of their work on behalf of the journal.

*Conflict of interest statement*. M.M. is an employee of Alnylam Pharmaceuticals.

<span style=color:blue>Alnylam 制药公司。 牛津大学出版社已免除本文的开放获取出版费——*NAR* 编辑委员会成员每年有权获得一篇免费论文，以表彰他们代表期刊所做的工作。<br>*利益冲突声明*。 M.M.是 Alnylam Pharmaceuticals 的员工。</span>
